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INTRODUCTION 
 
1. Stem cells and pluripotency 
1.1. Differentiation is the process of cell specialization 
Differentiation is a developmental process by which cells become more and more restricted to 
one particular fate. After fertilization and up to the two- to eight cell stage (depending on the 
species), the mammalian embryo contains cells that can in principle give rise to any cell type of 
the organism. These cells are said to be totipotent. The first visible sign of differentiation during 
development correlates with the formation of the blastocyst. The blastocyst consists of an inner 
cell mass (ICM), giving rise to the embryo proper, and the trophectoderm (TE), giving rise to 
extraembryonic tissues associated with formation of the placenta. 
 Massive reorganization of the embryo takes place during gastrulation when the three 
primary germ layers (the endoderm, mesoderm and ectoderm) are formed and organized in their 
proper locations. From the endodermal layer arise linings of lungs, tongue, tonsils, urethra and 
associated glands, bladder and digestive tract. The mesodermal layer forms muscles, bones, 
lymphatic tissue, spleen, blood cells, heart, lungs and reproductive and secretory systems. Skin, 
nails, hair, eye lens, lining of the internal and external ear, nose, sinuses, mouth, anus, tooth 
enamel, pituitary gland, mammary glands and all parts of the nervous system develop from the 
ectodermal layer. Organogenesis and tissue development occur through a series of successive 
differentiation events starting from stem cells, or precursor cells (Fig. 1). These divide to give 
rise to more of themselves (self-renewal) and can differentiate into more committed progenitor 
cells which in turn can give rise to more specialized cell types (Fig. 1). Thus as differentiation 
proceeds, cells become functionally distinct from each other. 
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A key feature of differentiation is dynamic changes in gene expression, which result in synthesis 
of proteins that characterize the different cell types. In particular, genes encoding markers of 
pluripotency are repressed while genes encoding lineage-specific markers are turned on.  
Tuning of gene expression is 
regulated by changes in chromatin 
organization in specific regions of 
the genome. These so-called 
epigenetic (epi- meaning besides in 
Greek) modifications are heritable 
and do not affect genome 
sequence.  
 
 
 
      Fig. 1. A simplified view of cellular differentiation  
 
1.2. Stem cells and their differentiation potential 
Stem cells can be derived from early embryos or can be found in most tissues. To be qualified as 
stem cells, cells must have the ability to at least (i) self-renew by symmetric division, where 
daughter cells retain the characteristics of the parent, and (ii) differentiate by dividing 
asymmetrically to give rise to at least one more committed cell type. Stem cells may be classified 
according to their differentiation potential. Pluripotent stem cells (such as embryonic stem (ES) 
cells, embryonic germ (EG) cells and embryonal carcinoma (EC) cells) can differentiate into any 
cell type of the body except extra-embryonic tissues (Fig. 2). Multipotent stem cells have been 
isolated from many tissue types and can differentiate into, primarily but not exclusively, cells of 
their own developmental lineage. Unipotent stem cells, in contrast, can differentiate into one cell 
type.  
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Fig. 2. Origin of embryonic stem cells, embryonic germ cells and embryonal carcinoma cells. ES cells are derived 
from the ICM of blastocysts; EG cells are derived from primordial germ (PG) cells isolated from the embryonic 
gonad; EC cells are derived from PG cells in the embryonic gonad but usually are detected as components of 
testicular tumors in the adult. Taken from (Donovan and Gearhart, 2001).  
 
 
1.2.1. Embryonic stem cells  
ES cells have been derived by culturing ICMs of mouse, human, rat and monkey blastocysts 
under specific conditions (Buehr et al., 2008; Evans and Kaufman, 1981; Thomson et al., 1995; 
Thomson et al., 1998) ES cells have the potential to proliferate indefinitely in culture and give 
rise to cells of all three germ layers upon differention in vitro or in teratomas after injection in 
nude mice (Reubinoff et al., 2000; Thomson et al., 1998). At the morphology level, ES cells are 
characterized by growth in colonies with well-defined edges, although signs of differentiation on 
the edges of the colonies are frequent. Interestingly, colonies of human ES cells are larger and 
not as compact as mouse ES cell colonies (Fig. 3). Unlike differentiated cells, ES cells have a 
high nucleus/cytoplasm ratio and the nucleus contains a large nucleolus.  
 
 
Fig 3. Brightfield images of (A) 
hES cell colonies and (B) mES cell 
colonies on inactivated mouse 
embryonic fibroblast (MEF) feeder 
layers. Both pictures are taken with 
a 10x objective. Taken from 
www.invitrogen.com
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 ES cells express surface markers including stage-specific embryonal antigens SSEA-3 
and SSEA-4 (human) or SSEA-1 (mouse) (Boiani and Scholer, 2005). In addition, although 
molecular identities of tumor rejection antigens TRA-1-60 and TRA-1-81 are unknown, they are 
commonly used as markers of human ES cells (Schopperle and DeWolf, 2007). Expression of 
TRA-2-54 and Thy1 antigen also characterize human pluripotent cells and are downregulated 
during differentiation; however, Thy1 is also expressed on the surface of multipotent 
mesenchymal stromal cells (MSCs). ES cells also express the tissue-nonspecific isoform of 
alkaline phosphatase isozyme TRA-2-49 and Nanog (Takahashi et al., 2007). 
Additionally, ES cells express transcription factors responsible for maintaining the 
undifferentiated state, among which Nanog, Oct4 and Sox2 have been proposed to constitute the 
core of an expanding transcriptional network controlling pluripotency (Boyer et al., 2005; Do and 
Scholer, 2009; Jaenisch and Young, 2008). Beside autoregulatory and feed-forward loops, Oct4, 
Nanog and Sox2 also target and regulate many downstream genes (Jaenisch and Young, 2008) 
(Fig. 4). Oct4 (also called Octamer-4, Oct3, Oct3/4 or Pou5F1) belongs to the Octamer class of 
the Pit-Oct-Unc (POU) protein family (Scholer et al., 1990). Oct4 binds DNA through two DNA 
binding POU-domains that recognize an 8-bp DNA sequence with the consensus ATGCAAAT 
(Chambers and Tomlinson, 2009). Oct4 controls pluripotency in a dose-dependent manner (Niwa 
et al., 2000a). A 150% increase in OCT4 gene expression turns pluripotent cells into primitive 
endoderm or mesoderm, while repression of OCT4 induces formation of TE (Niwa et al., 2000a). 
Thus, pluripotent cells possess a network of regulators to keep OCT4 expression at optimal level 
to ensure pluripotency.  
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 Fig. 4. A core transcriptional 
regulatory network maintaining 
pluripotency in human ES cells. 
Oct4, Nanog and Sox2 target 
genes that encode chromatin 
regulators or transcription 
factors. Some of the key genes 
co-occupied by the three 
altogether (blue) are shown. 
Bound promoters are in red and 
putative downstream targets are 
shown in grey. Taken from 
{Boyer, 2005 BOYER2005 /id].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oct4 can form a heterodimer with Sox2, so that both proteins can bind DNA together 
{Rodda, 2005 RODDA2005 /id}. Sex determining region Y (SRY)-box 2, or Sox2, is a high 
mobility group (HMG) family member with a single HMG DNA-binding domain. This domain 
binds to the consensus sequence A/T A/T CAAAG in the minor groove of the DNA helix.  Sox2 
is required for epiblast and extraembryonic ectoderm formation, suggesting cooperativity with 
Oct4 to control the fate of pluripotency at implantation (Avilion et al., 2003). Sox2 is, in contrast 
to Oct4, also expressed in multipotent and unipotent stem cells and can be replaced by other 
members of the Sox-family (reviewed in (Welstead et al., 2008)) in the induction of pluripotent 
stem cells, although with reduced efficiency.  
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 Oct4 frequently partners with Nanog in repressor complexes that control ES cell fate. 
Nanog was discovered based on its ability to sustain mouse ES cell renewal in the absence of 
leukemia inhibitory factor (Chambers et al., 2003; Niwa et al., 2000b). Nanog acts as a strong 
activator of the OCT4 promoter, thus participating in the regulation of OCT4 expression in 
pluripotent cells (Chambers et al., 2003; Niwa et al., 2000b).  
 The pluripotency of ES cells makes them a valuable tool for investigating differentiation. 
ES cells also constitute potentially material for testing novel therapies, drug screening and 
functional genomics applications. Because destruction of embryos is required for their derivation, 
there are however ethical concerns with derivation and use of human ES cells. Explantation of 
human blastocysts causes ethical difficulties in many countries and was prohibited in Norway 
until January, 2008. Moreover, there is to date no evidence to indicate that differentiated hES 
cells cannot revert to an undifferentiated, potentially tumorigenic state. Similarly, if cells are not 
fully differentiated, they may cause tumors. In this context, approaches to create pluripotent cells 
from sources other than embryos have been actively sought. 
 
1.2.2 Primordial germ cells and embryonal carcinoma cells 
Primordial germ (PG) cells are progenitors of the germ cell lineage. PG cells are not pluripotent 
but they are a source of pluripotent stem cells (Kerr et al., 2006). Under specific conditions, PG 
cells isolated from the gonadal ridge can convert into pluripotent EG cells (Shamblott et al., 
1998) which contribute to all lineages in chimeric fetuses, including the germline.  
Testicular cancer can arise from PG cells that have escaped normal differentiation. These 
tumors contain multiple differentiated tissues from all three germ layers, in addition to 
undifferentiated cells called embryonal carcinoma (EC) cells. EC cells are derived from 
teratocarcinomas and are considered to be the malignant counterparts of ES cells (Przyborski et 
al., 2004). Similarly to ES cells, EC cells are pluripotent and can form all three germ layers 
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(Przyborski et al., 2004). The gene expression profile of EC cells is similar to, but different from, 
that of ES cells. Both cell types express embryonic genes such as OCT4, SOX2, FOXD3, 
NANOG, FZD7, DNMT3B and TERF1 (Sperger et al., 2003). These similarities may reflect a 
necessity to maintain a pluripotent phenotype, whereas differences may reflect adaption of EC 
cells to tumor growth. Given the issues associated with use of human embryonic material, EC 
cells constitute an alternative (and simpler) system to investigate differentiation.  
Studies presented in this thesis rely on the use of the human EC cell line, NCCIT, as the 
basis for turning differentiated cells into ES-like cells. NCCIT cells have been characterized 
biochemically, immunochemically, functionally and at the gene expression level (Damjanov, 
1993; Sperger et al., 2003). The core stemness gene NANOG is abnormally overexpressed in 
NCCIT cells and down-regulation of NANOG causes down-regulation of OCT4, SOX2, REX1 
and FOXD3 expression, G2-M phase arrest, inhibition of colony formation and induction of 
differentiation into all three germ layers (You et al., 2009). NCCIT cells also display epigenetic 
differences with ES cells, notably at the level of DNA methylation and histone H3 and H4 
modifications, at least in the NANOG gene locus (You et al., 2009). Epigenetic states of 
pluripotent cells are described in Section 2.   
 
1.3. Cellular dedifferentiation 
The terminally differentiated state of a cell has long thought to be stable. Several lines of 
evidence indicate however that fate of terminally differentiated cells is not necessarily locked, 
and that de-differentiation events can occur. Dedifferentiation refers to the progression of a 
differentiated cell to a less differentiated state. It is charachterized by a loss of developmental or 
differentiation markers and a gain of proliferative capacity (Sakai and Takeuchi, 1971). 
 Some lower vertebrates have the ability to regenerate organs through a dedifferentiation 
process. Most commonly, wound healing after injury involves migration of epithelial cells to the 
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wounded site and formation of scar tissue (Heber-Katz, 1999). For more serious injury, such as 
damaged or lost tissue, regeneration maintains or restores the original architecture by 
recapitulating part of its original embryonic development. Urodele amphibians can replace lost 
anatomical parts by a process of migration, dedifferentiation, proliferation and redifferentiation 
of epithelial cells in the wounded area (Morgan, 1901). They also have the ability to regenerate 
complex structures such as limbs, tails and jaws (Brockes and Kumar, 2002; Stocum, 2004).  
 The ability to regenerate is thought to be a lost property in mammals, although sporadic 
examples of mammalian regeneration exist. These include the regrowth of fingertips, antlers and 
examples of complete ear hole closure in specific rabbit and mouse strains (Clark et al., 1998; 
Heber-Katz et al., 2004a). For example, MRL mice not only repair ear holes, but can also 
spontaneously repair heart tissue after a normally irreversible infarction (Heber-Katz et al., 
2004b; Leferovich and Heber-Katz, 2002). It is therefore reasonable to hypothesize that there is 
potential for restoring pluripotency in at least certain mammalian somatic cell types. Together 
with the motivation of producing ES-like cells without using embryos, the dedifferentiation 
ability of some cell types has triggered studies aiming at reprogramming cells to a pluripotent 
state. Approaches to reach this goal are addressed in Section 3.  
 
2. Epigenetic states in embryonic stem cells 
The extent of differentiation ability of stem cells is associated with the expression potential of 
developmentally- and differentiation-regulated genes. Such potential is regulated by epigenetic 
processes on DNA and chromatin. Epigenetic mechanisms refer to heritable modifications of 
DNA and chromatin that do not affect DNA sequence. Genome-wide mapping of DNA 
methylation and post-translational histone modifications, two primary epigenetic determinants, in 
stem- and differentiated cells have provided chromatin “maps” unveiling regulatory mechanisms 
by which genes are poised for transcription in undifferentiated cells. Potential for gene 
 18
expression is thus believed to be controlled by epigenetic processes that confer a specific 
chromatin configuration on regulatory, coding and intergenic regions. In addition to epigenetic 
modifications, positioning of transcriptional activators or repressors, ATP-dependent chromatin 
remodeling enzymes and small interfering RNAs on target genes also regulate expression.  
 
2.1. DNA methylation and gene expression 
DNA methylation consists of the addition of a methyl group to the 5 position of a cytosine in a 
cytosine-phosphate-guanine (CpG) dinucleotide. CpG methylation is symmetrical and targets 
isolated CpGs, clustered CpGs, or even CpGs within a CpG island (see (Gardiner-Garden and 
Frommer, 1987) and (Takai and Jones, 2002) for definitions of a CpG island) (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. CpG methylation. (A) Mechanism of DNA methylation. (B) CpG methylation is symmetrical and occurs on 
both DNA strands. (C) Simplified textbook view of the relationship between DNA methylation and gene expression. 
This relationship is clearly more complex (see main text). Taken from (Collas et al., 2007) 
 
 CpG methylation is catalyzed by DNA methyltransferase (DNMTs). Maintenance DNA 
methyltransferase DNMT1 recognizes hemi-methylated DNA and methylates the daughter 
strand, ensuring fidelity of methylation profile after replication (Jaenisch and Bird, 2003). In 
contrast to DNMT1, DNMT3a and DNMT3b are implicated in de novo DNA methylation that 
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takes place during development (Turek-Plewa and Jagodzinski, 2005), as a means of shutting 
down genes whose activity is no longer required. DNMT2 has no ascribed function in DNA 
methylation (Liu et al., 2003) but has transfer RNA methyltransferase activity (Goll et al., 2006).  
DNA methylation is as a hallmark of long-term gene silencing. Methyl groups create 
target sites for methyl-binding proteins which induce transcriptional repression by recruiting 
transcriptional co-repressor complexes including histone deacetylases (HDACs) (Klose and Bird, 
2006). DNA methylation is essential for development (Morgan et al., 2005; Razin and Shemer, 
1995), X chromosome inactivation (Hellman and Chess, 2007), genomic imprinting (Reik et al., 
1987; Sapienza et al., 1987), and repression of transposable elements (Yoder et al., 1997). 
 Genome-wide DNA methylation profiling has shown that the relationship between 
promoter DNA methylation and promoter activity depends on CpG content (Weber et al., 2007) 
(Table 1). Notably, low CpG content promoters (LCPs) show no correlation between promoter 
activity and methylation, and most LCPs are methylated regardless of their activity. On the 
contrary, activity of intermediate CpG promoters (ICPs) is inversely correlated with methylation, 
arguing that ICP methylation is incompatible with transcription. High CpG promoters (HCPs) in 
contrast display no or weak methylation even when inactive (Table 1).  
 
Table 1. Relationship between promoter DNA methylation and activity depends on CpG content. 
 
Promoter classa Promoter activity Methylation status 
HCP Active 
Inactive 
Unmethylated 
No or weakly methylated 
ICP Active 
Inactive 
Unmethylated 
Methylated 
LCP Active 
Inactive 
Unmethylated or methylated 
Unmethylated or methylated 
 
aPromoter class is defined by promoter CpG content (Weber et al., 2007). HCP, high  
CpG content promoter; ICP; intermediate CpG content promoter; LCP; low CpG content promoter. 
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2.2. Post-translational histone modifications 
The amino-terminal tails of core histones are post-translationally modified to confer physical 
properties that affect interaction with DNA on regulatory sequences (Fig. 6). Histone 
modifications influence chromatin packaging and are read by chromatin modifying enzymes and 
transcription factors, and thus contribute to the regulation of transcription (Jenuwein and Allis, 
2001).  
 Epigenetic histone modifications have been best characterized for histones H3 and H4 
and include combinatorial phosphorylation, ubiquitination, sumoylation, acetylation, 
methylation, proline isomerization, ADP-ribosylation and deamination (Kouzarides, 2007). 
Notably, di- and trimethylation of H3 lysine 9 (H3K9me2/me3) and trimethylation of H3K27 
(H3K27me3) elicit the formation of repressive heterochromatin through the recruitment of 
heterochromatin protein 1 (Lachner et al., 2001) and polycomb group (PcG) proteins, 
respectively (Cao et al., 2002). However, whereas H3K9me3 marks constitutive heterochromatin 
(Lachner and Jenuwein, 2002), H3K27me3 characterizes facultative heterochromatin, or 
chromatin domains harboring transcriptionally repressed genes that can potentially be activated 
(Azuara et al., 2006; Bernstein et al., 2006). 
 
 
 
 
 
Fig. 6. Post-translational 
histone modifications. (A) 
Core histones can be 
methylated, acetylated, 
phosphorylated, 
ubiquitinated or 
SUMOylated, to modulate 
gene expression. (B) 
Known modifications on 
the amino-terminal tails of 
core histones H3 and H4. 
Taken from (Collas et al., 
2007) 
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 In contrast, histone acetylation loosens interaction with DNA and creates a conformation 
suitable for targeting transcriptional activators. Thus, acetylation on H3K9 (H3K9ac) and H4K16 
(H4K16ac) (together with H3K4me2/me3) is often found in association with active genes 
(Bernstein et al., 2006; Schubeler et al., 2004; Struhl, 1998; Zhao et al., 2007). H3K4me3 and 
H3K9ac mediate recruitment of transcriptional activators (Kingston and Narlikar, 1999; Pray-
Grant et al., 2005). Taken together, methylation and acetylation of specific lysine residues on 
amino-terminal histone tails are fundamental for the formation of euchromatin and 
heterochromatin. The large number of combinatorial histone modifications mediated by 
acetylation and methylation (even only considering these two modifications) illustrate the 
enormous regulatory potential of post-translational histone modifications. 
 
 
2.3. DNA methylation patterns in ES cells  
The DNA methylation signature of ES cells is distinct from that of differentiated cells; however 
whether this reflects differences in gene expression or the pluripotent nature of ES cells is 
unclear. Mouse ES cells are less methylated than differentiated cells (Jackson et al., 2004; 
Zvetkova et al., 2005), and this hypomethylation affects repetitive and unique sequences 
including differentially methylated regions which regulate expression of paternally imprinted loci 
(Zvetkova et al., 2005). Methylation profiles of ES cells are also distinct from those of cancer 
cell lines and somatic stem cells, reflecting an epigenetic distance between ES cells and other cell 
types (Bibikova et al., 2006). Of note, genes differentially methylated in human ES cells relative 
to somatic cells include OCT4 and NANOG, which are unmethylated in hES cells. Thus the 
methylation pattern of a small number of developmentally-controlled genes may constitute an 
epigenetic mark of ES cells. 
           A recent genome-wide DNA methylation profiling across promoters in mouse ES cells 
annotated >5,000 unmethylated genes and >6,100 genes methylated in the promoter regions 
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examined (Fouse et al., 2008). Methylation was found to occur primarily in ICPs and LCPs or in 
non-CpG island regions of HCPs (Fig. 7A). Methylated genes included late-differentiation and 
signal transduction genes (not expressed in ES cells) (Fig.  7B). In contrast, unmethylated genes 
were associated with transcription, RNA and protein metabolic processes, cell survival and 
proliferation. Thus unmethylated promoters show good correlation with genes active in ES cells. 
In addition though, 10-15% of unmethylated genes are involved in developmentally-regulated 
and differentiation processes and not expressed in ES cells (Fouse et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Epigenetic states and transcriptional 
regulation in mouse embryonic stem cells. 
(A) Methylation state (blue gradient) relative 
to CpG density (black bar). (B) DNA 
methylation and state of 
H3K4me3/H3K27me3 “bivalency” in 
undifferentiated mouse ES cells. PcG refers 
to the polycomb group repressor complex 
(PRC) 2, which methylates H3K27 through 
activity of the histone methyltransferase 
Ezh2. Taken from (Collas, 2009) 
 
 
2.4. Chromatin states in ES cells 
2.4.1. Post-translational histone modifications 
Recent mapping of histone modifications has shown that lineage-specific genes, which are either 
silent or active in differentiated somatic cells, are in a potentially active state in pluripotent ES 
cells. Genome-wide and locus-specific chromatin immunoprecipitation (ChIP) analyses reveal 
that repressed but potentially active promoters in mouse ES cells are associated with “bivalent” 
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histone modifications characterized by H3K4me3, a mark of active genes, and H3K27me3, a 
mark of inactive genes (Azuara et al., 2006; Bernstein et al., 2006) (Fig. 7B). These bivalent 
domains consist of large regions of H3K27me3 embedding smaller areas of H3K4me3 (Bernstein 
et al., 2006; Mikkelsen et al., 2007; Zhao et al., 2007). These domains include transcription 
factor-encoding genes and early differentiation genes that are not expressed or expressed at low 
levels (Fig.  7B). The role of these genes in lineage determination suggests that they are in a 
poised state and await transcriptionally inductive cues.  
 DNA methylation and histone modification profiles in mouse ES cells reveal four classes 
of genes whose promoters are enriched in either H3K4me3 and H3K27me3, H3K4me3 alone, 
H3K27me3 alone, or neither of these modifications (Fouse et al., 2008) (Fig. 7B). Most 
promoters lacking both H3K4m3 and H3K27m3 are often methylated, suggesting exclusive 
H3K27 methylation and DNA methylation mechanisms of transcriptional repression. Indeed, 
about half of promoters with the H3K4me3/H3K27me3 marks are hypomethylated, arguing that 
transcriptional repression on these promoters is imposed by PcG proteins (see below). The 
remainder of these promoters appears to be hypermethylated, suggesting that DNA methylation 
in these instances may constitute an additional program of long-term transcriptional repression in 
undifferentiated ES cells.  
 
2.4.2. Polycomb-group proteins 
Polycomb group proteins (PcGs) are transcriptional repressors (Kennison, 1995; Ringrose and 
Paro, 2007) found in two distinct and conserved polycomb repressor complexes (PRC1 and 
PRC2) working cooperatively (Otte and Kwaks, 2003). Involvement of PRCs in pluripotency has 
been suggested by the requirement of PcG proteins for patterning of gene expression during 
development, and for establishing pluripotent ES cell cultures (Boyer et al., 2006a).  
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In ES cells, PcGs preferentially occupy genes that are activated upon differentiation, 
consistent with the view that these genes are poised for transcription (Boyer et al., 2006b; 
Bracken et al., 2006; Lee et al., 2006). Histone methyltransferase activity of enhancer of zeste 
homologue 2 (Ezh2; a PRC2 component) is responsible for trimethylation of H3K27 on these 
target genes (Cao et al., 2002; Cao and Zhang, 2004) (Fig. 7B). Trimethylation of H3K4 is 
mediated by Trithorax group (Trx) proteins (Ringrose and Paro, 2007). Thus, the interplay 
between PcG and Trx proteins is likely to establish bivalent histone modifications in pluripotent 
cells. For genes activated upon differentiation, PcGs are displaced from promoters (Bracken et 
al., 2006). Furthermore, genes that are repressed during differentiation have also been found to 
be occupied by PcGs in undifferentiated cells. These findings suggest that PRCs constitute a 
programmed memory system established during embryogenesis (Bracken et al., 2006). This 
program would mark certain genes for transcriptional repression upon differentiation, while other 
genes would be primed for activation. These observations suggest that combinations of CpG 
methylation, histone modifications, PcG occupancy, as well as nucleosome positioning (Ozsolak 
et al., 2007; Pusarla et al., 2007) on developmentally-regulated promoters, in the context of 
hyperdynamic chromatin (Meshorer et al., 2006), define a pluripotent genomic organization in 
ES cells.  
 
3. Reprogramming cells to pluripotency 
The reprogramming of a differentiated cell into a pluripotent cell that in turn could repopulate or 
repair sick or damaged tissue would present beneficial applications in regenerative medicine. 
Over the years, several strategies have been developed to reprogram cells to a pluripotent state 
(Fig. 8). Somatic cell nuclear transfer (SCNT) may offer this possibility (Fig. 8A) and is in 
principle possible in humans. However, technical hurdles and ethics regulations currently prevent 
application of this technology in a number of countries. As a result, alternative strategies to 
 25
reprogramming cell fate have been developed. In this section, we briefly address SCNT as a 
means of nuclear reprogramming and focus on recent non-SCNT approaches to reprogram cells 
and enhance their differentiation potential (Fig. 8B-D). These include fusion with ES cells, and 
forced expression of pluripotency factors in somatic cells to elicit overexpression of 
pluripotency-associated genes. Another approach consists in the treatment of somatic cells with 
extracts of pluripotent cells; this approach has been developed in the course of this work and is 
addressed at large in this thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  8. Approaches to 
reprogramming somatic cells. (A) 
Transplantation of a somatic cell 
nucleus into an  
unfertilized oocyte (therapeutic 
cloning). Growth of cloned 
embryos to the blastocyst stage and 
derivation of SCNT ES cells may 
be one option to create genetically 
matched replacement cells. (B) 
Fusion of somatic cells with ES 
cells results in tetraploid hybrids 
with ES cell properties. (C) 
Transient incubation of somatic 
cells with extracts of ES cells elicits 
some nuclear reprogramming 
events and enhances pluripotency 
in vitro (work presented in this 
thesis). (D) Retroviral transduction
of ES cell transcription factors 
(Oct4, Sox2, Klf4 and c-Myc) is 
sufficient to generate pluripotent 
induced pluripotent stem (iPS) 
cells. Taken from (Col
 
las, 2007) 
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3.1. Reprogramming by somatic cell nuclear transfer (SCNT) 
A classical experimental example of dedifferentiation is the reprogramming of a differentiated 
cell nucleus by transplantation into an unfertilized oocyte, a procedure referred to as SCNT (Fig. 
8A). SCNT can lead to derivation of pluripotent ES cells from cloned embryos (Cibelli et al., 
1998; Munsie et al., 2000; Wakayama et al., 2001) and in the birth of cloned offspring (Gurdon 
and Byrne, 2003; Rideout, III et al., 2002; Wilmut et al., 2002). The mechanisms of nuclear 
reprogramming by SCNT point to a process requiring DNA demethylation for reactivation of 
embryonic genes (Simonsson and Gurdon, 2004). However, SCNT is an inefficient process 
affected by differentiation and epigenetic state of the donor nucleus (Blelloch et al., 2006). Other 
approaches have been shown to elicit nuclear reprogramming and have been supported by 
modifications of the somatic cell’s epigenome.  
  
3.2. Reprogramming by fusion of a somatic cell with an ES cell  
Fusion of mouse thymocytes with EG or ES cells have shown that epigenetic reprogramming 
could be triggered in the thymocyte nuclei (Tada et al., 1997; Tada et al., 2001) (Fig. 8B). 
Notably, EG cell-thymocyte hybrids are characterized by heritable demethylation of imprinted 
and non-imprinted genes, and transcriptional activation of these genes. Epigenetic changes in the 
thymocyte nucleus are consistent with induction of pluripotency markers in the hybrids such as 
ability to differentiate into all three germ layers (Tada et al., 1997).  
Somatic-ES cell hybrids also elicit markers of nuclear reprogramming such as thymocyte-
derived X chromosome reactivation (Tada et al., 2001). Like EG cells, ES cells can induce 
pluripotency in somatic cells including thymocytes (Tada et al., 2001), neuronal progenitor cells 
(Pells et al., 2002; Ying et al., 2002) or bone marrow-derived cells (Terada et al., 2002). 
Similarly, fusion of EC cells with T-lymphoma cells promotes the formation of colonies 
expressing pluripotent cell transcripts from the lymphoma cell genome (Flasza et al., 2003). 
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Thus, factors originating from the undifferentiated cell can elicit some epigenetic reprogramming 
in a more differentiated cell type.  
 Further development in the cell fusion approach was reported by Cowan et al. (Cowan et 
al., 2005) to reprogram normal diploid human fibroblasts into human ES (or ES-like) cells. ES 
cells fused with the fibroblasts result in hybrids that maintain a tetraploid chromosome 
complement and display a morphology, growth rate, and surface molecules expression patterns 
characteristic of ES cells. Examination of genome-wide transcriptional changes, allele-specific 
gene expression and DNA methylation shows that the fibroblast genome is reprogrammed to near 
completion towards an embryonic state (Cowan et al., 2005). Further, differentiation of ES-
fibroblasts hybrids in vivo produces cell types from each germ layer. These results support the 
mouse studies and show that human ES cells can reprogram differentiated nuclei.  
 Cell fusion systems provide tools for investigating mechanisms of reprogramming. 
Epigenetic analyses of the somatic cell genome following fusion with ES cells have confirmed 
the ability of ES cells to reprogram DNA methylation and histone modification patterns (see e.g. 
(Do et al., 2006; Do et al., 2007; Do et al., 2008; Do et al., 2009a; Do et al., 2009b; Han et al., 
2008; Kimura et al., 2004)). These changes are compatible with acquisition of a pluripotent state. 
Notable changes were the CpG demethylation of Oct4 and Nanog regulatory regions and 
acquisition of a histone marks compatible with transcriptional activation of these genes. As 
illustrated in this thesis, such changes were also noted in our own nuclear reprogramming 
studies. An additional remarkable feature of nuclear reprogramming is reactivation of the 
inactive X chromosome in the somatic cell, a hallmark of the pluripotent state (Do et al., 2009a).  
 Despite these successes, a limitation of cell fusion-mediated reprogramming is that the 
tetraploid state of the reprogrammed cell makes epigenetic analyses of the reprogrammed 
somatic genome challenging. This can be dealt with at the sequence level (e.g., under analysis of 
DNA methylation by bisulfite sequencing) by taking advantage of polymorphism between the ES 
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and the somatic cell (Cowan et al., 2005) but limits the analysis to restricted genomic sites. 
Persistence of the ES cell genome is also undesirable for therapeutic applications. Targeted 
elimination of chromosomes from mouse somatic-ES cell hybrids once reprogramming of the 
somatic genome is completed has been reported (Matsumura et al., 2006), however efficient 
elimination of all ES cell chromosomes remains challenging.  
 
3.3. Reprogramming somatic cells with extracts  
SCNT and somatic-ES cell hybridization have provided a rationale for the development of egg or 
cell extracts for reprogramming cells (Fig. 8C), because extracts should contain all necessary 
“reprogramming factors”. Two advantages of extract-mediated reprogramming are the absence of 
introduction of ES cell chromosomes into the target cell, and the possibility of identifying 
reprogramming factors by manipulation of extract components.  
 Nuclear and cytoplasmic extracts from several cell types have been developed, which 
elicit changes in cell fate to various extents (Collas and Håkelien, 2003). Prior to the start of this 
thesis work, our laboratory developed a procedure to turn one differentiated cell type into another 
differentiated cell type (Håkelien et al., 2002). The approach involves the reversible 
permeabilization of a somatic cell with the bacterial toxin Streptolysin O (SLO), which cluster 
cholesterol in the plasma membrane, exposure of the permeabilized cells to the “reprogramming 
extract” for a defined period of time, and calcium-mediated resealing of the extract-treated cells 
(Fig. 8C). Using this approach, the group has shown that epithelial cells treated with extract of 
Jurkat T cells can take on T cell properties, including expression of T cell-specific genes, 
chromatin remodeling at a T cell-specific locus and induction of T cell signaling pathways 
including secretion of interleukin 2 (Håkelien et al., 2002; Håkelien et al., 2005) (Fig. 9).  
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Fig.  9. Indications of reprogramming of epithelial 293T cells in extract of Jurkat T cells. (A) 293T cells treated with 
an extract of activated Jurkat T cells, as opposed to (B) an extract of 293T cells, causes cells to bind beads (brown 
spots) bearing anti-CD3 and anti-CD28 antibodies (shown in the enlargement; compare pictures in (A) and (B)). 
Antibody-bound cells can be separated from unbound cells (Immuno-selection). Immunolabeling of antibody-bound 
and released cells confirms the expression of CD3 and CD28 antigens on the cell surface (Immunodetection). The 
sorted cells also display T cell-specific genes, as shown by quantitative RT-PCR. Data compiled from (Håkelien et 
al., 2005). 
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 A similar strategy has shown induction of cardiomyocyte functions in human adipose 
stem cells using extracts of rat fetal cardiomyocytes (Gaustad et al., 2004), and in another 
laboratory, the differentiation of mouse ES cells into pneumocytes using mouse pneumocyte 
extracts (Qin et al., 2005). Nonetheless, the long-term stability of the new program remains an 
issue (see Discussion).  
 Cell extracts may also be useful for reprogramming cells to pluripotency. A first example 
is the induction of dedifferentiation with extracts of regenerating newt limbs (McGann et al., 
2001). When continuously exposed to cultured differentiated C2C12 myotubes, these extracts 
promote cell cycle reentry and approximately half of these continue proliferating as 
mononucleated cells. This is accompanied by a downregulation of muscle-specific markers in 
some of the myotubes. These findings imply that the dedifferentiated phenotype is maintained 
even after removal of the extract, suggesting that reprogramming events have taken place.  
 As anticipated from SCNT work in Xenopus (Byrne et al., 2003; Simonsson and Gurdon, 
2004), extracts of Xenopus eggs can also induce expression of pluripotency markers in 293T cells 
and primary leukocytes while downregulating differentiation markers (Hansis et al., 2004). 
However, reprogrammed leukocytes have a limited life span and do not express surface markers 
characteristic of ES cells, so as observed with extract of other cell types, reprogramming under 
these conditions seems to be partial. Xenopus egg extract-treated porcine fibroblasts showed 
morphological changes, expression of Oct4 and Sox2, and deacetylation of H3K9 (Miyamoto et 
al., 2007). The ability of the Xenopus egg extract to reactivate Oct4 was also shown by EGFP 
expression in bovine fetal fibroblasts transformed by the Oct4-EGFP construct (Miyamoto et al., 
2007). Interestingly, deacetylation of H3K9 also occured in non-permeabilized porcine 
fibroblasts (Miyamoto et al., 2007), suggesting that reprogramming also can take place in non-
permeabilized cells. This was also the case in a very recent study where non-permeabilized 
mouse fibroblasts exposed to fish-egg extract (Zhu et al., 2009) reactivated Oct4 and Nanog, 
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were able to differentiate into a variety of cells, and to induce teratoma formation while the 
genomic imprinting status of insulin-like growth factor II (Igf2) and H19 was stable (Zhu et al., 
2009). When using SCNT, oocytes in metaphase II (mII) have shown to be most efficient 
whereas germinal vesicle (GV) oocytes are considered to be inadequate for use as recipients (Gao 
et al., 2002). Surprisingly, the opposite seems to be the case when it comes to extract-treatment 
because somatic cells exposed to mammalian mII-oocyte extract do not show any clear signs of 
reprogramming after culture and do not express Nanog after day 7 (Miyamoto et al., 2009). In 
contrast, mammalian GV oocyte-extract activates pluripotency genes as well as induces expected 
histone modification events, suggesting that MII and GV oocytes have different roles in nuclear 
reprogramming (Miyamoto et al., 2009). Mammalian cross-species experiments have also been 
reported where human somatic cells have been reprogrammed by mouse ES cell extract to 
reexpress Oct4, Sox2, c-Myc and Klf4 (Bru et al., 2008). This was associated with increased 
recruitment of RNA polymerase II (RNA pol II) at the promoters, removal of lamin A/C and loss 
of repressive H3 modifications on Nanog and Oct4 promoters. Alltogether, this shows that 
reprogramming of somatic cells using extracts is an efficient way of creating high potency cells 
without genetically altering them.  
 Today, many laboratories use the method for reprogramming cells with extracts based on 
the work done in our lab (Bru et al., 2008; Miyamoto et al., 2007; Miyamoto et al., 2009; Zhu et 
al., 2009). We show in this thesis that extracts of ES or EC cells can provide regulatory 
components required to direct a nuclear program characteristic of the pluripotent cell (Papers I, 
III). Changes in cell fate are accompanied by changes in DNA methylation and histone 
modifications on developmentally-regulated genes, indicating that functional epigenetic of the 
somatic genome can also occur in this way (Paper II).  
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3.4. Reprogramming by transduction of defined pluripotency factors 
The transcription factors Oct4, Sox2, Klf4 and c-Myc have been reported to reprogram primary 
mouse or human fibroblasts in culture (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). 
To induce pluripotency, combinations of first 24, then 10, then 4 factors normally expressed in 
ES cells were co-transduced in fibroblasts using retroviral vectors, each bearing one transgene 
(Fig. 8D). Oct4 and Sox2, have been known to be required for induction and maintenance of self-
renewal and pluripotency in ES cells (Mitsui et al., 2003; Pesce and Scholer, 2000). 
Overexpression of Nanog, however, another central component of self-renewal and pluripotency 
was against all expectations not necessary. It turns out that endogenous Nanog is activated in the 
transduced cells because Klf4 represses p53, which in turn represses Nanog upon differentiation 
of ES cells (Lin et al., 2005). A drawback of Klf4 overexpression, however, is that it also 
activates the tumor suppressor p21CIP1 and abolishes cell proliferation. Overexpression of c-Myc, 
however, is there to suppress expression of p21CIP1. So a balance between Klf4 and c-Myc is in 
all likelihood necessary to generate stable reprogramming in induced pluripotent stem (iPS) cells 
(Takahashi and Yamanaka, 2006).  
iPS cells display all indicators of pluripotency. Cells are morphologically similar to ES 
cells, display a transcription profile nearly identical to that of ES cells, express ES cell surface 
markers and contribute to all germ layers in teratomas and in chimeras (Takahashi and 
Yamanaka, 2006). Importantly, adult fibroblasts have been shown to be able to generate a mouse 
with its genetics entirely derived from the fibroblast (Boland et al., 2009; Zhao et al., 2009)}. Of 
note, followup studies based on induction of pluripotency factors have shown that the number of 
transduced factors can be reduced to two or even one, when using target cell types already 
expressing some of these pluripotency factors (see e.g., (Feng et al., 2009a; Kim et al., 2008; 
Kim and Buratowski, 2009; Li et al., 2009; Utikal et al., 2009a)). 
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 Nevertheless, limitations have until recently prohibited the use of first generation iPS 
cells in a clinical setting. 1) viral-induction of reprogramming factors creates risks of stable 
transgene integration into the genome; 2) c-Myc and Klf4 are oncogenic; and 3) production of 
iPS cells is inefficient with reprogramming often incomplete. For iPS cells to fulfill their 
potential in cell therapy, disease modeling or drug screening, non-genetic strategies have been 
devised. These include the use of inhibitors or epigenetic modifiers and signaling pathways that 
can replace the reprogramming factors or efficiently enhance genetic reprogramming (Feng et al., 
2009b) (Fig. 10). A promising approach involves the use of small molecules for reprogramming 
(Table 2). Notable examples include the DNMT inhibitors 5-azacytidine (5aza) or RG108, which 
rescue cells trapped in a partially reprogrammed state (Mikkelsen et al., 2008). The histone 
deacetylase inhibitors (HDACi’s) trichostatin A (TSA), valproic acid (VPA) or suberoylanilide 
hydroxamic acid (SAHA), the histone methyltransferase (HMT) inhibitor BIX, or the L-calcium 
channel agonist BayK also enhance reprogramming efficiency (Fig. 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Chemical-induced full reprogramming to pluripotency. Taken from (Feng et al., 2009b). 
 
 
Inhibitors (together referred to as ‘2i’) of the mitogen-activated protein kinase (MEK) and 
glycogen synthase kinase-3 (GSK3) pathways, involved in maintaining pluripotency in ES cells, 
have also been shown to elicit complete reprogramming of partially reprogrammed cells (Silva et 
al., 2008). Fibroblasts were also reprogrammed into iPS cells by combining 2i with A-83-01, an 
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inhibitor of TGF- signaling. These studies demonstrate the interplay between small molecules 
and epigenetic factors in inducing pluripotency.  
 
Table 2. Chemicals used to replace core reprogramming factors or enhance reprogramming 
 
Chemical Function Core factors used* Cell type 
5aza DNMT inhibitor OSKM Mouse fibroblast 
RG108 DNMT inhibitor OSKM Mouse fibroblast 
TSA HDAC inhibitor OSKM Mouse fibroblast 
VPA HDAC inhibitor OSKM, OSK, OS Mouse / human fibroblast 
SAHA HDAC inhibitor OSKM Mouse fibroblast 
BIX-01294 G9a HMT inhibitor OK Mouse fibroblast / neuronal progenitors 
BayK8644 L-Ca2+ channel agonist OSK Mouse fibroblast 
Dexamethasone Steroid glucocorticoid OSK/ OSK Mouse / human fibroblast 
PD0325901  + 
CHIR99021 (2i) 
MEK inhibitor  
GSK3 inhibitor 
OK Mouse neuronal progenitor cells 
A-83-01 TGF- inhibitor OSK Rat liver progenitors / human fibroblasts 
  
* O, Oct4; S, Sox2; K, Klf4; M, c-Myc  
 
 
 A prime application of the iPS cell technology in humans is the generation of disease- and 
patient-specific pluripotent cells suitable for the study of disease mechanisms in vitro and drug 
testing. Several such models have been recently published. Particularly relevant are generation of 
a large number of patient-specific iPS cell (Park et al., 2008), treatment of sickle cell anemia in a 
mouse model with autologous iPS cells (Hanna et al., 2007) and generation of motor neurons 
from a child with spinal muscular atrophy, with the demonstration of restoration of a defect 
phenotype in diseased iPS cell-derived motor neurons by treatment with VPA (Ebert et al., 
2009). These and other studies demonstrate the usefulness of iPS cells in drug testing and disease 
study.  
 The area of nuclear reprogramming to pluripotency has literally ‘exploded’ while work 
reported in this thesis was ongoing, in particular with the advent of the ‘iPS technology’ and its 
recent derivatives. Work presented here relies on a cell-free, non-genetic approach initially 
developed in the laboratory to initially induce a ‘transdifferentiation’ of epithelial 293T cells into 
other types of differentiated cells (Håkelien et al., 2002). The approach has been tailored to 
produce cells with ES-like properties (Papers I-III). 
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AIMS OF THE STUDY 
 
A differentiated cell can be reprogrammed to pluripotency by nuclear transplantation into 
oocytes, fusion with an ES cell or forced expression of pluripotency genes. Some of these genes 
can be substituted by proteins, suggesting that reprogramming cells by non-genetic means is 
possible. We rationalized that introduction into a target cell, of factors derived from pluripotent 
cells in the form of an extract could epigenetically and functionally reprogram the target cell.  
Aims of this study were therefore to: 
  
1. Determine whether extracts from EC cells and ES cells are capable of reprogramming 
epithelial cells and fibroblasts to a pluripotent-like state. 
2. Intitiate a characterization of components in ES cell extract that contribute to turning on 
Oct4 expression in extract-treated cells 
3. Demonstrate that EC cell extract treatment elicits a reprogramming of DNA methylation 
and histone modifications on genes associated with pluripotency 
4. Carry out a proteomic characterization of the nuclear reprogramming process in epithelial 
cells 
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SUMMARY OF PUBLICATIONS 
Paper I:  
Taranger, C.K., A.Noer, A.L.Sørensen, A.M.Håkelien, A.C.Boquest, and P.Collas. 2005. 
Induction of dedifferentiation, genome-wide transcriptional programming, and epigenetic 
reprogramming by extracts of carcinoma and embryonic stem cells. Mol. Biol. Cell. 16, 5719-
5735 
 
Reprogramming of a differentiated cell into a pluripotent cell may have long term applications in 
regenerative medicine. We report in this paper the induction of dedifferentiation, associated with 
genome-wide programming of gene expression and epigenetic reprogramming of an embryonic 
gene, in epithelial 293T cells treated with an extract of human NCCIT carcinoma cells. 293T 
cells exposed for 1 h to extract of NCCIT cells, but not of 293T or Jurkat T cells, form colonies 
that are maintained for at least 23 passages in culture. Microarray and quantitative analyses of 
gene expression reveal that transition from a 293T to a pluripotent cell phenotype involves the 
dynamic upregulation of hundreds of NCCIT genes, concomitant with the downregulation of 
293T genes and of indicators of differentiation such as A-type nuclear lamins. Upregulated genes 
encompass stem cell markers including OCT4 and Oct4-responsive genes. OCT4 activation is 
associated with DNA demethylation in the OCT4 promoter and nuclear targeting of Oct4 protein. 
In 3T3 fibroblasts exposed to an extract of embryonic stem cells, Oct4 activation is biphasic and 
RNA-PolII-dependent, with the first transient wave of Oct4 upregulation being necessary for the 
long term transcriptional activation of Oct4. Genes characteristic of multilineage differentiation 
potential are also upregulated in NCCIT extract-treated cells, suggesting establishment of 
‘multilineage priming’. Retinoic acid triggers Oct4 gene and protein downregulation, activation 
of A-type lamins and nestin, and promotes differentiation towards neurogenic, adipogenic, 
endothelial and osteogenic lineages in vitro. These data indicate that an extract of 
undifferentiated carcinoma cells can elicit differentiation plasticity in a developmentally 
restricted cell type.  
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 Paper II: 
Freberg, C.T., Dahl, J.A., Timoskainen, S., and Collas, P. 2007. Epigenetic reprogramming of 
OCT4 and NANOG by embryonal carcinoma cell extract. Mol. Biol. Cell. 18, 1543-1553. 
 
We reported in our previous paper the reprogramming of epithelial cells by extract of 
undifferentiated embryonal carcinoma NCCIT cells. We show in this paper the reprogramming 
of DNA methylation and histone modifications on regulatory regions of the developmentally 
regulated OCT4 and NANOG genes by exposure of 293T cells to NCCIT cell extract. OCT4 and 
NANOG are transcriptionally upregulated and undergo mosaic CpG demethylation. OCT4 
demethylation occurs as early as week 1, is enhanced by week 2, and is most prominent in the 
proximal promoter and distal enhancer. Targeted OCT4 and NANOG demethylation does not 
occur in 293T extract-treated cells. Retinoic acid-mediated differentiation of reprogrammed cells 
elicits OCT4 promoter remethylation and transcriptional repression. Chromatin 
immunoprecipitation analyses of lysines K4, K9 and K27 of histone H3 on OCT4 and NANOG 
indicate that primary chromatin remodeling determinants are acetylation of H3K9 and 
demethylation of dimethylated H3K9. H3K4 remains di- and trimethylated. Demethylation of 
trimethylated H3K9 and H3K27 also occurs; however, trimethylation appears more stable than 
dimethylation. We conclude that a central epigenetic reprogramming event is relaxation of 
chromatin at loci associated with pluripotency in order to create a conformation compatible with 
transcriptional activation.  
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 Paper III: 
Pewsey, E., Bruce, C., Georgiou, A.S., Jones, M., Baker, D., Ow, S.Y., Wright, P.C., Freberg, 
C.T., Collas, P. and Fazeli, A. Proteomic analysis of epithelial cells reprogramming in cell-
free extract. Mol. Cell Proteomics. 8, 1401-1412. 
 
We report in this publication the proteomic profile of epithelial cells reprogrammed to a more 
pluripotent state using undifferentiated embryonal carcinoma cellular extracts. 293T cells were 
reversibly permeabilised with Streptolysin O, transiently incubated in extract of NCCIT cells or, 
as a control extract of 293T cells, resealed and cultured. OCT4 and SOX2 gene expression was 
upregulated in NCCIT extract-teated cells relative to control cells, while there was no alteration 
in DNMT3B gene expression. Thirty percent of NCCIT extract-treated cells were positive for 
SSEA-4 and karyotyping confirmed their 293T origin, excluding the possibility of contamination 
from NCCIT cells. Two-dimensional PAGE revealed ~400 protein spots for each cell type 
studied. At least 10 protein spots in the proteome of NCCIT extrat-treated cells had an expression 
profile similar to NCCIT and remained unaltered in control cells. These proteins were identified 
using tandem mass spectrometry and include 78 kDa glucose-regulated protein precursor and 
Tropomyosin alpha-3 chain. This study constitutes to our knowledge the first report on the 
proteomic characterization of the nuclear reprogramming process. 
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DISCUSSION 
This thesis reports the reprogramming of function of somatic cells by transient exposure to a 
cytoplasmic and nuclear (whole-cell) extract from pluripotent cells. In light of previous work in 
our laboratory on transdifferentiation attempts using extracts from differentiated cells to redirect 
somatic cell fate (Håkelien et al., 2002; Håkelien et al., 2005; Landsverk et al., 2002), we set out 
to investigate whether extracts from pluripotent cells would de-differentiate cells and induce 
pluripotency. Altogether, morphological observations, gene expression microarray and RT-
qPCR, immunolabeling, in vitro differentiation assays, epigenetic alterations such as DNA 
methylation pattern and changes of histone modifications, as well as changes in surface markers 
and protein expression analysed by 2D gel electrophoresis and mass spectrometry are consistent 
with long-lasting alterations in somatic cell fate as a result of transient treatment with EC or ES 
cell extracts. Factors affecting efficiency of reprogramming, the nature of extract-derived 
reprogramming molecules, how epigenetic reprogramming of pluripotency-associated genes 
might take place in our system, and the extent of reprogramming to the pluripotent state, are 
discussed.  
 
1. Factors affecting the efficiency of reprogramming cells with extracts 
Reprogramming of a somatic nucleus in an amphibian egg has been shown to depend on the 
exchange of factors between the somatic nucleus and the egg cytoplasm (reviewed in (Kikyo and 
Wolffe, 2000). In heterokaryons and hybrid cells, factors from the “donor” cell, e.g. the ES cell), 
co-exist with the target cell nucleus, leading to transcriptional and epigenetic reprogramming 
(Tada et al., 1997). Moreover, the other known nuclear reprogramming approaches rely on the 
transfer of reprogramming factors and accompanying molecules (such as viruses, transposons, 
cytokines, small molecules) through the target somatic cell membrane (Huangfu et al., 2008; Shi 
et al., 2008; Woltjen et al., 2009). In contrast, removal of the ES cell genome from ES cell-
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fibroblast heterokaryons within 24 h of fusion is not conducive of reprogramming (Pralong et al., 
2006). Collectively, this shows that for reprogramming to occur, it is essential that the 
responsible factors gain access to the donor cell genome.  
Permeabilization of the cell membrane using the bacterial (Streptococcus pyogenes) toxin 
Streptolysin O (SLO) allows for the delivery of extract components across the cell membrane. 
Our laboratory has earlier tried other plasma membrane-disrupting approaches such as gentle 
physical sharing with acid-washed beads or passing through a needle, or submicromolar 
concentrations of non-ionic detergents such as Nonidet P-40 or digitonin, without success: in 
short, cells were either not permeabilized, permeabilized in very low proportion, or irreversibly 
lysed (A.-M. Håkelien, K. Gaustad and P. Collas, unpublished data). Thus, SLO has been the 
reagent of choice for reversible taget cell permabilization for this project. SLO is a cholesterol-
binding toxin that forms pores in the plasma membrane (Bhakdi et al., 1985; Bhakdi et al., 1993). 
Permeabilization is reversible as resealing can occur in a Ca2+-dependent pathway (Walev et al., 
2001). SLO-mediated permeabilization has proven valuable for delivery of macromolecules to 
cells (Fawcett et al., 1998; Walev et al., 2001) as pore size formed by SLO can be up to 30 nm in 
diameter (Bhakdi et al., 1993). This allows for uptake of proteins of over 100 kDa (Walev et al., 
2001). Futhermore, endotoxins delivered to SLO-permeabilized cells remain biologically active 
(Walev et al., 2001); hence, import through SLO-induced pores does not appear to affect protein 
activity. Moreover, properties other than molecular size (e.g. molecule conformation) are 
important for uptake through SLO-formed pores as Fura-2 free acid (Mr 832) is not taken up by 
permeabilized cells (Fawcett et al., 1998). Consequently, permeabilization elicited by SLO 
appears to impose a restriction on the nature of molecules to be taken up.  
Our protocol does not include any removal of excess SLO after binding of SLO to 
cholesterol and prior to the pore-forming step, and therefore some SLO can enter the cell. 
However, intracellular membranes, such as the endoplasmatic reticulum/nuclear envelope 
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network, contain much lower amounts of cholesterol than the plasma membrane and thus serve 
as poor substrates for SLO (Fawcett et al., 1998). Because diffusion through SLO-formed pores 
is expected to be bi-directional, soluble cytosolic components may leak out. We have observed 
that SLO-treated cells incubated in extract have higher survival rate than cells incubated in 
culture medium only. Cell survival could be greatly improved however when bovine serum 
albumin was added to the culture medium (A.M. Håkelien, unpublished observations), arguing 
that intracellular molecular crowding and/or maintenance of and isotonic osmonit pressure within 
the permeabilized cells was beneficial.  
Recently, a study showing reprogramming of mouse fibroblasts to induced multipotent 
stem (iMS) cells using fish oocyte extracts, based on work performed in our lab, showed that the 
cells were induced to express pluripotency markers regardless of plasma membrane 
permeabilization (Zhu et al., 2009). Without SLO permeabilization, a passive entry of large 
molecules, like Oct4, Sox2 and Nanog is unlikely and theoretically only small molecules can 
enter the cells. However, it is possible that large molecules are actively transported into the cells, 
but this has not been examined. Moreover, the fish oocyte extracts used in these experiments lack 
the additional ATP generating system, which we add to our extracts to improve the active 
transport of factors across the membranes and to increase the chromatin remodelling. There is a 
possibility that membrane receptors and intracellular transport molecules cooperate in delivering 
information from the new surroundings of the cells. It is known that cell microenvironment is 
able to change cell genotype and epigenotype, and the best example of that is the reprogramming 
of intact cells when inserted into enucleated oocytes (Chang et al., 2003; Lin et al., 2008). In 
either case, a detailed analysis of the extracts used for reprogramming should be performed. It 
will be of interest to determine which factors or fractions of the extract are responsible for the 
various events during reprogramming, whether the extract contains inhibitors that can be 
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excluded, and whether the extract reprograms cells using different active factors than the known 
factors used for creating iPS cells. 
The extracts used in the reprogramming experiments described in this thesis contain 25-
35 mg/ml protein (Bradford assay). Experiments using NCCIT extract with 12 mg/ml protein or 
less did not show signs of reprogramming other than upregulation of the REX1 (ZFP42) gene in 
293T cells (our unpublished data). In addition, it was recently shown that fish egg extract at <25 
μg/ml protein was able to reprogram mouse fibroblasts and that the “mild” reprogramming 
observed (see below) lead to lower cell death (Zhu et al., 2009). However, the treated cells 
showed stronger Oct4 labeling and a higher rate of colony formation after exposure to extract 
with higher protein concentration (10 mg/ml) (Zhu et al., 2009).  However, a lower protein 
concentration also means a more diluted extract, hence a less viscous extract with an altered 
hydration status, which in our hands has showed to be highly important for the success of 
reprogramming (reduction of protein concentration was achieved by diluting concentrated 
extracts prepared as described in Paper I 1:1 with H2O). The results from Zhu et al. (2009) are 
therefore consistent with our findings that dilution of the extract gives a higher survival rate than 
a non-diluted extract. Nonetheless, whether the beneficial effect of dilution on cell survical and 
reprogramming efficiency was due to a more appropriate concentration of (as yet undefined) 
factors or to reduced osmotic pressure upon exposure of the target cells to the extract, remains 
uncertain. Notably, NCCIT extracts prepared in this work were ~500-600 mOsM prior to dilution 
in MilliQ H2O. This proved to be rather detrimental despite the permeabilized (and there “open” 
or leaky state of the target cells). Indeed, maintaining the extract in the range of 280-300 mOsM 
elevated survival rate and reprogramming efficiency (Paper I). Thus, the combination of keeping 
the highest possible protein concentration and the balanced hydration status is most efficient 
when reprogramming cells using extracts. 
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2. What component(s) in the extract might elicit nuclear reprogramming? 
Induction of reprogramming by fusion with ES or EC cells or by exposure to pluripotent cell 
extracts indicates that the ES and EC cell contains the factors necessary to initiate this event. 
Experiments reported in Paper I together with recent published advancements point to possible 
candidates.  
Protein components are likely candidates because treatment of ES cell extract with 
Proteinase K or trypsin abolishes the short- and long-term expression of Oct4 in target cells 
(Paper I). Moreover these proteins are heat-labile because heat treatment of the extract also 
abolishes Oct4 expression. The nature of proteins implicated in extract-based induction of 
pluripotency is currently unknown (see below). Nonetheless, a likely candidate is the BRG1 
component of the SWI-SNF complex, whose depletion from Xenopus egg extract abolishes 
reprogramming (Hansis et al., 2004). Similar work in our laboratory also suggests that BRG1 is 
also implicated in reprogramming NIH3T3 cells in ES cell extract (our unpublished data) It is 
likely, therefore, that chromatin remodeling enzymes play an active role in the reprogramming 
process.  
 Could nucleic acids mediate extract-based reprogramming? This possibility has been 
examined to show by PCR that extracts contain no detectable genomic OCT4 DNA, and that 
DNase treatment of extracts does not affect Oct4 detection in the target cells (Paper I). Thus, it is 
unlikely that DNA transfer is a component of the reprogramming mechanism. It is possible, 
however, that RNAs are implicated. RT-PCR amplification of various transcripts indicates that 
the NCCIT extract contains RNAs; this was also evidenced by RNase treatment of the extract 
followed by agarose gel electrophoresis (our unpublished data). Thus, there is a formal 
possibility for transfer of RNAs from the extract into the permeabilized cells.  
Whether RNAs of extract origin play a role in reprogramming remains to be thoroughly 
investigated. Previous work has shown that RNase A-treated T cell extract was able to mediate 
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expression of T cell markers in 293T cells (Hakelien and Collas, 2002), and similarly, ES cell 
extract treatment with RNase A elicits the same pattern of Oct4 protein expression in target cells 
as untreated extract (Paper I). Further, pretreatment of fish oocyte extracts with RNase did not 
significantly alter efficiency of fibroblast reprogramming of to iMS cells (Zhu et al., 2009). This 
would suggest that mRNAs are not essential components of the mechanism of reprogramming. 
Alternatively, it is possible that RNAase treatment did not degrade RNA species that might be 
implicated in the reprogramming process.  
Of note, our extract preparation procedure does not include RNase treatment because it 
might have affected transcription or translation in the target cell. Thus, RNAs may be involved in 
the initial process of dedifferentiation either as templates for translation or through their 
involvement in forming an appropriate chromatin structure (Stevenson and Jarvis, 2003). 
However, the possibility that detection of pluripotency-specific transcripts in reprogrammed 
293T cells is due to mRNA contamination can reasonably be excluded. First, NCCIT extract-
treated cells harbor only approximately half of the number distinct transcripts detected on 
microarrays in NCCIT cells. Second, many transcripts are not detectable before week 2 after 
extract treatment, wich would not be expected from a direct mRNA uptake. Third, the dynamics 
of up- and downregulation of gene expression and the persistence of transcripts for over at least 
50 population doublings in extract-treated cells are inconsistent with uptake of mRNAs as the 
sole source of transcripts detected in these cells. Fourth, many 293T cell genes are 
downregulated after exposure to NCCIT extract, a feature difficult to explain merely by mRNA 
uptake. Lastly, as mentioned above, RNAse A treatment of ES cell extract is compatible with 
long term Oct4 expression and maintenance of an ES cell-like phenotype in NIH3T3 cells. Thus, 
we argue that transcription of pluripotency genes cannot occur as a result of direct mRNA 
uptake, but rather by altered transcription dynamics from the 293T cell genome.  
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It is tempting to speculate that non-coding RNAs, including microRNAs might be 
involved in eliciting nuclear reprogramming. Non-coding RNAs have been implicated in 
regulating expression of target genes by promoting the degradation of transcripts or by binding to 
regulatory sequences on target genes (Clark, 2007; Filipowicz et al., 2008; Jacquier, 2009; 
Mercer et al., 2009; Nesterova et al., 2008)thereby modulating transcription. Small non-coding 
RNAs also play a role in development (Stefani and Slack, 2008). Interestingly, non-coding RNAs 
have also recently been shown to regulate promoter methylation in ES cells by downregulating 
Dnmt3a (Nesterova et al., 2008) Thus, because a single non-coding RNA can have multiple (up 
to several hundreds) targets, it is conceivable that even a small number of such RNAs would 
affect the regulation of many genes, sufficiently to alter cell fate. An interesting approach would 
be to transfect various somatic cell types with a library of ES-cell derived microRNAs or long 
non-coding RNAs and assess any effect on induction of pluripotency.  
Another class of molecules possibly involved in extract-based nuclear reprogramming 
includes small molecules. These would easily be diffusible through pores generated with SLO, or 
could be taken up by intact cells. Earlier work from our laboratory has shown that cyclic AMP 
was likely involved in inducing Oct4 protein expression in cells juxtaposed to embryonic 
blastomeres, within mouse preimplantation embryos (Burnside and Collas, 2002). The effect was 
blocked with a gap junction inhibitor, arguing for a mechanism involving cAMP signaling 
through gap junctions (Burnside and Collas, 2002). A role of small molecules in induction of 
plutipotency is supported by the replacement of some of the established reprogramming factors 
with inhibitors of signaling pathways or epigenetic modifiers (see Introduction).   
 
3. A role of Oct4 in induction of pluripotency? 
The nature of protein factor(s) required for extract-based reprogramming remains currently 
unknown. Our studies however suggest that extract-derived Oct4 is probably not required: 
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immunodepletion of Oct4 and Oct4-associated proteins from ES cell extract maintains the 
biphasic Oct4 expression pattern, including its long-term expression, in the target cells (Paper I). 
This contradicts more recent findings that among the factors shown to be sufficient to elicit iPS 
cell formation (Oct4, Sox2, Klf4, c-Myc), Oct4 seems to be the only one required. Indeed, 
Nanog, Sox2, Klf4, C-myc or Lin28, but not Oct4, have shown to be dispensable (Kim et al., 
2009; Li et al., 2009). That makes Oct4 the only reprogramming factor that to date has not been 
replaced by other factors or drugs. It is however possible that low levels of Oct4 remain in the ES 
cell extract after immunodepletion (even though Western blotting shows undetectable Oct4; 
Paper I) that may be sufficient to elicit reprogramming. Alternatively, the early and short-term 
wave of Oct4 protein induction in the target cell may serve as a “primer” for subsequent long-
term Oct4 expression. Interestingly, we found that transient inhibition of RNA Pol II with DRB 
long enough to inhibit the first wave of Oct4 expression (24 h), also prevented the long-term 
induction of Oct4 (Paper I). This suggests that this first transient induction is necessary for 
subsequent long-term Oct4 expression, and thereby reprogramming, at least in these experiments.  
The time-lapse between extract treatment and detection of Oct4 mRNA and protein after 
1-2 weeks is consistent with the establishment of epigenetic modifications necessary for 
transcriptional activation of Oct4 shown in Xenopus egg extract (Simonsson and Gurdon, 2004). 
Timing of initiation and completion of these changes may vary with the systems investigated. In 
another study, SWI/SNF comlex dependent activation of Oct4 transcription in permeabilized 
somatic cells incubated in Xenopus egg extract occurs after 30 min (Hansis et al., 2004), 
indicating that not only chromatin remodeling events, but also transcriptional activation of a 
silent gene can occur within minutes in vitro. In contrast, when injecting permeabilized cells into 
the germinal vesicle of Amphibian oocytes, OCT4 transcription was not detected until after 2 
days of incubation (Byrne et al., 2003). Also, in ES cell-thymocyte hybrids, an Oct4-GFP 
transgene was activated 2 days after fusion (Tada et al., 2001). Thus the time frame for onset of 
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reprogramming events appears to depend on the system used. Conceivably, timing of Oct4 
expression in reprogrammed cells may be affected by the concentration of reprogramming factors 
required to turn on OCT4, and/or to the duration of exposure of the somatic nucleus to such 
factors. Collectively, these results suggest that induction of Oct4 expression in reprogrammed 
cells elicits a transcriptional activation pathway linked to Oct4 function.  
An interesting observation among 293T cells treated with NCCIT extract in the present 
work is the correlation between down-regulation and disappearance of perinuclear lamin A/C 
staining (a marker of differentiated cells; (Guilly et al., 1990)) and appearance of intranuclear 
Oct4 protein (Paper I). Detection of Oct4 and loss of lamin A/C staining in 60% of extract-
treated cells indicates that the extract is capable of inducing the start of translation of one protein 
and end translation of another. Nonetheless this does not imply that loss of lamin A/C stimulates 
Oct4 induction and vice versa. TSA-induced histone hyperacetylation decreases the amount of 
peripheral heterochromatin. The same pattern is shown in lamin A/C-deficient fibroblasts which 
display reorganization of centromeric heterochromatin (Galiova et al., 2008). Additionally, 
HDAC inhibition compensates for lamin A/C-dependent chromatin reorganization (Galiova et 
al., 2008), suggesting that interactions between lamins and specifically modified histones may 
play an important role in higher-order chromatin organization. These are in turn likely to 
influence transcriptional activity. Whether lamin A/C downregulation occurs before or after 
induction of OCT4 in our system is not known. However, it is tempting to speculate that 
pluripotent cell extract-elicited loss of lamin A/C in target cells leads to rearrangement of 
chromatin domains promoting expression of plrupotency-associated genes. To support this view, 
ES cells, EC cells, and other types of immature cells such as lymphoblasts (Guilly et al., 1990), 
do not express the LMNA gene (encoding lamins A and C). Noteably, differentiation of human 
ES cells starts with the downregulation of Tra-1-60, Tra-1-81 and SSEA-4. Next, and prior to 
downregulation of OCT4, lamin A/C is upregulated (Constantinescu et al., 2006). This does not 
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nessecarily mean that this is accurately reversed during reprogramming. But if this is the 
situation, the early activation of Oct4 may lead to lamin A/C downregulation and further Tra-1-
60, Tra-1-81 and SSEA-4 upregulation. The proteomic analyses of extract-treated cells (paper 
III) show that 30% are positive for SSEA-4, but not for Tra-1-60 or Tra-1-81. Perhaps the 
extract-treated cells have managed to go through the first steps, upregulating OCT4, 
downregulating lamin A/C and upregulating SSEA4 and are on their way to, but was investigated 
prior to, their upregulation of Tra-1-60 and Tra-1-81. 
 
4. Epigenetic mechanisms of reprogramming pluripotency-associated genes 
Epigenetic states of somatic cells and pluripotent cells are different. Histone modifications act in 
concert with DNA methylation to produce epigenetic modifications that regulate the balance of 
expression of pluripotency-associated genes and lineage-restricted genes. Thus, remodeling of 
the epigenome is essential in reprogramming.  
Genes associated with pluripotency and not expressed in differentiated cells are, prior to 
reprogramming, methylated in their promoters (except for CpG island promoters such as SOX2; 
(Barrand and Collas, 2010), show strong enrichment in repressive H3K27me3 and association 
with PcG proteins. During reprogramming, the promoters of these genes are DNA-demethylated 
and lose H3K27me3 so exhibit H3K4me3 (presumably in addition to acetylated epitopes) 
(Amabile and Meissner, 2009). Changes in H3K27me3 are highly significant for the 
reprogramming to iPS cells and suggest an important role for PcG proteins in reprogramming 
(Maherali et al., 2007). Genome-wide mapping studies of human and mouse ES cells divide 
genes into four classes based on their association with either one, two or none of the H3K4me3 
and H3K27me3 marks (Guenther et al., 2007; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et 
al., 2007). The class of genes associated with H3K4me3 only is most actively transcribed in 
pluripotent cells (Mikkelsen et al., 2007) and in mES cells, 60% of these genes have a high 
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proportion of unmethylated CpGs in the promoter region (Fouse et al., 2008). Notably, DNA 
methylation in mES cells primarily takes place on ICP and LCP promoters or on non-CpG island 
regions of HCP promoters (Fouse et al., 2008).  
Reprogramming of somatic cells also requires silencing of certain lineage-specific genes. 
Genome-wide mapping of Oct4, Sox2 and Nanog target genes revealed a large group of genes 
that are co-regulated by these factors in different combinations (Boyer et al., 2005; Loh et al., 
2006). Surprisingly, many of these target genes are not expressed in ES cells. In ES cells, many 
differention-associated genes as well as Oct4, Sox2 and Nanog target genes are silenced by PcG 
complexes and hold the bivalent H3K4me3/H3K27me3. PcG-mediated H3K27 trimethylation 
silences these genes in ES cells; nonetheless, they are primed for expression later during 
differentiation. This is consistent with the fact that pluripotent cells have a much higher amount 
of bivalent domains than have more lineage-restricted cells (Meissner et al., 2008). Interestingly, 
the class of genes associated with neither H3K4me3 nor H3K27me3 contains as much as one 
third of the genes, and of these the majority contain low- ro intermediate CpG content promoters. 
Further, 87% show a methylated proximal promoter and of these 80% are not expressed in mES 
cells (Fouse et al., 2008). In addition, a ChIP-chip study on H3K27me3- and H3K4me3 patterns 
in promoters of 16,500 genes in one iPS cell line found that reprogramming is largely associated 
with changes in H3K27me3 rather than H3K4me3 (Maherali et al., 2007), and failure in 
establishing repressive marks results in incompletely reprogrammed cells (Mikkelsen et al., 
2008; Sridharan et al., 2009). Thus, both activation of pluripotency-associated genes and 
repression of lineage-specific genes are two important events required for, or being a process of, 
complete nuclear reprogramming. 
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5. Epigenetic reprogramming of OCT4 in somatic cells by EC- and ES cell 
extracts 
In ES cells, the OCT4 TSS region contains unmethylated CpGs and is packaged with H3K9ac 
and H3K4me3, consistent with high expression of the gene. Conversely, OCT4 in 293T cells is 
highly CpG methylated, associated with low H3K9ac, high H3K9me2 and H3K27me3, and is not 
expressed. Extracts of pluripotent cells retain the ability to epigenetically reprogram OCT4 in 
293T cells (Papers I-II, (Bru et al., 2008)).  
In the NCCIT-extract system, nine amplicons of the OCT4 region examined by bisulfite 
sequencing (Paper II) included 47 CpGs that were largely methylated in 293T cells and largely 
unmethylated in NCCIT cells. 293T cells treated with NCCIT extract showed mosaic CpG 
demethylation in the OCT4 promoter. It is however not possible at present to determine whether 
some cells exhibited complete demethylation on all OCT4-containing alleles in the entire 
promoter region (as a side note, 293T cells are aneuploid so there might be more than two alleles 
bearing OCT4). However, whole regions within one amplicon are completely demethylated 
compared to 293T cells, indicating that when demethylation occurs, large promoter areas are 
affected. Moreover, differentiation of the reprogrammed 293T cells towards the neurogenic 
pathway showed “whole-amplicon” methylation on OCT4, suggesting that the cells that respond 
to the extract-treatment de-methylate the majority of the OCT4 promoter. 
Interestingly, as reported in another EC cell line (NT2) (Deb-Rinker et al., 2005), region 
of the OCT4 proximal enhancer (PE) show mosaic methylation in NCCIT cells. Further, NCCIT 
extract-treated cells do not show complete demethylation in this region, in contrast to all others 
examined. In mES cells, the Oct4 PE is hypomethylated and the gene highly expressed (Hattori 
et al., 2004). Distal regulatory elements such as enhancers may activate transcription over long 
distances. Their action must be restricted to prevent illegitimate activation of non-target genes. 
An Oct4-GFP transgene not containing the Oct4 PE was reactivated 40-48 h after cell fusion-
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induced reprogramming, wheras the effect of including the PE region was shown by activation 
already within 22 h (Han et al., 2008). Only the PE-containing transgene corresponded to 
endogenous Oct4 activation and DNA demethylation occurring 24 h after fusion. This suggests 
that the PE region may positively regulate Oct4 re-expression (Han et al., 2008) and that 
methylation of this region may affect the potential of the extracts used to reprogram cells to 
pluripotency.  
Oct4 DNA demethylation is required for Oct4 transcription after nuclear transplantation 
into Xenopus oocytes (Simonsson and Gurdon, 2004). Additionally, culture of NIH3T3 cells with 
TSA and/or 5aza showed that both chemicals were necessary for reactivation of Oct4 (Hattori et 
al., 2004). This treatment altered the enhancer/promoter region of Oct4 to become 
hyperacetylated and CpG demethylated (Hattori et al., 2004). This indicates that DNA 
demethylation is required but not sufficient to reprogram expression of Oct4. Activating 
H3K4me3 is crucial for complete reprogramming, especially at the Oct4 and Nanog promoters 
(Mikkelsen et al., 2008). There are only minor differences in the H3K4me3 level between 293T 
cells and NCCIT cells (Paper II). However, an exception is found in the proximal promoter (PP) 
of OCT4 (covered by ChIP primer-pair OCT4E in Paper II) where NCCIT cells and extract-
treated cells show a significantly higher level of H3K4me3 compared to 293T cells and the 
control. Further, bioinformatic analysis of the OCT4 promoter region using Genomatix 
MatInspector (www.genomatix.de) showed a putative overlapping binding site for both CTCF 
and Sp1 in the PP of OCT4 (our unpublished data). The transcription factor Sp1 is activated in 
mouse embryogenesis and activates Oct4 gene expression (Hattori et al., 2004). CTCF physically 
links cohesin to chromatin (Rubio et al., 2008) and is often bound (together with subunit of 
cohesin RAD21 (Hallson et al., 2008)) near the boundaries of regions rich in RNA Pol II and 
H3K4me3 (Wada et al., 2009). Thus, an interaction between Sp1, CTCF and H3K4me3 in the 
regulation of the PP/TSS region of OCT4 is possible. Also, the fact that 293T cells incubated in 
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mES extract induce OCT4 expression starting already after 4 h with the level of OCT4 increasing 
after return to cell culture (Bru et al., 2008) could indicate that ES cell extract triggers OCT4 
activation eaerlier than NCCIT extract (see also Paper I). The OCT4D ChIP amplicon covers this 
locus in our experiments (Paper II) and this region shows a similar H3K9ac level in extract-
treated cells as in NCCIT cells. Our ChIP results also show that the level of H3K9ac in extract-
treated cells in the more upstream region, but yet within the PE (covered by the OCT4C primer 
pair), shows only half the level of H3K9ac as NCCIT cells this region. DNA methylation, as well 
as histone acetylation and methylation, occur concominant with or prior to DNA replication and 
subsequent to cell division (Han et al., 2008). The extract-treated cells divide every 24 h. It is 
thus possible that reprogramming of the epigenome occurs immediately after extract treatment. 
Using an extract of mES cells showed that the re-expression of Oct4 is biphasic, RNA Pol 
II-dependent and occurs as early as 1 h after recovery from the extract with the first peak at 24 h 
(Paper I). This biphasic Oct4 expression could be explained by nuclear uptake of transcription 
factors and chromatin remodelers that promptly target the Oct4 promoter (see Discussion of 
Paper I). However, re-expression of genes can also start with incomplete elongation at first, then 
complete elongation after some time (Wada et al., 2009). Focusing on the first cycle of 
transcription after re-expression of five long human genes, an accumulation of RNA Pol II was 
seen at the TSS. These sites also contain boundaries marked with RAD21/CTCF binding. 
Knockdown of RAD21 abolished this accumulation suggesting that elongation by RNA Pol II 
can be regulated by an epigenetic mechanism (Wada et al., 2009). Alternatively, as a result of 
RNA Pol II stalling at sites where RAD21/CTCF are bound, the second wave of Oct4 can be 
expressed some time after extract-treatment. This suggests a link between RNA Pol II, H3K4me3 
and other factors bound close to the Oct4 TSS. A map of the histone methylations in the human 
genome was aligned with a map of CTCF binding sites (Bao et al., 2008). These authors found 
that the CTCF binding sites reside at the boundary between H3K4me3 and H3K27me3. It is 
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tempting to speculate that when PcG complexes and H3K27me3 are no longer present on the 
promoter, H3K4me3 will have a function in eliminating CTCF bound silencing of the gene, 
allowing RNA Pol II to elongate the gene. Stalling at the TSS may be different in a possible 
heterogenous population of donor cells and make the biphasic pattern of gene expression in the 
reprogrammed cells.  
 
6. How complete and stable is extract-based reprogramming? 
An issue under current debate is the extent to which induction (or maintenance) of pluripotency 
can be relied upon by mere morphology of cell colonies. Mouse and human ES cell colonies 
display distinct morphologies though growth in well-delimited “islands” is a common 
characteristic. Differentiation is often manifested by changes in cell shape at the ediges of the 
colonies. Colonies of distinct morphologies have also been reported during the generation of 
mouse and human iPS cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). 
Nonetheless, identification of reprogrammed colonies based on morphology among heterogenous 
types of colonies has been reported (Meissner et al., 2007; Sridharan et al., 2009; Wernig et al., 
2007). Delayed onset of selection for reprogrammed cells has been shown to be a critical factor 
to obtain fully reprogrammed cells, and pluripotent colonies have been successfully selected 
solely based on morphology (Blelloch et al., 2007; Meissner et al., 2007; Wernig et al., 2007) 
Interestingly, hES colonies form a flat monolayer, while mouse pluripotent colonies form thicker, 
multilayered colonies (Maherali and Hochedlinger, 2008). The morphology of the pluripotent 
reprogrammed cells should be round colonies with smooth edges. A recent live imaging study 
comparing ES cells, iPS cells and partial iPS cells characterized three types of colonies (Chan et 
al., 2009). Analysis of gene expression and epigenetic state showed that colonies of type I and II 
resembled intermediate stages of reprogramming while colonies of type III contained true iPS 
cells (Fig. 11).  
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Fig. 11. Three types of colonies in cultures 
of human iPS cells. (A) Phase contrast 
examination. (B) DAPI (blue) and Nanog 
(red) staining of colonies shown in (A). 
Taken from (Chan et al., 2009). Truly 
reprogrammed iPS cells are those of Type 
III.  
 
 
We observed a clear difference in morphology of extract-treated cells over time relative to 
293T cells (Paper I; Fig. 1). 293T cells undergo a morphological change when treated with 
NCCIT extract compared to control 293T extract already at week 1, and this change is not 
reversed even after 12 weeks (Paper 1) and beyond (our unpublished data). However, in the first 
4 weeks, our colonies resemble the Type I colonies in this paper (Chan et al., 2009) lacking the 
smooth, round edges of a completely reprogrammed colony (Fig. 11A; Type III). At week 8, our 
colonies round up to become more like Type II/III colonies, and are maintained at least through 
week 12. Notably, NCCIT cell cultures also contain colonies of all three types in addition to 
adherent cells growing like fibroblasts. Thus, an extract of this heterogenous source of cells can 
make the monolayer 293T cells round up to grow in Type II/III colonies. Establishment and 
maintenance of morphology requires the regulated expression of several genes involved in 
cytoskeletal organization, cell adhesion and cell locomotion. Thus, maintenance of round islands 
of reprogrammed cells for >12 weeks of culture shows that extract treatment is sufficient to 
maintain complex features of cell function, including cytoskeletal functions regulating cell shape. 
The increased expression of 78-kDa glucose-regulated protein (GRP78) precursor in 
NCCIT extract-treated cells compared to 293T cells for as long as 12 weeks suggests that GRP78 
is an important component of the reprogrammed cells (Paper III).  GRP78 is localized to the 
endoplasmic reticulum in normal tissues, and functions in Ca  homeostasis and the correct 2+
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folding of proteins (Shani et al., 2008). However, GRP78 is localized to the plasma membrane of 
tumor cells and plays a role in cellular proliferation, motility and survival by blocking the 
antiproliferative effects of TGF- signalling(Gray et al., 2006; Shani et al., 2008). Moreover, 
GRP78 is upregulated at the 2-cell stage and silenced at the blastula stage in early mouse 
development, and knock-out studies have shown that GRP78 is required for cell proliferation and 
protecting the ICM from apoptosis (Luo et al., 2006). GRP78 co-localizes with the 
developmental oncoprotein Cripto (Shani et al., 2008) where GRP78 is required for correct 
Cripto signalling in human tumor, mammary epithelial and embryonic stem cells via both the 
MAPK/PI3K and Smad2/3 pathways (Kelber et al., 2009). The Cripto/GRP78 complex is 
expressed at the surface of hES cells and NCCIT cells and knockdown of GRP78 disrupts Cripto 
effects on Smad2/3 signaling (Kelber et al., 2009). 293T cells also express GRP78, but at very 
low levels and not to the same extent as NCCIT (Paper III, (Shani et al., 2008). However, 293T 
cells do not express endogenous Cripto (Kelber et al., 2009; Shani et al., 2008). It would be 
interesting to know whether the increased expression of GRP78 in extract-treated cells is due to 
initiation of translation of Cripto in these cells. If this is the case, these two proteins could be 
potential candidates for promoting cellular proliferation and maintaining pluripotency in the 
extract-treated cells. 
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CONCLUSIONS AND PERSPECTIVES 
An important remaining question is whether extract-based reprogramming is effective in primary 
cells? Attempts reported in Papers I and II use epithelial 293T cells and NIH3T3 fibrobasts. One 
possibility is that the immortalized or transformed state of NIH3T3 cells creates an environment 
favorable to reprogramming. Support for this view is lent by recent reports that the 
immortalization state of cells to be reprogrammed by viral transduction enhances the efficiency 
of reprogramming by promoting the proliferative state (Marion et al., 2009; Utikal et al., 2009b). 
Furthermore, 293T cells are modified to constitutively express the large tumor-antigen (T-
antigen) of simian virus 40 (SV40). The SV40 large T-antigen is a multifunctional viral protein 
involved in viral and cellular transcriptional regulation, viron assembly, viral DNA replication 
and alteration of the cell cycle (Sullivan and Pipas, 2002). Incidently, it was reported that, when 
used in conjunction with transcription factors such as Oct4 and Sox2, large T could replace Klf4 
and c-Myc in the generation of human iPS cells (Mali et al., 2008). 293T cells already express 
some OCT4 and SOX2 transcripts and might therefore be easier to reprogram than, e.g., primary 
fibroblasts. Preliminary work from our laboratory supports this view.  
 Extract-based reprogramming constitutes an attractive method elucidating molecular 
mechanisms of reprogramming. Experimental approaches and results from Paper I indicate that 
the levels of some extract factors can be manipulated, for example by immunodepletion. It 
should also be possible to prepare extracts from mES cells with a gene knock-out for potentially 
critical components, such as Dnmts or histone methyltransferases, and thereby deermine the 
effect of these factors on nuclear reprogramming. Conversely, it is also straightforward to add 
derfine factors to the extract, which migh be expected to enhance reprogramming efficiency. It 
would also be relatively easy to treat target cells prior to, or after (or both), extract treatment with 
e.g., epigenetic modifiers, as discussed above in the iPS system. One migh hope that such 
combinations will assist in reprogramming primary cells. This option would be attractive in a 
 57
therapeutic context because, unlike retroviral-mediated transduction of reprogramming factors 
(the “Yamanaka approach”), extract-mediated reprogramming is non-genetic – and thus may be 
more easily ethically acceptable.  
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Functional reprogramming of a differentiated cell toward pluripotency may have long-term applications in regenerative
medicine. We report the induction of dedifferentiation, associated with genomewide programming of gene expression and
epigenetic reprogramming of an embryonic gene, in epithelial 293T cells treated with an extract of undifferentiated human
NCCIT carcinoma cells. 293T cells exposed for 1 h to extract of NCCIT cells, but not of 293T or Jurkat T-cells, form deﬁned
colonies that are maintained for at least 23 passages in culture. Microarray and quantitative analyses of gene expression
reveal that the transition from a 293T to a pluripotent cell phenotype involves a dynamic up-regulation of hundreds of
NCCIT genes, concomitant with down-regulation of 293T genes and of indicators of differentiation such as A-type lamins.
Up-regulated genes encompass embryonic and stem cell markers, including OCT4, SOX2, NANOG, and Oct4-responsive
genes. OCT4 activation is associated with DNA demethylation in the OCT4 promoter and nuclear targeting of Oct4
protein. In ﬁbroblasts exposed to extract of mouse embryonic stem cells, Oct4 activation is biphasic and RNA-PolII
dependent, with the ﬁrst transient rise of Oct4 up-regulation being necessary for the second, long-term activation of Oct4.
Genes characteristic of multilineage differentiation potential are also up-regulated in NCCIT extract-treated cells,
suggesting the establishment of “multilineage priming.” Retinoic acid triggers Oct4 down-regulation, de novo activation
of A-type lamins, and nestin. Furthermore, the cells can be induced to differentiate toward neurogenic, adipogenic,
osteogenic, and endothelial lineages. The data provide a proof-of-concept that an extract of undifferentiated carcinoma
cells can elicit differentiation plasticity in an otherwise more developmentally restricted cell type.
INTRODUCTION
Differentiated cells are thought to be stably committed to
their fate; however, there is evidence to indicate that dedif-
ferentiation events can take place. Urodele amphibians and
teleost ﬁsh can replace lost anatomical parts by a process of
migration, dedifferentiation, proliferation, and redifferentia-
tion of epithelial cells in the wounded area. Functional re-
programming of differentiated cell nuclei has also been il-
lustrated by the derivation of pluripotent embryonic stem
(ES) cells (ESCs) (Cibelli et al., 1998; Munsie et al., 2000;
Wakayama et al., 2001; Hwang et al., 2004) and by the live
birth of cloned animals (Wilmut et al., 2002; Gurdon and
Byrne, 2003) after nuclear transplantation into unfertilized
eggs. Notably, Xenopus eggs can reprogram mammalian so-
matic nuclei to express the POU family member homeodo-
main transcription factor gene Oct4 (Byrne et al., 2003) by a
process requiring DNA demethylation (Simonsson and Gur-
don, 2004). DNA demethylation also occurs after fusion of
mouse thymocytes with embryonic germ (EG) cells (EGCs)
or ESCs (Tada et al., 1997, 2001; but interestingly, only EG
cells are capable of demethylating imprinted genes (Tada et
al., 1997). Similarly, fusion of neuronal progenitor cells (Pells
et al., 2002; Ying et al., 2002) or bone marrow-derived cells
(Terada et al., 2002) with ESCs results in hybrids that express
markers of pluripotency (Pells et al., 2002), contribute to
chimeras (Ying et al., 2002), and form teratomas (Terada et
al., 2002). Similar observations resulted from fusing human
ﬁbroblasts with ESCs (Cowan et al., 2005). Fusion of embry-
onal carcinoma (EC) cells (ECCs) with T-lymphoma cells
also promotes the formation of colonies expressing pluripo-
tent cell transcripts from the lymphoma genome (Flasza et
al., 2003). Thus, components of pluripotent EG, ES, or EC
cells have the potential of eliciting reprogramming events in
a somatic genome.
As an alternative to fusion, somatic nuclear function may
also be altered using nuclear and cytoplasmic extracts, with
the rationale that extracts provide the necessary regulatory
components. Notably, extracts of regenerating newt limbs
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promote cell cycle reentry and down-regulation of myogenic
markers in differentiated myotubes (McGann et al., 2001).
Furthermore, we have shown that kidney epithelial 293T
cells permeabilized with streptolysin O (SLO) and brieﬂy
exposed to an extract of Jurkat T-cells take on T-cell prop-
erties, including growth in aggregates, chromatin remodel-
ing, expression of T-cell-speciﬁc genes and surface receptors,
secretion of interleukin-2, and stimulation-dependent as-
sembly of the interleukin-2 receptor (Håkelien et al., 2002,
2005; Landsverk et al., 2002). Similarly, lysates of cardiomy-
ocytes or insulinoma cells elicit expression of cardiomyocyte
or -cell markers in adipose stem cells (Gaustad et al., 2004)
and ﬁbroblasts (Håkelien et al., 2004), and a pneumocyte
extract was recently shown to induce differentiation of ESCs
into a pneumocyte phenotype (Qin et al., 2005). 293T cells
were also shown to express pluripotency markers such
OCT4 and GCAP and down-regulate a kidney marker after
coculture with extract of Xenopus eggs (Hansis et al., 2004).
Despite these observations, evidence for induction of epige-
netic reprogramming events in large numbers of cells by
extracts is lacking.
Teratocarcinomas are a particular type of germ cell tu-
mors that contain undifferentiated stem cells and differenti-
ated derivatives that can include endoderm, mesoderm, and
ectoderm germ layers (Chambers and Smith, 2004). Undif-
ferentiated carcinoma cells can be cultured to give rise to
lines of ECCs. ECCs form malignant teratocarcinomas when
transplanted into ectopic sites; however, some ECC lines can
also contribute to tissues of the developing fetus when in-
troduced into a blastocyst (Blelloch et al., 2004). Undifferen-
tiated human teratocarcinoma NCCIT cells were established
from a mediastinal mixed germ cell tumor (Teshima et al.,
1988). NCCIT is at a stage intermediate between a seminoma
(a precursor of germ cell tumors) and an embryonal carci-
noma (Damjanov et al., 1993). NCCIT is a developmentally
pluripotent cell line that can differentiate into derivatives of
all three embryonic germ layers and extraembryonic cell
lineages (Damjanov et al., 1993).
This study tests the hypothesis that an extract of undiffer-
entiated somatic cells can elicit dedifferentiation in a somatic
cell line. Based on morphological and immunolabeling ob-
servations, gene expression proﬁling, DNA methylation as-
says, and functional assessments, we show that 293T and
NIH3T3 cells can be programmed by extracts of undifferen-
tiated NCCIT cells or mouse ES cells to acquire characteris-
tics of pluripotency.
MATERIALS AND METHODS
Cells
NCCIT, Jurkat (clone E6-1), and 293T cells (American Type Culture Collec-
tion, Vanassas, MD) were cultured in RPMI 1640 medium (Sigma-Aldrich, St.
Louis, MO) with 10% fetal calf serum (FCS), 2 mM l-glutamine, 1 mM sodium
pyruvate, and nonessential amino acids (complete RPMI 1640 medium).
NIH3T3 Swiss-Albino ﬁbroblasts (American Type Culture Collection) were
cultured in DMEM (Sigma-Aldrich) with 10% FCS, l-glutamine, and 0.1 mM
-mercaptoethanol. Mouse ESCs were isolated from inner cell masses of
strain sv129 blastocysts and plated on mouse ﬁbroblast -irradiated feeder
layers in ESC medium (DMEM, 15% FCS, 0.1 mM -mercaptoethanol, non-
essential amino acids, and 1% penicillin/streptomycin) supplemented with
1000 U/ml (10 ng/ml) recombinant leukemia inhibitory factor (LIF; Sigma-
Aldrich) on gelatin-coated plates. Before harvesting for preparing extracts,
ESCs were passaged and cultured under feeder-free conditions in RPMI 1640
medium containing 10 ng/ml LIF. Cells treated with NCCIT or 293T extract
were seeded at 100,000 cells per well in a 48-well plate and cultured in 250 l
of complete RMPI 1640 medium with antibiotics. Cells exposed to ESC extract
were cultured as ESCs with 10 ng/ml LIF under feeder-free conditions.
Cell Extracts
To prepare NCCIT extracts, cells were washed in phosphate-buffered saline
(PBS) and in cell lysis buffer (100 mM HEPES, pH 8.2, 50 mM NaCl, 5 mM
MgCl2, 1 mM dithiothreitol, and protease inhibitors), sedimented at 400  g,
resuspended in 1 volume of cold cell lysis buffer, and incubated for 30–45 min
on ice. Cells were sonicated on ice in 200-l aliquots using a Labsonic-M pulse
sonicator ﬁtted with a 3-mm-diameter probe (B. Braun Biotech, Melsungen,
Germany) until all cells and nuclei were lysed, as judged by microscopy (our
unpublished data). The lysate was sedimented at 15,000  g for 15 min at 4°C
to pellet the coarse material. The supernatant was aliquoted, frozen in liquid
nitrogen, and stored for up to 9 mo at 80°C. Lysate of 95,583  10,966
NCCIT cells was used to generate 1 l of extract. Protein concentration of the
NCCIT extract was 29.5  4.6 mg/ml (Bradford) and pH was 7.0  0.0 (4
batches). ESC extracts (25–30 mg/ml protein) were similarly prepared from
LIF-adapted ESC cultures. 293T, Jurkat, and NIH3T3 extracts were also pre-
pared as described above. If necessary, extracts were diluted with H2O before
use to adjust osmolarity to 300 mOsM.
SLO-mediated Permeabilization and Cell Extract
Treatment
293T and 3T3 cells were washed in cold PBS and in cold Ca2- and Mg2-free
Hank’s balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA). Cells were
resuspended in aliquots of 100,000 cells/100 l of HBSS, or multiples thereof;
placed in 1.5-ml tubes; and centrifuged at 120  g for 5 min at 4°C in a
swing-out rotor. Sedimented cells were suspended in 97.7 l of cold HBSS,
tubes were placed in a H2O bath at 37°C for 2 min, and 2.3 l of SLO
(Sigma-Aldrich) (100 g/ml stock diluted 1:10 in cold HBSS) was added to a
ﬁnal SLO concentration of 230 ng/ml. Samples were incubated horizontally in
a H2O bath for 50 min at 37°C with occasional agitation and set on ice.
Samples were diluted with 200 l of cold HBSS, and cells were sedimented at
120 g for 5 min at 4°C. Permeabilization was assessed by monitoring uptake
of a 70,000-Mr Texas Red-conjugated dextran (50 g/ml; Invitrogen) in a
separate sample 24 h after resealing and replating the cells (our unpublished
data). Permeabilization efﬁciency under these conditions was 80%.
After permeabilization, cells were suspended at 1000 cells/l in 100 l of
NCCIT, ESC or indicated control extract (or multiples thereof) containing an
ATP-regenerating system (1 mM ATP, 10 mM creatine phosphate, and 25
g/ml creatine kinase; Sigma-Aldrich), 100 M GTP (Sigma-Aldrich), and 1
mM each nucleotide triphosphate (NTP; Roche Diagnostics, Mannheim, Ger-
many). The tube containing cells was incubated horizontally for 1 h at 37°C in
a H2O bath with occasional agitation. To reseal plasma membranes, the
extract was diluted with complete RPMI 1640 medium containing 2 mM
CaCl2 and antibiotics, and cells were seeded at 100,000 cells per well on a
48-well plate. After 2 h, ﬂoating cells were removed, and plated cells were
cultured in complete RPMI 1640 medium.
Microarray Analysis of Gene Expression
Microarrays. Gene expression analysis was performed using Human Genome
Affymetrix U133A GeneChips as described previously (Ji et al., 2004). Total
RNA was isolated using a Stratagene RNA Nanoprep isolation kit, treated
with DNAse I, and puriﬁed with RNeasy Mini columns (QIAGEN, Valencia,
CA).
PCRcDNA. First-strand cDNA was prepared as described previously (Ji et al.,
2004) using a SMART PCRcDNA synthesis kit (BE Biosciences Clontech, Palo
Alto, CA). Brieﬂy, total RNA was reverse transcribed using Superscript II
reverse transcriptase (Invitrogen). cDNA was ampliﬁed by PCR as follows:
95°C for 1 min, 20–30 cycles of 95°C for 15 s, 65°C for 30 s, and 68°C for 3 min.
PCRcDNA was puriﬁed with QIAquick columns (QIAGEN) and ethanol
precipitation and dissolved in H2O.
Biotin-labeling of cRNA. Biotin-labeled cRNA was prepared from PCRcDNA
using a T7 RNA polymerase MEGAscript T7 kit (Ambion, Austin, TX),
puriﬁed with an RNeasy mini kit and fragmented as described (Ji et al., 2004).
Fragmented cRNA was used for hybridization or stored at 80°C.
Hybridization to GeneChips, Labeling, and Scanning. Hybridization was
performed using 50 g of fragmented cRNA at 45°C for 16 h as described
previously (Ji et al., 2004). Chips were washed, stained at 35°C for 15 min with
a phycoerythrin-strepavidin conjugate (Invitrogen), washed, and scanned on
an HP GeneArray scanner Hewlett Packard (Palo Alto, CA).
GeneChip Image Quantiﬁcation and Data Processing. GeneChip images were
quantiﬁed and gene expression values calculated using the Affymetrix Mi-
croarray suite version 5.0 (MAS 5.0; Affymetrix, Santa Clara, CA). Expression
ratios were calculated relative to mean hybridization level of three glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) oligonucleotide spots on the
arrays, and plots were drawn using Microsoft Excel 2002 (Microsoft, Red-
mond, WA).
Polymerase Chain Reaction
PCR ampliﬁcation of the simian virus SV40 large T antigen was performed
using primers 5-GTGGCTATGGGAACTGGAG-3 and 5-CTCTACAGAT-
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GTGATATGGCTG-3, which cover nucleotides 39–265 of GenBank locus
AF168998. PCR conditions were 95°C for 3 min and 30 cycles of 95°C for 45 s,
60°C for 45 s, and 72°C for 45 s followed by 10 min at 72°C. PCR products
were visualized by ethidium bromide staining in a 2% agarose gel.
Reverse transcription (RT)-PCR reactions were carried from 200 to 1000 ng
of total RNA using the Iscript cDNA synthesis kit (Bio-Rad, Hercules, CA).
Quantitative RT-PCR reactions were performed in triplicates on a MyiQ
real-time PCR detection system using either IQ SYBR Green (Bio-Rad) or
ProbeLibrary probes (Exiqon, Vedbæk, Denmark) as indicated in Table S1.
SYBR Green PCR conditions were 95°C for 4.5 min and 40 cycles of 95°C for
30 s, 60°C for 30 s, and 72°C for 30 s, using GAPDH as normalization control.
ProbeLibrary PCR conditions were 95°C for 7 min and 40 cycles of 94°C for
20 s and 60°C for 1 min using ACTB as standard.
Bisulﬁte Sequencing
DNA was puriﬁed by phenol-chloroform-isoamylalcohol extraction or by
using the GenElute mammalian genomic DNA miniprep kit (Sigma-Aldrich).
Bisulﬁte conversion was performed using the MethylEasy DNA bisulphite
modiﬁcation kit (Human Genetic Signatures, Sydney, Australia) as described
by the manufacturer. Converted DNA was ampliﬁed by seminested PCR
using primers (Human Genetic Signatures) speciﬁc for the human OCT4,
LMNA, and LMNB1 genes (see Results), and PCR products were sequenced.
PCR conditions were, for each of the nested PCRs, 95°C for 3 min and 30
cycles of 95°C for 1 min, 50°C for 2 min, and 72°C for 2 min, followed by 10
min at 72°C.
Induction of Neuronal Differentiation
To generate neuronal derivatives (Stewart et al., 2003), cells were seeded in
complete RPMI 1640 medium at 5  105 cells per 90-mm sterile bacterial
culture dish. Suspension cultures were maintained for 24 h before adding 10
M all-trans-retinoic acid (Sigma-Aldrich). Cells were cultured for 3–5 wk in
retinoic acid, replacing the medium every 2–3 d. Subsequently, cell aggregates
were washed in complete RPMI 1640 medium and plated onto poly-l-lysine
(10 g/ml; Sigma-Aldrich)-coated plates in complete RPMI 1640 medium
containing the mitotic inhibitors ﬂuorodeoxyuridine (10 M; Sigma-Aldrich),
cytosine arabinosine (1 M; Sigma-Aldrich), and uridine (10 M; Sigma-
Aldrich).
Mesodermal Lineage Differentiation
Cells were cultured for 21 d in complete RPMI 1640 medium containing 10
M all-trans-retinoic acid and washed in complete RPMI 1640 medium. For
adipogenic differentiation, cells were cultured for a further 21 d in DMEM/
Ham’s F-12 supplemented with 10% FCS, dexamethasone, insulin, and indo-
methacin (Boquest et al., 2005). Cells were ﬁxed with 4% formalin, washed in
5% isopropanol, and stained for 15 min with Oil-Red-O (Sigma-Aldrich). For
osteogenic differentiation, cells were cultured for 21 d in DMEM containing
10% FCS, dexamethasone, -glycerophosphate, and l-ascorbate-2-phosphate
(Boquest et al., 2005). Extracellular matrix mineralization nodules were visu-
alized by Alzarin red staining. Endothelial differentiation was performed as
described previously (Planat-Benard et al., 2004). Brieﬂy, NCCIT extract-
treated cells and controls were harvested by ﬂask shaking and plated at 2 
105 cells per milliliter in 3 ml of methylcellulose (Methocult GF H4434; Stem
Cell Technologies, Vancouver, British Columbia, Canada) and cultured for
7 d.
Immunological Procedures
For immunoﬂuorescence, cells were seeded onto coverslips, ﬁxed with 3%
paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with bo-
vine serum albumin, and hybridized with relevant antibodies. Antibodies
used were a rabbit polyclonal anti-Oct4 (1:1000 dilution; Santa Cruz Biotech-
nology, Santa Cruz, CA), an anti-lamin A/C monoclonal antibody (mAb)
(1:50 dilution; mAb XB10; BAbCO, Covance Research Products, Grand Rap-
ids, MI), and a rabbit polyclonal antibody against a peptide of human B-type
lamins (1:1000) (Chaudhary and Courvalin, 1993). Rabbit polyclonal antibod-
ies (1:200) against neuroﬁlament NF200 were from Sigma-Aldrich, and anti-
NeuN (mAb377) and anti-nestin antibodies (mAb5362; 1:200) were from
Chemicon International (Temecula, CA). Secondary antibodies were Cy2- and
Cy3-conjugated anti-mouse and anti-rabbit antibodies and Cy3-conjugated
anti-rabbit antibodies (1:1000 dilution; Jackson ImmunoResearch Laborato-
ries, West Grove, PA). For direct immunolabeling, cells (300,000) were
incubated with ﬂuorescein isothiocyanate-conjugated mouse anti-human
CD31 or rabbit anti-human CD144 antibodies (1:10 dilution; Serotec, Oxford,
United Kingdom) in 100 l of PBS. After extensive washing in PBS, cells were
ﬁxed with 3% paraformaldehyde before viewing. For Western blotting, anti-
bodies used were anti-Oct4 (1:250), anti-lamin A/C (1:500), anti-lamin B
(1:5000), and anti-tubulin (1:250; Santa Cruz Biotechnology). Immunodeple-
tion of Oct4 from mouse ESC extract was performed using anti-Oct4 antibod-
ies (1:50 dilution) bound to protein A/G-Sepharose beads. After 1-h incuba-
tion in extract at 4°C, bead complexes were removed by sedimentation at
4000  g for 5 min, and a second round of immunoprecipitation was carried
out for 30 min at 4°C. After sedimentation of the beads, an aliquot of the
supernatant was removed for Western blotting, whereas the extract was used
for cell treatment.
Alkaline Phosphatase Assay
Relative intracellular ALP levels were determined using a dot-blot assay. Two
microliters of soluble lysate (15,000 g supernatant at 20 g/l protein) from
indicated cell types were spotted on a dry 45-m nitrocellulose membrane
(Bio-Rad). The membrane was wetted in 50 mM NaCl, 10 mM Tris-HCl, pH
7.0, and ALP was revealed by applying an Alk-Phos Direct detection solution
(GE Healthcare, Piscataway, NJ). Light emission on ﬁlm was quantiﬁed by
densitometry within a linear signal range.
RESULTS
Treatment of 293T Cells with NCCIT Extract Promotes
Colony Formation
293T cells were permeabilized with SLO and exposed for 1 h
to an extract of undifferentiated NCCIT cells. In vitro culture
of extract-treated cells was accompanied by morphological,
immunological, gene expression, and functional analyses over
8–12 wk to evaluate induction of dedifferentiation in two to six
independent experiments. As controls, permeabilized 293T
cells were treated with extract of 293T or Jurkat T-cells.
A ﬁrst result of NCCIT extract exposure was a change in
morphology of 293T cells. Within 2 wk, colonies with de-
ﬁned edges developed and resembled NCCIT colonies (Fig-
ure 1A and B, a–e). This phenotype was maintained for at
least 12 wk in culture, corresponding to 50 population
doublings and 23 passages (Figure 1B, a–e). The phenotype
was not a mere consequence of treatment with any extract as
293T cells incubated in their own extract did not form colo-
nies (Figure 1B, f–j), and 293T cells treated with an extract of
Jurkat cells formed clearly morphologically distinct aggre-
gates (Figure 1C). The latter were reminiscent of Jurkat T-cell
clusters (Håkelien et al., 2005).
The NCCIT Extract Elicits Expression of Oct4 and Oct4-
responsive Genes, Expression of ESC Markers, and
Repression of A-Type Lamins
Expression of the homeodomain protein Oct4, a POU family
transcription factor, is restricted to germ cells, preimplanta-
tion embryos, the epiblast of early postimplantation em-
bryos and ESCs (Chambers and Smith, 2004). As expected,
Oct4 was detected in the nucleus of NCCIT but not 293T
cells (Figure 2A), and identity of the protein was conﬁrmed
by immunoblotting (our unpublished data). One week after
treatment with NCCIT extract,60% of 293T cells displayed
intranuclear Oct4, whereas Oct4 remained undetectable in
293T extract-treated cells (Figure 2, B and C).
We next monitored the loss A-type nuclear lamins, a
marker of differentiated cells (Hutchison and Worman,
2004), from 293T cells. mAbs against lamins A and C (lamin
A/C) decorated the nuclear periphery of 293T but not
NCCIT cells (Figure 2A). In contrast, 1 wk after NCCIT
extract treatment, lamin A/C was undetectable in 60% of
the cells, whereas controls displayed lamin A/C labeling
(Figure 2, B and C). Notably, Oct4 expression paralleled the
loss of lamin A/C expression in the same cells (Figure 2C),
suggesting that these cells were undergoing dedifferentia-
tion. Expression of the ubiquitously expressed B-type lamins
(Hutchison and Worman, 2004) remained unaltered (Figure
2, A–C).
Induction of OCT4 (POU5F1) transcription and loss of
LMNA (lamin A) gene expression over time were demon-
strated by quantitative RT-PCR analysis 4 wk after extract
treatment (Table 1). Several target genes of Oct4 were also
up-regulated, including UTF1, OXT2, REX1, and NANOG.
Interestingly, Oct4 is known to act in cooperation with Sox2
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(Avilion et al., 2003), which was also found to be induced
in extract-treated cells. Additional markers of pluripoten-
tiality (Hoffman and Carpenter, 2005) up-regulated in
NCCIT extract-treated cells and veriﬁed by quantitative
RT-PCR included ALP 1 (APL), STELLA, AC133, CD9,
DMNT3B, and DNMT3L (Table 1). Expression of these
genes was examined and conﬁrmed at 2, 4, and 6 wk after
extract treatment but not examined thereafter (our unpub-
lished data). However, genes such as PDGFR, FGF2,
LEFTY1, LEFTY2, CD135, or CD117 were not expressed in
any cell type or were not altered by extract treatment (our
unpublished data). As expected, transcripts for the ubiq-
uitously expressed lamin B1 (LMNB1) were not altered by
exposure to either extract (Table 1), supporting our im-
munoﬂuorescence observations. None of the pluripotency
marker transcripts examined by real time RT-PCR were
elicited in 293T cells treated with their own extract (our
unpublished data).
Figure 1. Morphology of 293T cells treated
with NCCIT extract. (A) Untreated 293T and
NCCIT cells. (B) 293T cells at indicated time
points after exposure to NCCIT (a–e) or 293T
(f–j) extract. (C) 293T cells 10 d after exposure
to Jurkat extract and cultured under T-cell
growth conditions. Dark spots are Dynal Bio-
tech (Montebello, Norway) magnetic beads
bearing antibodies against CD3 and CD28
surface antigens and used to promote T-cell
expansion. Bars, 30 m.
Figure 2. Immunoﬂuorescence analysis of Oct4, lamin A/C and B-type lamin expression in 293T cells exposed to NCCIT extract. Untreated
NCCIT and 293T cells (A) and 293T cells (B) treated with NCCIT or 293T extract were immunolabeled with antibodies against Oct4, lamin
A/C, and B-type lamins (B, 1 wk after extract treatment). Bars, 20 m. (C) Proportions (mean  SD) of untreated NCCIT and 293T cells and
of extract-treated cells expressing Oct4, lamin A/C, and B-type lamins. Three sets of 200 cells were examined for each marker. *p 	 0.05
compared with 293T cells (t test); **p 	 0.001 compared with 293T cells and 293T cells treated with 293T extract (t test).
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To verify that expression of Oct4 and reduction of A-type
lamin expression did take place in 293T cells, 293T cells
stably expressing an enhanced green ﬂuorescent protein
(EGFP) and a geneticin-resistance gene (293T-EGFP-GenR
cells) were treated with NCCIT extract. After 2 wk of culture
with 700 g/ml geneticin, which kills NCCIT cells (our
unpublished data), the majority of 293T-EGFP-GenR cells
stained positive for Oct4 (Figure 3A). Strong up-regulation
of OCT4, SOX2, and APL and moderate up-regulation of
STELLA (2-fold) gene expression were also detected in
these cells, whereas LMNA was repressed (Figure 3B). We
also took advantage of the large T antigen marker carried by
293T cells. PCR analysis indicated that 293T-EGFP-GenR
cells, but not NCCIT cells, contained the SV40 large T anti-
gen transgene (Figure 3C), conﬁrming that cells expressing
Oct4 were of 293T origin. Of note, karyotyping analysis of
293T cells before and after extract treatment was inconclu-
sive due to the severe aneuploidy and genomic instability of
untreated 293T cells (our unpublished data). 293T cell aneu-
ploidy was expected to occur as a result of large T antigen
transformation, which is known to cause endoreplication
(Wu et al., 2004).
Last, treatment of NCCIT extract with 500 g/ml DNAse
I, which eliminates most detectable DNA in the extract (our
unpublished data), before incubating 293T-EGFP-GenR cells
did not affect induction of OCT4, SOX2, APL, and STELLA
expression or LMNA repression (Figure 3B; DNAse). This
argues that Oct4 expression in 293T cells did not emanate
from intact DNA derived from the NCCIT extract.
The NCCIT Extract Promotes OCT4 DNA Demethylation
Transfer of mammalian cells into the germinal vesicle of
Xenopus oocytes elicits DNA demethylation in the OCT4
promoter, a prerequisite for OCT4 expression in this system
(Simonsson and Gurdon, 2004). The OCT4 region analyzed
in our study was from nucleotide 1433–1671 (GenBank se-
quence AJ297527), encompassing eight potentially methyl-
ated cytosines in CpG dinucleotides between conserved re-
gions CR2 and CR3 in the OCT4 promoter (Nordhoff et al.,
2001) (Figure 4A). Bisulﬁte sequencing showed that this
region was unmethylated in NCCIT but methylated in 293T
cells (Figure 4A). In 293T cells exposed to their own extract,
OCT4 remained methylated. However, in NCCIT extract-
treated cells, OCT4 demethylation was evident after 4 and 9
wk of culture (Figure 4A) and provided molecular support
for long-term transcriptional activation of OCT4. Two CpGs
showed apparent partial demethylation (Figure 4A), which
was interpreted as the expected presence of a mixed cell
population in which cytosines 1686 and 1676 did not
undergo demethylation. We concluded therefore that the
NCCIT extract was capable of eliciting OCT4 demethylation in
293T cells. OCT4 demethylation was speciﬁc for the NCCIT
extract and it did not occur in 293T extract (Figure 4A).
We also examined the DNA methylation status of LMNA,
whose expression is virtually repressed in NCCIT extract-
treated cells. The LMNA region analyzed spanned nucleo-
Table 1. Quantitative RT-PCR analysis of expression of indicated
stem cell genes in 293T cells treated with NCCIT extract
Gene
Fold up- or down-regulation
293T extract NCCIT extract NCCIT cells
AC133 2Œ 260 Œ 271Œ
APL 2Œ 35 Œ 28Œ
CD9 1 3 Œ 4Œ
DNMT3B 1 16 Œ 11Œ
DNMT3L 3Œ 36 Œ 23Œ
NANOG 1 2513 Œ 1541Œ
OXT2 0 20 Œ 23Œ
POU5F1 1 600 Œ 410Œ
REX1 1 1994 Œ 1985Œ
SOX2 1 18 Œ 27Œ
STELLA 1 88 Œ 48Œ
UTF1 2Œ 121 Œ 133Œ
LMNA 2 370  15
LMNB1 1 1.5Œ 1
Table indicates fold up-regulation (Œ) or down-regulation () of
indicated genes in 293T cells exposed to 293T or NCCIT extract and
cultured for 4 wk. Reference level (1) was that of untreated 293T
cells. Transcript levels in NCCIT cells relative to 293T cells are also
shown.
Figure 3. Oct4 expression in EGFP-labeled 293T cells. (A) 293T cells stably expressing EGFP and a geneticin resistance (GenR) gene were
treated with 293T or NCCIT extract and cultured for 2 wk with 700 ng/ml geneticin before immunolabeling with anti-Oct4 antibodies. NCCIT
extract was also treated with 500 g/ml DNAse I before incubating cells (bottom row). Bar, 20 m. (B) Quantitative RT-PCR analysis of
expression of indicated genes in 293T-EGFP-GenR cells 2 wk after incubation in intact or DNAse I-treated NCCIT extract (relative to 293T
extract-treated controls). (C) PCR analysis of the presence of SV40 large T antigen in 293T, NCCIT, and extract-treated cells. Ladder is a
123-base pair DNA ladder.
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tides 2379–2648 (GenBank L12399), encompassing 34 poten-
tially methylated cytosines found in CpG dinucleotides
ﬂanking the ATG translation start (Figure 4B). This region is
unmethylated in 293T cells and clearly remained unmethyl-
ated in NCCIT extract-treated cells (Figure 4B). However,
we also found an absence of LMNA DNA methylation in this
region in NCCIT cells despite the repression of LMNA in
these cells (Figure 4B). Thus, we concluded that NCCIT
extract-treated cells did not undergo aberrant DNA methyl-
ation in this region. We cannot ascertain, however, that other
regions in the LMNA locus were modiﬁed by extract treat-
ment. Last, LMNB1 remained unmethylated regardless of
extract treatment (Figure 4C), in agreement with its ubiqui-
tous expression. The LMNB1 region examined spanned nu-
cleotides 1594–1828 (GenBank L37737), encompassing 35
potentially methylated cytosine nucleotides in a CpG island
around the ATG start. GAPDH, also ubiquitously expressed
and used as reference in our quantitative RT-PCR analyses,
also remained largely unmethylated in any cell type exam-
ined (our unpublished data).
Transcriptional Proﬁling of NCCIT Cells Relative to 293T
Cells
To evaluate the extent of transcriptional alterations elicited
by the NCCIT extract, an Affymetrix U133A GeneChip mi-
croarray analysis of 293T cell gene expression was carried
out for 8 wk after extract treatment. We took advantage of a
SMART PCRcDNA approach that combines PCR ampliﬁca-
tion and T7 RNA polymerase to amplify submicrogram
RNA samples (Ji et al., 2004). Although some distortion of
within-sample stoichiometry occurs with this method, one
can assume the same distortion between samples, thus
maintenance of between-sample stoichiometry allows com-
parative analyses.
We ﬁrst assessed genes signiﬁcantly (p 	 0.001) up- or
down-regulated at a more than threefold difference level in
NCCIT compared with 293T cells. A total of 2950 genes were
up-regulated, whereas 2528 genes were down-regulated in
NCCIT cells, in two independent analyses performed in
duplicate. Distributions of up- and down-regulated genes
into functional classes were similar, with most genes encod-
ing elements involved in transcription regulation (22 and
19%, respectively), cytoskeletal organization (6 and 3%),
metabolism (4 and 10%), protein synthesis and processing (6
and 4%), cell signaling (10 and 8%), and chromatin organi-
zation (6 and 4%) (Figure S1).
NCCIT Extract Induces Expression of NCCIT-speciﬁc
Genes and Down-Regulation of 293T Genes
The NCCIT extract elicited up- and down-regulation of
1700–2000 and 1650–1800 genes, respectively, on any
given week relative to 293T cells (Figure 5B, green and red
bars). Of these, 70 and 34%, respectively, were shared
with NCCIT cells and qualiﬁed as “NCCIT genes” (Figure 5,
A and B, yellow bars; E). Furthermore, the likelihood that
expression of these genes was altered by chance rather than
as a result of extract treatment was extremely low (p 	 105
and p 	 104, respectively; t tests), indicating that changes
were elicited by the NCCIT extract.
We then addressed the speciﬁcity of gene expression
changes elicited by NCCIT extract. First, exposure of 293T
cells to their own extract induced up- or down-regulation of
1600 and 600 genes, respectively (Figure 5C, green and
red bars), of which only 6% were identiﬁed as NCCIT
genes (Figure 5C, yellow bars; E; listed in Table S2). Simi-
larly, treatment of 293T cells with Jurkat T-cell extract al-
tered expression of a negligible proportion of NCCIT genes
(Figure 5, D and E). Furthermore, nearly all NCCIT genes
affected by 293T or Jurkat extract were the same (Table S2;
annotationsa,b), and probabilities that these genes were al-
tered by chance rather than by extract treatment were rela-
tively high (p  0.07 and p  0.08, respectively; t tests).
Resulting numbers of NCCIT genes speciﬁcally up- or
down-regulated by NCCIT extract and reproducibly in both
experiments are shown in Figure 5F (green and red bars,
respectively). Thus, the NCCIT extract elicits speciﬁc alter-
ations in the 293T cell expression proﬁle. Genes not differ-
entially expressed in NCCIT compared with 293T also seem
to be affected.
The consistency of NCCIT gene expression changes in
NCCIT extract-treated cells over time was subsequently as-
sessed. Figure 5G (gray bars) shows that 686 genes were
consistently up-regulated from weeks 1–8, whereas 161
genes were consistently down-regulated (these genes were
shared between both experiments). These genes are listed in
Table S3. The remaining affected genes included those with
an onset of up- or down-regulation later than week 1, or
Figure 4. Bisulﬁte sequencing analysis of DNA methylation
changes in extract-treated cells. 293T cells, NCCIT cells, and cells
treated with 293T or NCCIT extract were examined for cytosine
methylation in underlined CpG dinucleotides within shown
genomic regions of the human OCT4 (A), LMNA (B), and LMNB1
(C) genes. Diagrams show localization (nucleotide numbers) of
regions examined relative to the ATG translation start (1).
C. K. Taranger et al.
Molecular Biology of the Cell5724
those with a more ﬂuctuating expression level. For example,
a large number of genes were up-regulated from week 2
onward, and thus they were not taken into account in the
above-mentioned analysis. Functional class distribution of
the consistently up- or down-regulated genes (Figure 5H)
shows that most annotated up-regulated genes encoded el-
ements involved in transcription, cytoskeletal organization,
metabolism, signaling, and chromatin remodeling, whereas
down-regulated genes were more evenly distributed across
functional classes.
Treatment with NCCIT Extract Up-Regulates Markers of
Pluripotency and Genes Indicative of Multilineage
Priming
Table 2 lists markers of pluripotency represented in the
array and that were up-regulated in extract-treated cells. In
agreement with our immunolabeling and DNA methylation
data, OCT4 (POU5F1) was up-regulated from week 2 on-
ward. Notably, the Oct4-responsive genes UTF1 and REX1/
DRN3 (Hosler et al., 1989; Okuda et al., 1998) were also
up-regulated together with SOX2, suggesting the induction
Figure 5. Microarray analysis of gene ex-
pression in extract-treated 293T cells. (A)
Venn diagram identifying “NCCIT-speciﬁc”
genes (yellow area). Numbers of genes up- or
down-regulated more than threefold (relative
to input 293T cells) in cells incubated in ex-
tract of NCCIT (B), 293T (C), and Jurkat (D)
cells (mean  SD of two [B and C] and four
[D] experiments). Yellow bars indicate genes
up- or down-regulated in extract-treated cells
and shared with NCCIT cells. In B, the like-
lihood that NCCIT genes are up- or down-
regulated by chance rather than by extract
treatment is extremely low (p	 105 and p	
104, respectively; t tests). By contrast, in C
and D these probabilities are relatively high
(p  0.07 and p  0.08, respectively; t tests).
(E) Percentage of NCCIT genes up- or down-
regulated in extract-treated cells (percentage
of total up- or down-regulated genes). (F)
Number of NCCIT genes speciﬁcally up- or
down-regulated by treatment with NCCIT
extract, over time. (G) Consistency of gene
up- or down-regulation over time after treat-
ment with NCCIT extract. Numbers of up-
and down-regulated NCCIT genes in cells
exposed to NCCIT extract are shown in green
and red. Gray bars represent genes consis-
tently up- or down-regulated at weeks 1 and
2 (gray bars at week 2), weeks 1, 2, and 4
(gray bars at week 4), etc., and shared be-
tween the two experiments. (H) Functional
class distribution of genes consistently up- or
down-regulated over 8 wk in two experi-
ments (gray bars in G). These genes are listed
in Table S3.
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Table 2. Changes in expression level of selected markers of dedifferentiation and multi-lineage differentiation potential in NCCIT
extract-treated cells
Name
GenBank
accession no. Description
NCCIT cells
(fold up-
regulation)a
NCCIT extract-treated cells
(fold up-regulation)a
Wk 1 Wk 2 Wk 4 Wk 8
Somatic cell markers
LMNA M13452.1 Nuclear lamin A 0.0015 0.9 0.0011 0.0014 0.0011
LMNB1 NM_005573.1 Nuclear lamin B1 2.5 1.7 1.0 1.5 1.4
LMNB2 M94363 Nuclear lamin B2 0.8 1.1 1.1 0.9 1.1
NPR3 NM_000908.1 Atrionatriuretic peptide receptor C 0.001 0.001 0.001 0.001 0.001
Embryonic, germ cell and stem cell markers
OCT4 (POU5F1) and Oct4-responsive genes
POU5F1 NM_002701.1 POU domain, class 5, TF1 (Oct4) 36 2 17 35 36
UTF1 N_003577.1 Undifferentiated embryonic cell transcription factor 1 317 2 213 293 318
REX1 AJ243797 Deoxyribonuclease III (Drn3) 5 1 2.5 6 9
FOXD3 N_012183.1 Forkhead box D3 (FoxD3) 847 38 283 295 254
Telomerase and telomerase-associated factors
TERT N_003219.1 Telomerase reverse transcriptase 102 2.5 22 76 89
TERF1 N_017489.1 Telomerase-associated factor 1 3.5 3 3.2 4.5 3.5
TERF2 N_005652.1 Telomerase-associated factor 2 0.7 0.5 0.9 0.6 0.6
SOX2 AI356682 Sex determining region Y-box 2 (Sox2) 119 1 12 118 121
POU3F1 L26494.1 POU domain, class 3, TF1 (Oct-6) 164 1.5 3 106 84
ALP1 M13077 Placental alkaline phosphatase 1 1311 38 292 928 927
ALP1 J04948.1 Placental alkaline phosphatase 1 2124 56 344 651 1337
CD44 N_000610.1 CD44 antigen (homing function) 1028 102 205 622 663
LIF N_002309.2 Leukemia inhibitory factor 221 7 27 127 271
FZD9 N_003508.1 Frizzled (Drosophila) homologue 9 331 10 101 102 107
TEF U06935.1 Thyrotroph embryonic factor 423 69 126 222 273
SCGF D86586.1 Stem cell growth factor  934 234 917 939 906
GCNF AF004291.1 Germ cell nuclear factor 1105 27 71 424 696
SPINK2 N_021114.1 Serine protease inhibitor, Kazal type, 2 662 2.5 65 257 555
DKK2 N_014421.1 Dickkopf (Xenopus laevis) homolog 2b 1122 345 457 473 476
INTA6 AV733308 Integrin 6 3.1 1.5 4.5 10 15
Markers of potential lineage- speciﬁc differentiation
Osteogenic lineage
BMP1 N_006129.2 Bone morphogenic protein 1 870 67 169 367 470
BMP2 NM_001200.1 Bone morphogenic protein 2 655 166 333 653 663
OGN N_014057.1 Osteoglycin 17 2 4 14 17
CTSK N_000396.1 Cathepsin K 8 4 5 5 6
TNFRSF11BN_002546.1 Osteoprotegerin 82 1 14 94 65
Endothelial lineage
VWF N_000552.2 Von Willebrand Factor 629 604 598 734 647
NOS3 N_000603.1 Nitric oxide synthase 3 (endothelial cell) 421 127 167 129 306
Myogenic lineage
MYF5 N_005593.1 Myogenic factor 5 13 10 13 30 23
TMP1 N_000366.1 Tropomyosin 1 alpha 46 14 12 11 16
MYH11 N_022844.1 Myosin, heavy polypeptide 11 98 4 22 28 69
Neurogenic lineage
NTS N_006183.2 Neurotensin 73 7 20 27 48
NRG1 N_004495.1 Neuregulin 1 isoform gamma 857 60 56 66 86
MBP M13577.1 Myelin basic protein 21 2 7 11 14
MOBP D28114.1 Myelin-associated oligodend. basic protein 43 22 24 24 22
NCAM1 BF348061 Neural cell adhesion molecule 1 18 1 7 17 20
CD56 U63041.1 Neural cell adhesion molecule CD56 16 1.5 2 4 11
Adipogenic lineage
APOA2 N_001643.1 Apolipoprotein A-II 13 4 5 9 9
APOD N_001647.1 Apolipoprotein D 11 3 11 10 12
APOE N33009 Apolipoprotein E 21 2 11 22 2
APOC1 N_001645.2 Apolipoprotein C1 4 0.5 1.5 3 4
PPARG2 N_015869.1 Peroxisome prolif. activated receptor 2 80 1 1.5 10 22
FAD1 BG165833 Fatty acid desaturase 1 10 3 4 7 5
Chondrogenic lineage
COL4A3 U02520 Collagen type IV alpha 3 36 3 9 27 31
COL5A2 N_000393.1 Collagen, type V, alpha 2 44 2 4 12 16
COL8A1 BE877796 Collagen, type VIII, alpha 1 19 1 5 9 15
COL11A1 J04177 Collagen, type X1, alpha 1 251 1 10 42 230
CSPG2 N_004385.1 Chondroitin sulfate proteoglycan 2 85 1 10 92 87
AGC1 N_013227.1 Aggrecan 1 15 5.5 4.5 50 46
DSPG3 N_004950.2 Dermatan sulphate proteoglycan 3 310 1.5 3 52 157
CSPG1 X17406.1 Aggrecan 1 9 1 2 13 16
FNP X02761.1 Fibronectin precursor 9 4 9 4 2
FN1 AK026737.1 Fibronectin 1 12 4 10 7 6
a Relative to 293Tcells.
b Also up-regulated in cells exposed to 293T or Jurkat extract.
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of Oct4-dependent functions in reprogrammed cells. Telom-
erase (TERT) and telomerase-associated factor 1 (TERF1)
were also increasingly up-regulated. Other pluripotency
markers up-regulated were the CD44 stem cell antigen, pla-
cental ALP (APL1), LIF, stem cell growth factor  (SCGF),
germ cell nuclear factor (GCNF), and integrin 6 (INTA6), a
putative marker of “stemness” shared between three gene
expression proﬁle analyses of mouse ESCs (Fortunel et al.,
2003). Remarkably, except for Dikkopf2 (DKK2), none of the
stem cell marker genes listed in Table 2 was affected by
treatment with 293T or Jurkat extract, illustrating the extract
speciﬁcity of changes elicited (Table S4). In parallel, LMNA
was essentially repressed, whereas expression of B-type
lamins (LMNB1 and LMNB2) persisted, consistent with our
RT-PCR and immunolabeling data. The kidney-derived
293T cell marker natriuretic peptide receptor C (NPR3) was
also strongly down-regulated (Hansis et al., 2004).
We also noted the up-regulation of markers of lineage-
speciﬁc differentiation to levels comparable with NCCIT
expression levels. These included markers of osteogenic,
endothelial, myogenic, neurogenic, adipogenic, and chon-
drogenic lineages (Boquest et al., 2005). Expression of mark-
ers of chondrogenic (DSPG3), neuronal (NRG1, NTS, and
MBP), endothelial (VWF), and adipocyte (APOA2) lineages
was conﬁrmed by real-time RT-PCR (Figure 6). Further-
more, expression of several housekeeping genes, including
18S, 28S, GAPDH, HPRT1, and ACTB and 35 genes for
ribosomal proteins, was unaffected in extract-treated cells
(Table S5). Collectively, these results indicate that the
NCCIT extract promotes the up-regulation of markers of
pluripotency typically expressed in ECCs or ESCs and sug-
gest, in addition, the establishment of a “multilineage prim-
ing” in 293T cells treated with NCCIT extract.
Oncogenes and Tumor Suppressor Genes Are Not Affected
by NCCIT Extract Treatment
NCCIT is a tumor cell line that bears genetic mutations
required for its expansion and phenotypic characteristics.
We determined whether mRNA levels for oncogenes and
tumor suppressor genes were altered in 293T cells exposed
to NCCIT extract, relative to untreated cells. We did not
observe any up-regulation or induction of oncogene expres-
sion in NCCIT extract-treated cells. Genes such c-MYC, c-
MYC-responsive genes, genes encoding Myc-interacting or
Myc-regulated proteins, and genes encoding RAB and RAF
isoforms were not signiﬁcantly expressed in any of the cell
types examined nor were they altered by NCCIT extract.
Among tumor suppressor genes, P53 was strongly up-reg-
ulated in NCCIT compared with 293T (p 	 104) but re-
mained unaltered in NCCIT extract-treated cells (p  0.05).
Other tumor suppressor genes, however, were either not
signiﬁcantly expressed in 293T or NCCIT [RB1, TSC1,
TSC22, BRCA1, BRCA2, CDKN2A (p16), CDKN1A (p21,
Cip1), CDKN1C (P57, Kip2), MSH2, STK11, MEN1, and
MEN2] or were expressed at similar levels in both cell types
(PTCH, PTEN, and WT1D). These genes remained unaltered
by treatment with NCCIT extract (p 0.05). Similarly, genes
encoding enzymes involved in DNA repair (XPA, ERCC5,
FANCA, -C, -E, -F, and -G) were not signiﬁcantly expressed
in either cell types nor altered by extract treatment. ATM
was highly expressed in 293T and NCCIT cells and re-
mained unchanged in extract-treated cells. Because it is un-
likely that NCCIT genetic lesions are passed onto the 293T
cell genome through extract treatment, acquisition of an
NCCIT phenotype by 293T cells implies that either the phe-
notype obtained is independent of NCCIT lesions or that
genetic mutations that gave rise to the NCCIT tumor phe-
notype are dispensable for the maintenance of this state.
Retinoic Acid Stimulation of NCCIT Extract-treated Cells
Induces Neuronal Differentiation
To determine whether NCCIT extract-treated 293T cells ac-
quired a potential for pluripotency, we attempted to induce
neuronal differentiation in vitro with retinoic acid (Stewart et
al., 2003). 293T, NCCIT (our unpublished data), and extract-
treated cells were exposed to 10 M all-trans-retinoic acid
and were maintained as suspended aggregation cultures
(Figure 7A). Suspensions of all cell types formed disorga-
nized aggregates in bacteriological dishes but after 2 wk in
retinoic acid, the cells formed spheres that sometimes fused
with one another (Figure 7A). This was particularly evident
for NCCIT extract-treated 293T cells (Figure 7A, top). After
washing and replating, cells adhered to poly-l-lysine-coated
coverslips. However, only NCCIT and NCCIT extract-
treated cells showed evidence of neurite outgrowth already
after culture for 2 d in the absence of retinoic acid but in the
presence of mitotic inhibitors (Figure 7A, bottom, and S2A).
This suggested that neuronal progenitor cells emanated
from NCCIT extract-treated 293T cells.
Immmunolabeling and real-time RT-PCR analyses con-
ﬁrmed the induction of a neuronal phenotype. Spheres of
NCCIT cells and of NCCIT extract-treated cells showed a
reduction of Oct4 protein to a level nearly undetectable by
immunoﬂuorescence in 90% of the cells (Figure 7B). This
was conﬁrmed by a threefold reduction of OCT4 transcript
levels in these cells compared with cells not stimulated with
retinoic acid (Figure 7C). Moreover, expression of the inter-
mediate ﬁlament nestin (NES), a marker of neuronal precur-
sor cells (Cattaneo and McKay, 1990), was induced at the
transcriptional and translational levels by retinoic acid in
NCCIT extract-treated but not 293T extract-treated, cells
(Figure 7, B and C). Furthermore, LMNA, repressed after
exposure to NCCIT extract (Figure 2 and Table 1) was
strongly up-regulated de novo by retinoic acid but only in
NCCIT extract-treated cells (Figure 7C). This indicated that
the cells redifferentiated upon retinoic acid exposure. Last,
the majority of NCCIT extract-treated cells, as NCCIT cells
(Figure S2B and S2C) were positive for the neuronal markers
NeuN and NF200 (Figure 7D). We concluded that NCCIT
extract-treated 293T cells can be induced to differentiate into
a neuronal phenotype in vitro.
Figure 6. Quantitative RT-PCR analysis of expression of indicated
multilineage priming genes in 293T cells treated with NCCIT extract
relative to transcript levels in 293T cells exposed to 293T extract.
Expression levels were adjusted to those of GAPDH in triplicate
samples. Single data points show mean expression level in NCCIT
cells.
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NCCIT Extract Enhances Differentiation Potential toward
Adipogenic, Osteogenic, and Endothelial Lineages
To provide additional evidence for induction of differentia-
tion potential in 293T cells treated with NCCIT extract, we
determined whether the cells would acquire phenotypic
characteristics of adipocytes and osteoblasts. After 3 wk of
retinoic acid treatment and 3 wk of stimulation in appropri-
ate differentiation medium (see Materials and Methods), a
proportion of 293T cells, NCCIT cells, and of cells treated
with 293T or NCCIT extract were induced to differentiate
toward adipogenic and osteogenic pathways (Figures 8, A
and B, and S2D and S2E). Intracellular lipid staining with
Oil-Red-O showed enhanced differentiation of NCCIT ex-
tract-treated cells relative to any other cell type toward the
adipogenic pathway (Figure 8A). Moreover, signiﬁcantly
more Alzarin red-stained mineralized nodules were de-
tected in NCCIT extract-treated 293T cells compared with
any other cell type (Figure 8B, arrows; p 	 106; t tests).
Additionally, induction of endothelial differentiation of
NCCIT extract-treated cells in methylcellulose triggered the
appearance of an endothelial cell phenotype after 7 d. With
cells forming elongated “tracks” in methylcellulose (Figure
8C; see controls in Figure S2F). Morphological changes were
supported by immunoreactivity to CD31 and CD144, two
endothelial cell surface markers (Boquest et al., 2005) (Figure
8D), and by induction of expression of CD31 (2  0.15-fold
up-regulation compared with undifferentiated, extract-
treated cells) and CD144 (347  97.6-fold up-regulation).
Collectively, these results indicate that treatment with
NCCIT extract enhances the ability of 293T cells to differen-
tiate into ectoderm and several mesoderm lineages.
A Mouse ES Cell Extract Promotes A-Type Lamin Down-
Regulation and Oct4 Transcription in NIH3T3 Fibroblasts
A nuclear and cytoplasmic extract of mouse ESCs was pre-
pared to determine whether it was capable of eliciting mark-
Figure 7. Neuronal differentiation of 293T cells treated with 293T or NCCIT extract. (A) Top, induction of differentiation. Suspended
aggregates after 2 wk of culture with 10 M all-trans-retinoic acid. Bottom, differentiation. Cells were plated onto poly-l-lysine-coated
coverslips after 2 d of culture in the absence of retinoic acid but with mitotic inhibitors. Note neurite extensions in NCCIT extract-treated cells.
(B) NCCIT extract-treated cells either treated with retinoic acid (RA) or not (RA) for 3 wk were immunolabeled using antibodies against
Oct4 and nestin. Graph shows proportions (mean  SD) of cells immunolabeled with anti-Oct4 and anti-nestin antibodies (n 
 200 cells in
each of a triplicate analysis for each treatment). (C) Quantitative RT-PCR analysis of expression of OCT4, NES (nestin), LMNA and LMNB1
in 293T cells treated with 293T or NCCIT extract, in absence (RA) or presence (RA) or retinoic acid for 3 wk. (D) NeuN and NF200
immunoﬂuorescence analysis of indicated cell types induced to differentiate as described in A. Insets, DNA labeled with Hoechst 33342. Bars,
400 m (A, top); 40 m (A, bottom); 40 m (B and D).
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ers of pluripotency, as with the NCCIT extract. Within 4–9 d
after ESC extract treatment, a proportion 3T3 cells formed
distinct colonies of small round cells that lifted from the
surface to form embryoid-like bodies (Figure 9A). Fifty to
100 embryoid-like bodies were identiﬁed in 100-mm culture
plates, whereas most remaining cells retained a ﬁbroblast
morphology. Smaller aggregates of round (nonmitotic) cells
were also detected. In contrast, 3T3 cells exposed to their
own extract grew as ﬁbroblasts and were not distinguishable
from untreated cells (Figure 9A). The ESC-like phenotype
was maintained after passaging cells weekly for at least 10
wk. RT-PCR analysis of the embryoid body-like structures
clearly revealed Oct4 transcripts (see below), whereas Lmna,
but not Lmnb1, was strongly down-regulated (Figure 9B).
Embryoid-like bodies derived from ESC extract-treated
cells expressed ALP, another embryonic and ESC marker,
after 8 d of culture (Figure 9, C and D; 1 wk after extract
exposure). ALP expression was inhibited by a 24-h exposure
to 25 M RNA PolII inhibitor 5,6-dichloro-1-d-ribofuranosyl
benzimidazole (DRB) or to 10 g/ml protein synthesis in-
hibitor cycloheximide (CHX) (Figure 9D). Thus, ALP expres-
sion was endogenous to the extract-treated cells. No expres-
sion was detected in control cells (Figure 9, C and D).
Furthermore, immunoﬂuorescence analysis showed that
90% of embryoid-like body-derived cells expressed in-
tranuclear Oct-4, whereas in the same cells lamin A/C ex-
pression was reduced to undetectable levels (our unpub-
lished data). Immunoblots conﬁrmed this observation
(Figure 9E) and indicated that ESC extract-treated cells ex-
pressed Oct4 to levels similar to ESCs. Oct4 not was detected
in 3T3 cells incubated in their own extract or in intact (non-
permeabilized) 3T3 cells treated with ESC extract (Figure
9E). This ruled out the detection of an unspeciﬁc anti-Oct4
immunoreactive product and of any extract-derived Oct4
protein that would stick to the cell surface. Detection of
Oct4 protein in ESC extract-treated cells required a threshold
Figure 8. Induction of adipogenic, osteo-
genic, and endothelial differentiation of 293T
cells treated with 293T or NCCIT extract. (A
and B) Cells were exposed to 10 M retinoic
acid for 21 d, washed, and cultured in the
absence of retinoic acid in adipocyte (A) or
osteoblast (B) differentiation medium for 21 d.
(A) Cells were stained with Oil-Red-O to re-
veal lipid droplets. Images on the right are
enlargements of two areas framed in white in
the adjacent panel (top right-hand quadrant).
Arrows point to strongly stained lipid drop-
lets. (B) Cells were stained with Alzarin red to
visualize mineralized nodules (arrows).
Graph shows mean  SD number of distinct
strongly mineralized nodules (arrows) per
unit area (area shown in B). Twenty-four to 27
areas were analyzed within wells of six-well
culture plates. *p 	 106 relative to other
treatments (ANOVA). (C) 293T and NCCIT
extract-treated cells were passaged onto
methylcellulose for 7 d to elicit endothelial
differentiation. Note the formation of a track
phenotype characteristic of cultured endothe-
lial cells (right). (D) Direct immunoﬂuores-
cence labeling of CD31 and CD144 surface
antigens in extract-treated cells induced to
differentiate as described in C. After differen-
tiation, cells were loosened from the methyl-
cellulose semisolid substrate by dilution with
PBS and thus lost their elongated phenotype.
Bars, 40 m (A), 200 m (B and C), and 40 m
(D).
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(10 M) concentration of NTPs in the extract (Figure 9F),
providing additional evidence for the lack of unspeciﬁc
detection of Oct4 in these cells.
Closer examination of the need for exogenous nucleotides
to promote Oct4 detection indicated a requirement for ATP
and GTP hydrolysis (Figure 9G). Indeed, ATP depletion
from the extract with glucose and hexokinase, replacement
of exogenous ATP with adenosine-5-O-(3-thio)triphosphate
or adenyl-5-yl imidodiphosphate, or GTP removal or sub-
stitution with guanosine 5-O-(3-thio)triphosphate or
guanosine 5-[,-imido]triphosphate abrogated Oct4 detec-
tion (Figure 9G). This is consistent with a role of active
nuclear import for transcription in cell extracts (Håkelien et
al., 2002). Furthermore, heat treatment (95°C; 5 min),
trypsinization, or proteinase K treatment of the ESC extract
abolished Oct4 detection in 3T3 cells (Figure 10). However,
DNAse I (100 mg/ml) or RNAse A (50 mg/ml) did not affect
Oct4 levels in extract-treated cells (see below; Figure 10),
ruling out a signiﬁcant contribution of mRNA or DNA of
extract origin.
The ESC Extract Induces a Biphasic Wave of Oct4
Transcription and Translation
To gain insight on the dynamics of Oct4 induction in ESC
extract-treated cells and evaluate any putative contribution
of extract-derived Oct4 protein, we assessed intracellular
Oct4 protein levels over time after extract treatment and
determined the effect of PolII and protein synthesis inhibi-
tors on Oct4 induction. Relative Oct4 levels in ESC extract-
treated cells are shown in Figure 11A. A biphasic response to
extract exposure was observed. First, Oct4 was detected as
early as 1 h after recovery of the cells from the extract, and
the level peaked at 24 h (Figure 11A). This peak was fol-
lowed by a marked reduction of Oct4 by 36 h to a level
barely detectable by 48 h. By 72 h, however, a second wave
of Oct4 was detected of amplitude similar to or higher than
the ﬁrst wave, and it persisted for at least 5 d (Figure 11A).
Oct4 protein was also detected in these cells 5 and 10 wk
after extract treatment (our unpublished data); thus, we
anticipate that the second elevation of Oct4 in these cells is
long-lasting. Of note, the biphasic Oct4 protein elevation
paralleled ﬂuctuations in Oct4 transcripts, as determined by
real-time RT-.PCR (Figure 11D), suggesting a short half-life
(a few hours) of Oct4 RNA and protein.
Culture of ESC extract-treated cells with 25 M DRB
from 1 to 24 h after extract treatment dramatically re-
duced Oct4 levels by 1 h (Figure 11B, top), suggesting that
Oct4 detection at this time point resulted primarily from
transcription but also to a minor extent from uptake of
Oct4 protein from the extract. This hypothesis was veri-
ﬁed by a complete double immunodepletion of Oct4 from
the ESC extract (Figure 12A), which resulted in a reduced
Oct4 level by 1 h in non-DRB-treated 3T3 cells, without
affecting subsequent levels (Figure 12, B and 1C). DRB
exposure of cells treated with Oct4-depleted extract com-
pletely abolished Oct4 detection by 1 h (our unpublished
data). We concluded, therefore, that Oct4 detected by the
ﬁrst hour of culture after extract exposure originated from
the extract and from RNA PolII-mediated transcription
and translation.
The effect of PolII inhibition on the dynamics of Oct4
expression in ESC extract-treated cells differed with timing
of drug exposure after extract treatment. A 1- to 24-h DRB
treatment almost completely blocked the ﬁst Oct4 elevation
Figure 9. Induction of Oct4 and ALP ex-
pression in 3T3 cells exposed to mouse ESC
extract. (A) 3T3 cells 10 d after treatment with
ESC extract (ES ex.) or 3T3 extract (3T3 ex.).
Bar, 20 m. (B) RT-PCR analysis of expres-
sion of indicated genes in ESCs, 3T3 cells and
3T3 cells at 2 wk after treatment with ESC
extract. (C) ALP expression in cells treated as
described in B (2 wk after extract treatment).
(D) Relative ALP level in ESCs, 3T3 cells, and
in 3T3 cells treated in 3T3 extract or in ESC
extract alone or with 25 M DRB or 10 g/ml
CHX, as indicated. Cells were analyzed 2 wk
after extract treatment. (E) Indicated cell
types (as in B) were analyzed by Western
blotting for expression of Oct4, lamin A/C,
B-type lamins, and -tubulin, 2 wk after ex-
tract treatment. (F) Relative Oct4 level in 3T3
cells treated with ESC extract containing de-
creasing concentrations of NTPs (1 wk after
extract treatment). (G) Relative Oct4 level in
3T3 cells exposed to ESC extract containing
indicated ATP or GTP analogues. ATP-RS,
ATP-regenerating system (2 wk after extract
treatment).
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(Figure 11B, top), supporting a role of RNA PolII in this
process. In addition, and unexpectedly, the second wave of
Oct4 induction was also dramatically impaired (Figure 11B,
top). Again, these changes paralleled Oct4 transcript levels:
the ﬁrst up-regulation of Oct4 mRNA was inhibited, the
second rise in Oct4 transcription was also severely compro-
mised, albeit not fully blocked, such that Oct4 transcripts
were up-regulated ﬁve- to sevenfold above the 48-h baseline
Figure 10. Relative Oct4 protein levels in
3T3 cells exposed to ESC extract pretreated as
indicated in each panel. Cells were cultured
for 1–96 h after extract treatment, lysed, and
analyzed by Western blotting. Oct4 protein
levels were determined by densitometric
analysis of duplicate blots for each time point
under each condition. Level 1 indicates Oct4
level at 1 h after removal of cells from an
untreated ESC extract (top left).
Figure 11. Oct4 expression in ESC extract-
treated cells is biphasic and RNA PolII de-
pendent. (A) Immunoblotting analysis of in-
tracellular Oct4 levels in 3T3 cells treated
with ESC extract and cultured for indicated
time periods. (B) Cells were exposed to 25 M
DRB at 1–24 h (top), 36–60 h (middle), and
60–84 h (bottom) of culture. (C) Cells were
exposed to 10 g/ml CHX at 1–24 h (left) or
60–84 h (right) of culture before immunoblot-
ting. (D) Real-time RT-PCR analysis of Oct4
expression in 3T3 cells exposed to ESC ex-
tract. Cells were cultured with 0 or 25 M
DRB at indicated time periods as described in
B. Reference level (level 1) is Oct4 mRNA
level in 3T3 cells immediately upon plating
cells after recovery from extract. Data show a
representative set from two experiments.
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instead of the 25-fold normally observed (Figure 11D).
This suggests that the second, long-lasting induction of Oct4
up-regulation is dependent on an early, short-term boost of
Oct4 transcription and/or translation.
DRB exposure from 36 to 60 h after extract treatment,
during the dip in Oct4 mRNA and protein levels, did not
affect early Oct4 transcript and protein levels and only
slightly delayed the second rise of Oct4 (Figure 11B, mid-
dle). This delay was also noticed at the transcript level,
but it did not signiﬁcantly affect Oct4 mRNA or protein
level at 7 d (168 h; Figure 11D). Moreover, DRB applied
from 55 to 84 h after extract treatment completely abro-
gated Oct4 transcription and translation by 72 h, but
removal of the drug ultimately restored control Oct4 lev-
els (Figure 11B, bottom, and D). Thus, there is a require-
ment for PolII activity for de novo transcription of Oct4
3 d after extract treatment. Last, both Oct4 elevations were
abolished upon incubation with 10 g/ml CHX, a protein
synthesis inhibitor (Figure 11C). We concluded that
whereas uptake of limited amounts of short-lived extract-
derived Oct4 protein probably occurs, the two phases of
Oct4 induction result from transcriptional and transla-
tional activity in extract-treated cells.
In summary, this study provides transcriptional and func-
tional evidence that an extract of undifferentiated EC or ES
cells can induce markers of dedifferentiation and signs of
differentiation plasticity in an otherwise more developmen-
tally restricted cell type. Furthermore, the NCCIT extract
induces DNA demethylation of OCT4, indicative of an epi-
genetic reprogramming event at this locus.
DISCUSSION
Target Cell Type-speciﬁc Programming of Gene Expression
The induction of a transcriptional proﬁle of, according to our
data, uncertain stability, suggests the establishment of a
program of gene expression, as opposed to a complete func-
tional reprogramming such as that occurring after nuclear
transfer. Of the hundreds of NCCIT-speciﬁc genes up- or
down-regulated on any given week after NCCIT extract
treatment, only 5–7% are altered by Jurkat extract, and most
of these genes overlap with genes altered (statistically by
chance) in cells exposed to their own extract. This argues for
some cell-type speciﬁcity in the nature of genes modulated
by extract treatment. Despite some stability in the expression
proﬁle of speciﬁc genes after extract exposure, not all
changes seem to be heritable. Genes with unstable expres-
sion pattern may include “passive bystanders” that generate
a transcriptional noise (Paulsson, 2004) and result from more
speciﬁc alterations in the transcriptional network. Perturba-
tion in the network, however, would be expected to lead to
changes trickling down the network until a transcriptional
equilibrium is reached (Miklos and Maleszka, 2004). Fluctu-
ations in the gene expression proﬁle therefore may result
from incomplete reprogramming and from heterogeneity in
the transcriptional response to extract treatment. Neverthe-
less, the dynamics of gene expression may also illustrate a
temporal compartmentalization, in terms of timing, dura-
tion, and periodicity of gene activity required to establish a
heritable transcriptional network (Klevecz et al., 2004).
Figure 12. Immunodepletion of Oct4 from ESC extract maintains Oct4 expression proﬁle. (A) Immunoprecipitation of Oct4 from ESC
extract. Numbers indicate rounds of immunoprecipitation (IP). Resulting extracts were immunoblotted using anti-Oct4 antibodies. (B) 3T3
cells were exposed to immunodepleted ESC extract, cultured for indicated time periods, and blotted using anti-Oct4 antibodies. (C) Relative
intracellular Oct4 protein level in 3T3 cells exposed to control (no antibody), mock-depleted (IgG), or anti-Oct4-depleted ESC extract and
cultured for indicated time periods. *p 	 0.001 relative to the 1-h time point in other treatments (ANOVA). Data from two experiments. (D)
Real-time RT-PCR analysis of Oct4 expression in 3T3 cells exposed to intact, mock-depleted, or Oct4-depleted ESC extract. Reference level
(level 1) is Oct4 transcript level in 3T3 cells immediately upon plating cells after recovery from extract. Data show a representative set of two
experiments.
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Evidence of Induction of Potential for Pluripotency
The gene expression program elicited by NCCIT extract
suggests the establishment of a potential for multilineage
differentiation in otherwise more developmentally restricted
cells. An indicator of dedifferentiation is the down-regula-
tion of genes indicative of a differentiated state. This is
exempliﬁed by the down-regulation of many 293T cell
genes, including the kidney natriuretic peptide receptor C
(NPR3), and the repression of lamin A (LMNA), a marker of
differentiated cells (Hutchison and Worman, 2004). LMNA
down-regulation seems speciﬁc for extracts of undifferenti-
ated cells that do not express lamin A/C. In contrast, cardi-
omyocyte extracts can up-regulate LMNA expression in
adipose stem cells, an event that correlates with differen-
tiation toward a cardiomyocyte phenotype (Gaustad et al.,
2004), and LMNA is reactivated upon retinoic acid-medi-
ated differentiation of NCCIT extract-treated cells. Thus,
the transcriptional status of LMNA provides a direct as-
sessment of (de)differentiation transitions mediated by
cell extracts. The mechanism of gene inactivation in ex-
tracts is unclear. However, evidence for the down-regu-
lation of many genes by single small interfering RNAs
(Mathieu and Bender, 2004), possibly through a control of
DNA methylation (Matzke and Birchler, 2005), raises the
hypothesis of a contribution of small RNAs in extract-
based nuclear (re)programming.
An indicator of pluripotency is the up-regulation of
genes characteristic of undifferentiated EC (NCCIT) or ES
cells. Several embryonic, germ cell, and stem cell genes
are activated to levels similar to those of NCCIT cells. Of
note, Oct4 is expressed in ESCs to maintain pluripotency
and acts in cooperation with SOX2 (Avilion et al., 2003).
The latter is also expressed in extract-treated cells. The
Oct4 transcription factor acts on a subset of target genes,
including UTF1, REX1, OCT2, and NANOG (see Hoffman
and Carpenter, 2005 for an updated review of human
embryonic and ESC genes). These were found to be up-
regulated by NCCIT extract. Furthermore, because UTF1
expression requires synergistic activities of Oct4 and Sox2
(Nishimoto et al., 1999), our results suggest the formation
of a functional transcriptional complex between these fac-
tors.
Another feature of NCCIT extract-treated cells is the
expression of genes suggestive of a potential for multiple
lineage differentiation and acquisition of neurogenic, adi-
pogenic, osteogenic, and endothelial differentiation abil-
ity. Differentiation potential toward other lineages was
not investigated. Multilineage priming is a hallmark of
hematopoietic stem cells (Akashi et al., 2003) and mesen-
chymal stem cells from bone marrow (Woodbury et al.,
2002) and adipose tissue (Boquest et al., 2005). It may
reﬂect their ability to promptly differentiate into a speciﬁc
cell type in the tissue in which they reside, in response to
simulation. Thus, similarly to somatic stem cells, the tran-
scriptional signature of NCCIT extract-treated cells ex-
tends across germ layer boundaries. Additionally, be-
cause they also express embryonic and ESC markers,
these cells display characteristics of a perhaps more pre-
cursor cell than the starting epithelial cell type.
Chromatin Remodeling Associated with Nuclear
Reprogramming
The NCCIT extract retains the ability to elicit epigenetic
reprogramming of OCT4 in 293T cells. Our data illustrate
the demethylation of six of eight cytosines in CpG
dinucleotides between CR2 and CR3 in the OCT4 pro-
moter (Nordhoff et al., 2001). Oct4 DNA demethylation in
thymocyte nuclei has been reported after fusion with EG
or ES cells (Tada et al., 1997, 2001) and is required for Oct4
transcription after nuclear transplantation into Xenopus
oocytes (Simonsson and Gurdon, 2004). The process driv-
ing OCT4 DNA demethylation remains unclear but seems
to require deproteinization (Simonsson and Gurdon,
2004), and it may involve cleavage of methyl groups
(Ramchandani et al., 1999) or cytosine deamination (Mor-
gan et al., 2004). The ability to induce DNA demethylation
in bulk cells or nuclei incubated in extracts raises the
possibility of isolating the DNA demethylation activity
involved.
A transient induction of Oct4 transcription and transla-
tion—independent of uptake of residual Oct4 protein
from the extract—is triggered within the ﬁrst hours after
extract exposure. This early Oct4 up-regulation may be
explained by nuclear uptake of extract-derived transcrip-
tion factors and chromatin remodelers that target the Oct4
promoter (Nordhoff et al., 2001). This possibility is sup-
ported by the inhibitory effect of removing proteins from
the extract (Figure 10) and of immunodepleting BRG1
from mouse ESC extracts on Oct4 transcription in 3T3 cells
(our unpublished data). The transient (24- to 48-h) nature
of this ﬁrst wave of Oct4 activation presumably results
from depletion of factors (most transcription factors have
a half-life of hours). This suggests that transcription factor
synthesis and targeting are not optimally sustained dur-
ing the ﬁrst hours after extract treatment. The second
wave of Oct4 up-regulation, however, is sustained for
several days and weeks. Long-term Oct4 expression is
consistent with DNA demethylation taking place in our
system. Timing of long-term Oct4 activation by ESC ex-
tract is consistent with the time interval observed between
introduction of nuclei into oocytes and Oct4 demethyl-
ation in Xenopus oocytes (Simonsson and Gurdon, 2004).
How early Oct4 demethylation occurs after extract expo-
sure, however, remains undetermined, Nevertheless, if
Oct4 demethylation is required for expression of the gene
(Simonsson and Gurdon, 2004), the rapid induction of
RNA PolII-dependent Oct4 transcription in ESC extract
(Figure 11) also suggests that demethylation (at least of
Oct4) is very rapidly triggered upon extract treatment.
Alteration of gene expression in extract-treated cells im-
plies a global and locus-speciﬁc remodeling of chromatin.
Remodeling of mammalian chromatin by Xenopus egg ex-
tract depends on ATPase activity of a chromatin remodeling
complex (Kikyo et al., 2000), and in a similar system BRG1
was shown to be involved in OCT4 activation (Hansis et al.,
2004). We have to date no evidence for ATP-dependent
chromatin remodeling in our system. However, OCT4 acti-
vation requires ATP hydrolysis, and immunodepletion of
BRG1 from mouse ESC extracts abolishes OCT4 transcrip-
tion (our unpublished data). OCT4 promoter DNA demeth-
ylation (this study), and hyperacetylation of histone H4 at
the IL2 locus in cells treated with Jurkat extract (Håkelien et
al., 2002) provide evidence that locus-speciﬁc chromatin re-
modeling takes place in our system. Conceivably, controlled
manipulations of epigenetic alterations may enhance the
heritability of gene expression in (re)programmed cells and
may prove beneﬁcial for reprogramming cell fate in a ther-
apeutic context.
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Supplementary Table S1. Real-time RT-PCR primers used in this study 
 
Gene name 
Forward primer (F) 5’3’ 
Reverse primer (R) 5’3’ 
SYBR® Green or Probe no. (ProbeLibrary) 
 
Product 
size (bp) 
AC133 F: GGGAGAACAATAATAGGATATTTTGAA 
R: CGATGCCACTTTCTCACTGAT 
Probe 86 
 
75 
ACTB 
 
F: CCAACCGCGAGAAGATGA 
R: TTGTCACCAGGATCAATGACA 
Probe 64 
 
97 
Actb 
(mouse) 
F: TGACAGGATGCAGAAGGAGA 
R: CGCTCAGGAGGAGCAATG 
Not real time PCR 
 
75 
APL F: CCTACCAGCTCATGCATAACATC 
R: TGGCTTTCTCGTCACTCTCATAC 
SYBR® Green 
 
114 
APOA2 
 
F: AGGTCAAGAGCCCAGAGCTT 
R: CCTTCTTGATCAGGGGTGTC 
Probe 68 
 
84 
 
CD9 F: TCGGATTTAACTTCATCTTCTGG 
R: GTCGAATCGGAGCCATAGTC 
Probe 56 
 
71 
CD31 F: CCACTGCAGAGTACCAGGTG 
R: TGGCCTCTTTCTTGTCCAGT      
Probe 12 
 
72 
CD144 F: GCAGTCCAACGGAACAGAA 
R: CATCTTCCCAGGAGGAACAG 
Probe 30 
 
65 
DNMT3B F: CTGCTTTGCAGCAACACG 
R: CAGCACCTCCAGGCACTC 
Probe 74 
 
60 
DNMT3L F: CTCTCAAGCTCCGTTTCACC 
R: GTACAGGAAGAGGGCATCCA 
SYBR® Green 
 
189 
DSPG3 
 
F: CAGGAGCCTGAATTCACAGG  
R: CCAAAGACAGGTTGGAAAGTCT 
Probe 57 
 
66 
GAPDH F: TCGGAGTCAACGGATTTGGT 
R: TTGCCATGGGTGGAATCATA 
SYBR® Green 
 
148 
LMNA F: CTGTGGTTGAGGACGACGAG 
R: TGCGGTAGCTGCGAGTGA 
SYBR® Green 
 
240 
Lmna 
(mouse) 
F: AGCAAGTTGCGTGAGGAGTT 
R: ACAAGTCCCCCTCCTTCTTG 
Not real time PCR 
 
64 
LMNB1 F: AAGGCGAAGAAGAGAGGTTGAAG 
R: GCGGAATGAGAGATGCTAACACT 
 
163 
 1
SYBR® Green 
Lmnb1 
(mouse) 
F: GACCACCATACCCGAGGAGG 
R: AATGGCACAGCTTTATTCCA 
Not real time PCR 
 
118 
MBP 
 
F: GGGCACGCTTTCCAAAAT 
R: CCATGGGTGATCCAGAGC 
Probe 33 
 
62 
NANOG F: CAAAGGCAAACAACCCACTT 
R: TCTGCTGGAGGCTGAGGTAT 
SYBR® Green 
 
158 
NES F: CACCTGTGCCAGCCTTTCTTA 
R: TTTCCTCCCACCCTGTGTCT 
SYBR® Green 
 
170 
NRG1 
 
F: GATCAGCAAATTAGGAAATGACAG 
R: GGCATACCAGTGATGATCTCG 
Probe 53 
 
78 
NTS 
 
F: AGCTCCTGGAGTCTGTGCTC 
R: GGTCAAGAAATCTGCTTCTAATGC 
Probe 35 
 
66 
OTX2 F: GGTACCCAGACATCTTCATGC 
R: CTTAGCTCTTCGATTCTTAAACCATAC 
Probe 10 
 
95 
POU5F1 F: AAGCGATCAAGCAGCGACTAT 
R: GGAAAGGGACCGAGGAGTACA 
SYBR® Green 
 
127 
Pou5f1 
(mouse) 
F: GTTGGAGAAGGTGGAACCAA 
R: CTCCTTCTGCAGGGCTTTC
SYBR® Green 
 
61 
REX1 F: CAGAACAGAAGAGGCCTTCAC 
R: TCTGAGTAAGCTGTCTTCAGCAA 
Probe 62 
 
73 
SOX2 F: GCGCCCTGCAGTACAACTC 
R: GCTGGCCTCGGACTTGAC 
SYBR® Green 
 
140 
STELLA F: GACCAACAAACAAGGAGCCTAAG  
R: AGAAGGATCCATCCATTAGACA 
SYBR® Green 
 
95 
Tubb 
(mouse) 
F: CAATGTATACTACAATGAAGCAACTGG 
R: CCAGACCTGACTGAGTCCATT 
Not real time PCR 
 
96 
UTF1 F: ACCAGCTGCTGACCTTGAAC 
R: TTGAACGTACCCAAGAACGA 
SYBR® Green 
 
230 
VWF 
 
F: AGTGCAGACCCAACTTCACC 
R: GTGGGGACACTCTTTTGCAC 
Probe 04 
 
60 
 
Table shows primers to human transcripts. Primers to mouse transcripts are specified in parentheses. 
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Supplementary Table S2. NCCIT genes up- or downregulated >3-fold at week eight after treatment 
with control 293T and Jurkat extracts 
 
Genebank 
Accession No. 
 
Description 
293T extract-treated cells 
Upregulated genes (n=112) 
NM_005345.3 Heat shock 70kD protein 1A (HSPA1A) 
NM_004039.1 Annexin A2 (ANXA2) 
BC002666.1 Guanylate binding protein 1, interferon-inducible 
AW117368 a KIAA0942 protein 
NM_012200.2 Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) (B3GAT3) 
NM_000227.1 Laminin, alpha 3 
BE791251 Claudin 3 
NM_001218.2 Carbonic anhydrase XII (CA12) 
NM_023037.1 a Putative gene product (13CDNA73) 
AF280546.1   Neuropilin-2 soluble isoform 9 (NRP2) 
AA502912 a KIAA0906 protein 
AK026815.1 a KIAA1102 protein 
AW043713 a KIAA1077 protein 
AL045513 a KIAA0180 protein 
AI282485 HLA-B associated transcript-1 
BE901081 a H2A histone family, member X 
AL023584 a Contains the HIVEP2 (Schnurri-2) 
AK026529.1 Highly similar to transducin (beta)-like 2 
AL569804 a KIAA1095 protein 
BF968960 Glucose phosphate isomerase 
AI401612 a DKFZP434M154 protein 
R68573 a Mitochondrial ribosomal protein S12 
T90013 C1orf20 gene, partial sequence 
AU117487 cAMP responsive element binding protein-like 1 
NM_019009.1   TOLLIP protein (LOC54472) 
AW189430 a   KIAA0244 protein 
NM_024952.1 a Hypothetical protein FLJ20950 
NM_016234.2 Long-chain fatty acid coenzyme A ligase 5 (FACL5) 
NM_016046.1 a Homolog of yeast exosomal core protein CSL4 (CSL4) 
NM_024118.1 a   Hypothetical protein MGC4692 
NM_017842.1 a Hypothetical protein FLJ20489 
NM_024105.1 a Hypothetical protein MGC3136 
NM_018095.1 a Hypothetical protein FLJ10450 
NM_020672.1 S100-type calcium binding protein A14 
NM_004422.1 Dishevelled 2 (homologous to Drosophila dsh) (DVL2) 
NM_022752.1 a Hypothetical protein FLJ22059 
NM_024956.1 Hypothetical protein FLJ23375 
NM_022777.1 a Hypothetical protein FLJ14117 
AW304174 a Chitobiase, di-N-acetyl 
NM_017631.1 Hypothetical protein FLJ20035 
NM_014322.1 Opsin 3 (encephalopsin) (OPN3) 
NM_023923.1 Hypothetical protein FLJ13171 
NM_017912.1 a Hypothetical protein FLJ20637 
NM_018534.1 a Hypothetical protein PRO2714 
NM_018190.1 a Hypothetical protein FLJ10715 
NM_018219.1 Hypothetical protein FLJ10786 
NM_014421.1 Dickkopf (Xenopus laevis) homolog 2 (DKK2) 
NM_005021.1 Ectonucleotide pyrophosphatase phosphodiesterase 3 (ENPP3) 
NM_007167.1   Zinc finger protein 258 (ZNF258) 
NM_022741.1 a Hypothetical protein FLJ11850 
NM_024708.1 a   Hypothetical protein FLJ2255 
NM_012282.1 Potassium voltage-gated channel, Isk-related family, 1-like (KCNE1L) 
NM_016644.1 Mesenchymal stem cell protein DSC54 
NM_017805.1 a Hypothetical protein FLJ20401 
NM_024923.1   Hypothetical protein FLJ22389 
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NM_018001.1 a Hypothetical protein FLJ10120 
NM_024907.1 Hypothetical protein FLJ11798  
NM_017658.1 a Hypothetical protein FLJ20081 
NM_024795.1 a Hypothetical protein FLJ22800  
NM_014137.1 a PRO0650 protein  
NM_024873.1 a Hypothetical protein FLJ21162  
NM_021208.1 EST-YD1 protein (EST-YD1) 
NM_018068.1 a Hypothetical protein FLJ10351 
NM_014147.1 a HSPC047 protein (HSPC047) 
NM_024720.1 Hypothetical protein FLJ23510 
NM_013348.1 Potassium inwardly-rectifying channel,subfamily J, 14 (KCNJ14) 
NM_018277.1 a Hypothetical protein FLJ10932 
NM_025093.1 a Hypothetical protein FLJ11827 
NM_013453.1 Sperm protein associated with  nucleus, X chromosome, member A1 (SPANXA1) 
NM_030900.1 a KIAA0948 protein 
NM_030974.1 a Hypothetical protein DKFZp434N1923 
NM_024734.1 a Hypothetical protein FLJ12383 
NM_018485.1 a G protein-coupled receptor C5L2 
NM_020351.1 Macrophage conditioned medium-induced protein smag-64  
NM_005417.1   v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC) 
NM_001279.1 a Cell death-inducing DFFA-like effector a (CIDEA) 
NM_005092.1 Tumor necrosis factor (ligand) 18 (TNFSF18) 
NM_031275.1 Testis expressed sequence 12 (TEX12) 
AF181985.1 Serinethreonine kinase (KDS) 
AY009401.1 WNT6 precursor (WNT6) 
AA456973 Activated RNA polymerase II transcription cofactor 4 
NM_000393.1 Collagen, type V, alpha 2 (COL5A2) 
AL540260 a Human PAC clone RP3-515N1 from 22q11.2-q22 
AL571723 a Weakly similar to human tyrosine kinase receptor Tie-1 precursor 
AI138993   Uncharacterized hematopoietic stem cells protein MDS026 
AI089655 a Hypothetical protein DKFZp547M136 
AI828531 a Hypothetical protein DKFZp547M136 
AB037823.1 a KIAA1402 protein 
AL566528 Neurofilament, light polypeptide 
AK025059.1 KIAA1332 protein 
AK024432.1   FLJ00022 protein 
AL121845 a Contains TNFRSF6B, an ADP-ribosylation factor family protein 
AL035588 a Contains genes for TFEB, NPM1 (Nucleophosmin) pseudogene and the MDFI gene  
AI279819 a DKFZp564O1763  
AW026481 Similar to A41784 tumor necrosis factor-alpha-induced protein B12 
AI809961 a Hypothetical protein from BCRA2 region 
AI806793   Collagen, type VIII, alpha 2 
BF513089 Thioredoxin reductase 3 (TRXR3) 
BE881590 a Homo sapiens clone 24421 mRNA 
AK023140.1 a Hypothetical protein FLJ13078 
AA906578 CLONE=IMAGE:1524202  
BF732879 a FLJ14307 
AI478455 Empty spiracles (Drosophila) homolog 2 
CAI933199 Neurexophilin 4 
AW006750 a Hypothetical protein FLJ20059 
AI199589 a Hypothetical protein DKFZp434E1723 
AK026747.1 FLJ23094 hypothetical protein 
AC003982 a Sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 4 
AK026947.1 3-phosphoinositide dependent protein kinase-1 
AA129909 a Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ 
AW301937 a CLONE=IMAGE:2766893 
AW514038 Olfactory receptor, family 7, subfamily E, member 47 pseudogene 
  
Downregulated genes (n=36) 
L13852   Ubiquitin-activating enzyme E1 related protein 
S72904 b APK1 antigen=MAb KI recognized 
AB011174 b   KIAA0602 protein 
L06147 b Human (clone SY11) golgin-95 mRNA 
D87470 b KIAA0280 protein 
U46024 b Myotubularin (MTM1) 
AB029343 HCR (alpha-helix coiled-coil rod homologue) 
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X74496 b Prolyl oligopeptidase 
AI984221 b Clone=IMAGE-2562160 
N92501 b Spectrin, beta, non-erythrocytic 1 
NM_001387.1 dihydropyrimidinase-like 3 (DPYSL3) 
D13891.1 b   Id-2H 
AI937543 b DC12 protein 
NM_002345.1 b Lumican (LUM) 
AF324888.1 Myosin phosphatase target subunit 2 
NM_005228.1 Epidermal growth factor receptor (EGFR) 
AV757675 b Tumor necrosis factor alpha-inducible 
NM_003367.1 b Upstream transcription factor 2, c-fos interacting (USF2) 
BG434168 b KIAA0254 gene product 
X98405.1 b Myelin associated glycoprotein, S-MAG 
M90355 b BTF3 protein homologue, basic transcription factor 3, like 2 
BG290532 b Moderately similar to Z137_HUMAN ZINC FINGER PROTEIN 13 
AW007368 Heme-regulated initiation factor 2-alpha kinase 
NM_012141.1 b Deleted in cancer 1; RNA helicase HDBDICE1 (DDX26) 
NM_018048.1 b Hypothetical protein FLJ10292 
NM_020379.1 1,2-alpha-mannosidase IC (HMIC) 
NM_014650.1 b KIAA0798 gene product 
NM_019618.1 b Interleukin-1 homolog 1 (IL-1H1) 
NM_020358.1 b Ring finger protein 18 (RNF18) 
NM_018603.1 b Hypothetical protein PRO1496 
NM_005712.1 b HERV-H LTR-associating 1 (HHLA1) 
NM_025042.1 b Hypothetical protein FLJ22367 
AI948472 Paired box gene 8 
AK021672.1 b Hypothetical protein FLJ21820 
AW979196 b Moderately similar to ALU1_HUMAN ALU SUBFAMILY J 
BF573849 b Weakly similar to ALUC_HUMAN 
  
NCCIT genes specifically upregulated in Jurkat extract-treated cells  (n=12/70) 
AA772285 c Vitamin D (1,25- dihydroxyvitamin D3) receptor 
AF208043.1 c IFI16b (IFI16b) 
NM_000954.1 c Prostaglandin D2 synthase (21kD, brain) (PTGDS) 
BG484069 c FANCA gene, exon 10a 
AL031228 c Contains BING5, exons 11-15 of BING4, GalT3, RPS18,  SACM2L 
AW085172 c Highly similar to KPCM_HUMAN PROTEIN KINASE C, MU TYPE 
NM_017699.1 c Hypothetical protein FLJ20174 
NM_017713.1 c Hypothetical protein FLJ20211 
NM_002420.2 c Melastatin 1 (MLSN1) 
U46010.1 c Hepatocyte growth factor agonist-antagonist 
AI803302 c Z-band alternatively spliced PDZ-motif 
NM_024123.1 c Putative Ly-6 superfamily member (G6E) 
 
 
a Gene also upregulated in 293T cells treated with Jurkat extract (n=58).   
b Gene also downregulated in 293T cells treated with Jurkat extract (n=28).   
c Gene not detected in 293T extract-treated cells. Total numbers of NCCIT genes up- or 
downregulated in Jurkat extract-treated cells are 70 (58 annoted a + 12 annotated c) and 28 (annoted b), 
respectively.  
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Supplementary Table S3. NCCIT genes consistently up- or downregulated over eight weeks after 
treatment with NCCIT extract  
Upregulated genes (n=686)a
Cluster Incl. AB006533:Homo sapiens RecQ5 mRNA for DNA helicase, complete cds  
Cluster Incl. M24899:Human triiodothyronine (ear7) mRNA, complete cds  
Cluster Incl. AB015331:Homo sapiens HRIHFB2017 mRNA, partial cds  
Cluster Incl. M96789:Homo sapiens connexin 37 (GJA4) mRNA, complete cds  
Cluster Incl. AI003763:ou91e02.x1 Homo sapiens cDNA, 3' end  
Cluster Incl. AL047020:DKFZp586N1517_s1 Homo sapiens cDNA, 3' end  
Cluster Incl. AA402435:zt60g10.r1 Homo sapiens cDNA, 5' end  
Cluster Incl. W72694:zd68f10.s1 Homo sapiens cDNA, 3' end  
Cluster Incl. AI161338:qb80a04.x1 Homo sapiens cDNA, 3' end  
gb:BC001643.1 /DEF=Homo sapiens, tumor necrosis factor, alpha-induced protein 1 (endothelial) 
gb:AF119897.1 /DEF=Homo sapiens PRO2760 mRNA, complete cds.  
gb:NM_022844.1 /DEF=Homo sapiens myosin, heavy polypeptide 11, smooth muscle (MYH11), transcript variant SM2, mRNA.   
gb:NM_000552.2 /DEF=Homo sapiens von Willebrand factor (VWF), mRNA.  
gb:NM_005562.1 /DEF=Homo sapiens laminin, gamma 2, mRNA.   
Consensus includes gb:BC000023.1 /DEF=Homo sapiens, ribosomal protein S19, clone MGC:1630, mRNA, complete cds.  
Consensus includes gb:AI467916 AXL receptor tyrosine kinase 
gb:NM_006129.2 /DEF=Homo sapiens bone morphogenetic protein 1 (BMP1), transcript variant BMP1-3, mRNA. 
gb:NM_014672.1 /DEF=Homo sapiens KIAA0391 gene product (KIAA0391), mRNA.  
Consensus includes gb:AW117498 forkhead box O1A (rhabdomyosarcoma)  
Consensus includes gb:W72082 complement component C1q receptor  
gb:NM_002342.1 /DEF=Homo sapiens lymphotoxin beta receptor (TNFR superfamily, member 3 (LTBR), mRNA.  
gb:AF097493.1 /DEF=Homo sapiens glutaminase kidney isoform mRNA, complete cds.  
Consensus includes gb:AB007869.1 /DEF=Homo sapiens KIAA0409 mRNA, partial cds. 
Consensus includes gb:AW139152  Notch (Drosophila) homolog 3  
gb:NM_000702.1 /DEF=Homo sapiens ATPase, Na+K+ transporting, alpha 2 (+) polypeptide (ATP1A2), mRNA.  
gb:NM_000129.2 /DEF=Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), mRNA. 
gb:NM_014782.1 /DEF=Homo sapiens KIAA0512 gene product (KIAA0512), mRNA.  
Consensus includes gb:T79216 KIAA1046 protein  
gb:NM_012306.1 /DEF=Homo sapiens lifeguard (KIAA0950), mRNA. 
gb:NM_004244.1 /DEF=Homo sapiens CD163 antigen (CD163), mRNA.  
gb:NM_002996.1 /DEF=Homo sapiens small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (SCYD1), mRNA.   
gb:NM_014961.1 /DEF=Homo sapiens KIAA0871 protein (KIAA0871), mRNA.  
gb:NM_020991.2 /DEF=Homo sapiens chorionic somatomammotropin hormone 2 (CSH2), transcript variant 1, mRNA. 
gb:NM_005781.2 /DEF=Homo sapiens activated p21cdc42Hs kinase (ACK1), mRNA. 
gb:NM_001998.1 /DEF=Homo sapiens fibulin 2 (FBLN2), mRNA.  
gb:NM_000361.1 /DEF=Homo sapiens thrombomodulin (THBD), mRNA. 
gb:NM_000397.2 /DEF=Homo sapiens cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB), mRNA. 
gb:J02694.1 /DEF=Human myeloperoxidase mRNA, complete cds. 
gb:NM_004688.1 Homo sapiens N-myc (and STAT) interactor (NMI), mRNA. 
gb:NM_000570.1  Fc fragment of IgG, low affinity IIIb, receptor for (CD16) (FCGR3B), mRNA. 
gb:NM_000314.1 /DEF=Homo sapiens phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), mRNA 
gb:NM_014963.1 /DEF=Homo sapiens KIAA0963 protein (KIAA0963), mRNA. 
Consensus includes gb:AI655714 KIAA1052 protein 
Consensus includes gb:AA772285  vitamin D (1,25- dihydroxyvitamin D3) receptor  
gb:NM_006017.1 /DEF=Homo sapiens prominin (mouse)-like 1 (PROML1), mRNA.  
Consensus includes gb:BF305380 G-2 and S-phase expressed 1 /FL=gb:AF223408.1 gb:NM_016426.1 
Consensus includes gb:N46430  zinc finger protein 202 /FL=gb:NM_003455.1 gb:AF027218.1 gb:AF027219.1 
gb:BC000737.1 /DEF=Homo sapiens, regulator of G-protein signalling 4, clone MGC:2124, mRNA, complete cds.   
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gb:NM_005980.1 /DEF=Homo sapiens S100 calcium-binding protein P (S100P), mRNA.  
Consensus includes gb:BG474736 galactokinase 1  
gb:NM_003657.1 /DEF=Homo sapiens breast carcinoma amplified sequence 1 (BCAS1), mRNA. 
gb:BC005248.1 /DEF=Homo sapiens, clone MGC:12282, mRNA, complete cds.  
gb:NM_000184.1 /DEF=Homo sapiens hemoglobin, gamma G (HBG2), mRNA. 
gb:NM_000610.1 /DEF=Homo sapiens CD44 antigen (homing function and Indian blood group system) (CD44), mRNA. 
gb:NM_014800.1 /DEF=Homo sapiens KIAA0281 gene product (KIAA0281), mRNA.  
gb:NM_000862.1 /DEF=Homo sapiens hydroxy-delta-5-steroid dehydrogenase, 3 beta 1 (HSD3B1), mRNA.  
gb:NM_000638.1 /DEF=Homo sapiens vitronectin  (VTN), mRNA.  
gb:U38321.1 /DEF=Homo sapiens clone rasi-11 matrix metalloproteinase RASI-1 mRNA, complete cds. 
gb:NM_004496.1 /DEF=Homo sapiens hepatocyte nuclear factor 3, alpha (HNF3A), mRNA.  
gb:NM_004809.1 /DEF=Homo sapiens stomatin-like 1 (STOML1), mRNA.  
gb:NM_000035.1 /DEF=Homo sapiens aldolase B, fructose-bisphosphate (ALDOB), mRNA.  
gb:NM_000130.2 /DEF=Homo sapiens coagulation factor V (proaccelerin, labile factor) (F5), mRNA.  
gb:NM_001714.1 /DEF=Homo sapiens Bicaudal D (Drosophila) homolog 1 (BICD1), mRNA.  
gb:NM_014714.1 /DEF=Homo sapiens KIAA0590 gene product (KIAA0590), mRNA. 
gb:NM_003716.1 /DEF=Homo sapiens Ca2+-dependent activator protein for secretion (CADPS), mRNA.   
gb:NM_006994.2 /DEF=Homo sapiens butyrophilin, subfamily 3, member A3 (BTN3A3), mRNA.  
gb:NM_014381.1 /DEF=Homo sapiens mutL (E. coli) homolog 3 (MLH3), mRNA. 
gb:NM_002832.1 /DEF=Homo sapiens protein tyrosine phosphatase, non-receptor type 7 (PTPN7), mRNA.  
gb:NM_002594.1 /DEF=Homo sapiens proprotein convertase subtilisinkexin type 2 (PCSK2), mRNA.  
gb:NM_014882.1 /DEF=Homo sapiens KIAA0053 gene product (KIAA0053), mRNA.  
gb:NM_004507.1 /DEF=Homo sapiens HUS1 (S. pombe) checkpoint homolog (HUS1), mRNA.  
gb:NM_002060.1 /DEF=Homo sapiens gap junction protein, alpha 4, 37kD (connexin 37) (GJA4), mRNA.   
Consensus includes gb:AI419307  ring finger protein 22  
gb:NM_002667.1 /DEF=Homo sapiens phospholamban (PLN), mRNA.  
gb:NM_002846.1 /DEF=Homo sapiens protein tyrosine phosphatase, receptor type, N (PTPRN), mRNA.  
gb:NM_014400.1 /DEF=Homo sapiens GPI-anchored metastasis-associated protein homolog (C4.4A), mRNA.  
gb:NM_005213.1 /DEF=Homo sapiens cystatin A (stefin A) (CSTA), mRNA.  
gb:NM_002216.1 /DEF=Homo sapiens inter-alpha (globulin) inhibitor, H2 polypeptide (ITIH2), mRNA.  
gb:NM_014622.1 /DEF=Homo sapiens loss of heterozygosity, 11, chromosomal region 2, gene A (LOH11CR2A), mRNA.  
gb:NM_005130.1 /DEF=Homo sapiens heparin-binding growth factor binding protein (HBP17), mRNA.   
gb:NM_012448.1 /DEF=Homo sapiens signal transducer and activator of transcription 5B (STAT5B), mRNA. 
Consensus includes gb:BG540504 zinc finger protein, subfamily 1A, 1 (Ikaros)  
gb:NM_014221.1 /DEF=Homo sapiens mature T-cell proliferation 1 (MTCP1), mRNA.  
gb:NM_000232.1 /DEF=Homo sapiens sarcoglycan, beta (43kD dystrophin-associated glycoprotein) (SGCB), mRNA.  
gb:NM_002975.1 /DEF=Homo sapiens stem cell growth factor; lymphocyte secreted C-type lectin (SCGF), mRNA.  
gb:NM_006946.1 /DEF=Homo sapiens spectrin, beta, non-erythrocytic 2 (SPTBN2), mRNA.  
gb:NM_022829.1 /DEF=Homo sapiens sodium-dependent high-affinity dicarboxylate transporter 3 (NADC3), mRNA.  
gb:NM_000399.2 /DEF=Homo sapiens early growth response 2 (Krox-20 (Drosophila) homolog) (EGR2), mRNA.  
gb:NM_000238.1 /DEF=Homo sapiens potassium voltage-gated channel, subfamily H (eag-related), member 2 (KCNH2), mRNA.   
gb:NM_002309.2 /DEF=Homo sapiens leukemia inhibitory factor (cholinergic differentiation factor) (LIF), mRNA.  
gb:NM_001200.1 /DEF=Homo sapiens bone morphogenetic protein 2 (BMP2), mRNA.  
gb:NM_002854.1 /DEF=Homo sapiens parvalbumin (PVALB), mRNA. /FEA=mRNA  
Consensus includes gb:AL139318 Contains  DCT gene for dopachrome tautomerase, gene for DTDP-D-glucose 4,6-dehydratase 
Consensus includes gb:AA527340 homeo box B6 /FL=gb:NM_018952.1 
gb:NM_014690.1 /DEF=Homo sapiens KIAA0773 gene product (KIAA0773), mRNA. 
gb:M28880.1 /DEF=Human erythroid ankyrin mRNA, complete cds. 
gb:NM_002005.2 /DEF=Homo sapiens feline sarcoma viral (v-fes) (PRCII) viral (v-fps) oncogene homolog (FES), mRNA. 
gb:NM_000854.2 /DEF=Homo sapiens glutathione S-transferase theta 2 (GSTT2), mRNA.  
gb:NM_001230.1 /DEF=Homo sapiens caspase 10, apoptosis-related cysteine protease (CASP10), mRNA.   
gb:NM_006144.2 /DEF=Homo sapiens granzyme (GZMA), mRNA.   
gb:NM_024009.1 /DEF=Homo sapiens gap junction protein, beta 3, 31kD (connexin 31) (GJB3), mRNA.  
gb:NM_005401.1 /DEF=Homo sapiens protein tyrosine phosphatase, non-receptor type 14 (PTPN14), mRNA. 
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gb:NM_001490.1 /DEF=Homo sapiens glucosaminyl (N-acetyl) transferase 1, core 2 (GCNT1), mRNA.   
gb:NM_006200.1 /DEF=Homo sapiens proprotein convertase subtilisinkexin type 5 (PCSK5), mRNA. 
gb:NM_020980.2 /DEF=Homo sapiens aquaporin 9 (AQP9), mRNA.  
gb:NM_000603.1 /DEF=Homo sapiens nitric oxide synthase 3 (endothelial cell) (NOS3), mRNA.  
Consensus includes gb:NM_007045.1 /DEF=Homo sapiens FGFR1 oncogene partner (FOP), mRNA 
gb:NM_005658.1 /DEF=Homo sapiens TNF receptor-associated factor 1 (TRAF1), mRNA.  
gb:NM_002336.1 /DEF=Homo sapiens low density lipoprotein receptor-related protein 6 (LRP6), mRNA.  
gb:NM_001870.1 /DEF=Homo sapiens carboxypeptidase A3 (mast cell) (CPA3), mRNA. 
gb:NM_000756.1 /DEF=Homo sapiens corticotropin releasing hormone (CRH), mRNA.  
gb:NM_018843.1 /DEF=Homo sapiens mitochondrial carrier family protein (LOC55972), mRNA.  
gb:NM_000499.2 /DEF=Homo sapiens cytochrome P450, subfamily I, polypeptide 1 (CYP1A1), mRNA. 
gb:NM_001461.1 /DEF=Homo sapiens flavin containing monooxygenase 5 (FMO5), mRNA.  
gb:NM_025228.1 /DEF=Homo sapiens hypothetical protein dJ434O14.3 (DJ434O14.3), mRNA.  
gb:NM_005012.1 /DEF=Homo sapiens receptor tyrosine kinase-like orphan receptor 1 (ROR1), mRNA.  
gb:NM_002214.1 /DEF=Homo sapiens integrin, beta 8 (ITGB8), mRNA.  
gb:NM_001541.1 /DEF=Homo sapiens heat shock 27kD protein 2 (HSPB2), mRNA. 
Consensus includes gb:AW975818  hypothetical protein FLJ21940 /FL=gb:NM_022828.1 
Consensus includes gb:AI269290 solute carrier family 18 (vesicular monoamine), member 2  
gb:NM_002220.1 /DEF=Homo sapiens inositol 1,4,5-trisphosphate 3-kinase A (ITPKA), mRNA.  
gb:NM_016381.1 /DEF=Homo sapiens hypothetical protein (DKFZp434J0310), mRNA. 
gb:NM_002960.1 /DEF=Homo sapiens S100 calcium-binding protein A3 (S100A3), mRNA. 
gb:NM_002908.1 /DEF=Homo sapiens v-rel avian reticuloendotheliosis viral oncogene homolog (REL), mRNA.  
gb:NM_003298.1 Homo sapiens nuclear receptor subfamily 2, group C, member 2 (NR2C2), mRNA.  
gb:NM_001821.1 /DEF=Homo sapiens choroideremia-like (Rab escort protein 2) (CHML), mRNA.  
gb:NM_006674.1 /DEF=Homo sapiens MHC class I region ORF (P5-1), mRNA. 
gb:NM_007105.1 /DEF=Homo sapiens solute carrier family 22, member 1-like antisense (SLC22A1LS), mRNA.  
gb:NM_000366.1 /DEF=Homo sapiens tropomyosin 1 (alpha) (TPM1), mRNA.  
gb:NM_004742.1 /DEF=Homo sapiens BAI1-associated protein 1 (BAIAP1), mRNA.  
gb:NM_001174.2 /DEF=Homo sapiens Rho GTPase activating protein 6 (ARHGAP6), transcript variant 2, mRNA.  
gb:NM_025013.1 /DEF=Homo sapiens KIAA1031 protein (KIAA1031), mRNA. 
gb:NM_007368.1 /DEF=Homo sapiens RAS p21 protein activator 3 (Ins(1,3,4,5)P4-binding protein) (RASA3), mRNA.  
gb:NM_002312.1 /DEF=Homo sapiens ligase IV, DNA, ATP-dependent (LIG4), mRNA. 
gb:NM_006183.2 /DEF=Homo sapiens neurotensin (NTS), mRNA. 
gb:NM_021114.1 /DEF=Homo sapiens serine protease inhibitor, Kazal type, 2 (acrosin-trypsin inhibitor) (SPINK2), mRNA.  
gb:NM_000928.1 /DEF=Homo sapiens phospholipase A2, group IB (pancreas) (PLA2G1B), mRNA.   
gb:NM_018651.1 /DEF=Homo sapiens zinc finger protein (ZFP), mRNA 
gb:NM_004778.1 /DEF=Homo sapiens G protein-coupled receptor 44 (GPR44), mRNA. 
gb:NM_002411.1 /DEF=Homo sapiens mammaglobin 1 (MGB1), mRNA. 
gb:NM_007314.1 /DEF=Homo sapiens v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2), variant b, mRNA.   
Consensus includes gb:AI769310 tolloid-like 1 /FL=gb:U91963.1 gb:NM_012464.1 gb:AF282732.1 
gb:NM_003456.1 /DEF=Homo sapiens zinc finger protein 205 (ZNF205), mRNA. 
gb:NM_005849.1 /DEF=Homo sapiens immunoglobulin superfamily, member 6 (IGSF6), mRNA. 
Consensus includes gb:BE856376 very long-chain acyl-CoA synthetase; lipidosin /FL=gb:NM_015162.1 gb:AF179481.1 
gb:NM_002420.2 /DEF=Homo sapiens melastatin 1 (MLSN1), mRNA. 
gb:NM_002652.1 /DEF=Homo sapiens prolactin-induced protein (PIP), mRNA. 
gb:NM_004062.1 /DEF=Homo sapiens cadherin 16, KSP-cadherin (CDH16), mRNA. 
gb:NM_003381.1 /DEF=Homo sapiens vasoactive intestinal peptide (VIP), mRNA.  
gb:NM_000448.1 /DEF=Homo sapiens recombination activating gene 1 (RAG1), mRNA. 
gb:BC005124.1 /DEF=Homo sapiens, homeo box D3, clone MGC:10470, mRNA, complete cds.  
gb:NM_006898.2 /DEF=Homo sapiens homeo box D3 (HOXD3), mRNA. 
gb:NM_000236.1 /DEF=Homo sapiens lipase, hepatic (LIPC), mRNA. 
gb:NM_000128.2 /DEF=Homo sapiens coagulation factor XI (plasma thromboplastin antecedent) (F11), variant 1, mRNA. 
gb:NM_002910.4 Homo sapiens renin-binding protein (RENBP), mRNA. 
gb:NM_000372.1 /DEF=Homo sapiens tyrosinase (oculocutaneous albinism IA) (TYR), mRNA. 
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gb:NM_016384.1 /DEF=Homo sapiens hypothetical protein (HSPC050), mRNA.  
gb:NM_002104.1 /DEF=Homo sapiens granzyme K (serine protease, granzyme 3; tryptase II) (GZMK), mRNA.  
gb:NM_007223.1 /DEF=Homo sapiens putative G protein coupled receptor (GPR), mRNA. 
gb:NM_002277.1 /DEF=Homo sapiens keratin, hair, acidic,1 (KRTHA1), mRNA. / 
gb:NM_006344.1 /DEF=Homo sapiens macrophage lectin 2 (calcium dependent) (HML2), mRNA.  
gb:NM_006229.1 /DEF=Homo sapiens pancreatic lipase-related protein 1 (PNLIPRP1), mRNA.  
gb:NM_014907.1 /DEF=Homo sapiens KIAA0967 protein (KIAA0967), mRNA. 
gb:NM_004101.1 /DEF=Homo sapiens coagulation factor II (thrombin) receptor-like 2 (F2RL2), mRNA.  
gb:NM_005106.2 /DEF=Homo sapiens deleted in lung and esophageal cancer 1 (DLEC1), transcript variant DLEC1-N1, mRNA.  
gb:NM_014274.1 /DEF=Homo sapiens Alu-binding protein with zinc finger domain (ABPZF), mRNA.  
gb:NM_004186.1 /DEF=Homo sapiens sema domain, immunoglobulin domain 3F (SEMA3F), mRNA. 
gb:NM_015370.1 /DEF=Homo sapiens hypothetical protein (HS747E2A), mRNA.  
gb:NM_001794.1 /DEF=Homo sapiens cadherin 4, type 1, R-cadherin (retinal) (CDH4), mRNA. 
gb:NM_001104.1 /DEF=Homo sapiens actinin, alpha 3 (ACTN3), mRNA.  
gb:NM_005728.1 /DEF=Homo sapiens endonuclease G-like 2 (ENDOGL2), mRNA.  
gb:NM_005666.1 /DEF=Homo sapiens H factor (complement)-like 3 (HFL3), mRNA.  
gb:NM_005838.1 /DEF=Homo sapiens putative glycine-N-acyltransferase (GAT), mRNA.   
gb:NM_006065.1 /DEF=Homo sapiens signal regulatory protein, beta, 1 (SIRP-BETA-1), mRNA.  
gb:NM_003126.1 /DEF=Homo sapiens spectrin, alpha, erythrocytic 1 (elliptocytosis 2) (SPTA1), mRNA.  
gb:NM_014120.1 /DEF=Homo sapiens PRO0214 protein (PRO0214), mRNA. 
gb:NM_000197.1 /DEF=Homo sapiens hydroxysteroid (17-beta) dehydrogenase 3 (HSD17B3), mRNA.  
gb:NM_001899.1 /DEF=Homo sapiens cystatin S (CST4), mRNA.  
gb:NM_005605.1 /DEF=Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (PPP3CC), mRNA.  
gb:NM_030379.1 /DEF=Homo sapiens GLI-Kruppel family member GLI2 (GLI2), transcript variant 1, mRNA.  
gb:NM_006140.1 /DEF=Homo sapiens colony stimulating factor 2 receptor, alpha, low-affinity (CSF2RA), mRNA.   
gb:AF005213.1 /DEF=Homo sapiens ankyrin 1 (ANK1) mRNA, complete cds.  
gb:NM_002039.1 /DEF=Homo sapiens GRB2-associated binding protein 1 (GAB1), mRNA.  
gb:NM_003833.2 /DEF=Homo sapiens matrilin 4 (MATN4), transcript variant 1, mRNA. 
gb:NM_018634.1 /DEF=Homo sapiens hypothetical protein PRO2893 (PRO2893), mRNA.  
gb:NM_001118.1 /DEF=Homo sapiens adenylate cyclase activating polypeptide 1 receptor type I (ADCYAP1R1), mRNA.  
gb:NM_004258.1 /DEF=Homo sapiens immunoglobulin superfamily, member 2 (IGSF2), mRNA.  
gb:NM_003561.1 /DEF=Homo sapiens phospholipase A2, group X (PLA2G10), mRNA.  
gb:NM_000762.2 /DEF=Homo sapiens cytochrome P450, subfamily IIA, polypeptide 6 (CYP2A6), mRNA.  
gb:NM_004212.1 /DEF=Homo sapiens solute carrier family 28, member 2 (SLC28A2), mRNA.   
gb:NM_006678.1 Homo sapiens CMRF35 leukocyte immunoglobulin-like receptor (CMRF35), mRNA. 
gb:NM_024325.1 /DEF=Homo sapiens hypothetical protein MGC10715 (MGC10715), mRNA.  
gb:NM_001523.1 /DEF=Homo sapiens hyaluronan synthase 1 (HAS1), mRNA. 
gb:NM_001729.1 /DEF=Homo sapiens betacellulin (BTC), mRNA. 
gb:NM_016343.1 /DEF=Homo sapiens centromere protein F (350400kD, mitosin) (CENPF), mRNA.  
gb:NM_002777.2 /DEF=Homo sapiens proteinase 3 (PRTN3), mRNA.   
gb:NM_017513.1 /DEF=Homo sapiens metaphase chromosome protein 1 (HSMCR30), mRNA.  
gb:NM_000335.1 /DEF=Homo sapiens sodium channel, voltage-gated, type V, alpha polypeptide (SCN5A), mRNA.  
gb:NM_005593.1 /DEF=Homo sapiens myogenic factor 5 (MYF5), mRNA.  
gb:NM_006640.1 /DEF=Homo sapiens MLL septin-like fusion (MSF), mRNA.  
gb:NM_004256.1 /DEF=Homo sapiens organic cationic transporter-like 3 (ORCTL3), mRNA.  
gb:NM_018546.1 /DEF=Homo sapiens hypothetical protein PRO2958 (PRO2958), mRNA. 
gb:NM_002363.1 /DEF=Homo sapiens melanoma antigen, family B, 1 (MAGEB1), mRNA.  
gb:NM_003744.1 /DEF=Homo sapiens numb (Drosophila) homolog (NUMB), mRNA.  
gb:NM_001531.1 /DEF=Homo sapiens major histocompatibility complex, class I-like sequence (HLALS), mRNA.   
gb:NM_000451.2 /DEF=Homo sapiens short stature homeobox (SHOX), transcript variant SHOXa, mRNA.  
gb:NM_024716.1 /DEF=Homo sapiens hypothetical protein FLJ23505 (FLJ23505), mRNA.  
gb:NM_003508.1 /DEF=Homo sapiens frizzled (Drosophila) homolog 9 (FZD9), mRNA.  
gb:NM_004680.1 /DEF=Homo sapiens chromodomain protein, Y chromosome, 1 (CDY1), mRNA. 
gb:NM_013308.1 /DEF=Homo sapiens platelet activating receptor homolog (H963), mRNA.  
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gb:NM_013416.1 /DEF=Homo sapiens neutrophil cytosolic factor 4 (40kD) (NCF4), transcript variant 2, mRNA.   
gb:NM_001187.1 /DEF=Homo sapiens B melanoma antigen (BAGE), mRNA.  
gb:NM_021981.1 /DEF=Homo sapiens pre-TNK cell associated protein (1D12A), mRNA.  
gb:NM_025068.1 /DEF=Homo sapiens hypothetical protein FLJ13381 (FLJ13381), mRNA. 
gb:NM_004857.1 /DEF=Homo sapiens A kinase (PRKA) anchor protein 5 (AKAP5), mRNA. 
gb:NM_002188.1 /DEF=Homo sapiens interleukin 13 (IL13), mRNA.  
gb:NM_006866.1 /DEF=Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A, member 2 (LILRA2), mRNA.   
gb:NM_018896.1 /DEF=Homo sapiens calcium channel, voltage-dependent, alpha 1G subunit (CACNA1G), mRNA.  
gb:NM_002390.2 /DEF=Homo sapiens a disintegrin and metalloproteinase domain 11 (ADAM11), transcript variant 1, mRNA.   
gb:NM_005468.1 /DEF=Homo sapiens N-acetylated alpha-linked acidic dipeptidase-like (NAALADASEL), mRNA.  
gb:NM_005575.1 /DEF=Homo sapiens leucylcystinyl aminopeptidase (LNPEP), mRNA.  
gb:NM_001989.1 /DEF=Homo sapiens even-skipped homeo box 1 (homolog of Drosophila) (EVX1), mRNA.   
gb:NM_001840.1 /DEF=Homo sapiens cannabinoid receptor 1 (brain) (CNR1), mRNA.  
gb:NM_006664.1 /DEF=Homo sapiens small inducible cytokine subfamily A (Cys-Cys), member 27 (SCYA27), mRNA.  
gb:NM_002738.1 /DEF=Homo sapiens protein kinase C, beta 1 (PRKCB1), mRNA.  
gb:NM_000825.1 /DEF=Homo sapiens gonadotropin-releasing hormone 1 (leutinizing-releasing hormone) (GNRH1), mRNA.  
gb:NM_006885.1 /DEF=Homo sapiens AT-binding transcription factor 1 (ATBF1), mRNA.  
gb:NM_003891.1 /DEF=Homo sapiens protein Z, vitamin K-dependent plasma glycoprotein (PROZ), mRNA.  
gb:NM_015601.1 /DEF=Homo sapiens DKFZP564G092 protein (DKFZP564G092), mRNA. 
gb:NM_015879.1 /DEF=Homo sapiens sialyltransferase 8C (SIAT8C), mRNA.   
gb:NM_000888.3 /DEF=Homo sapiens integrin, beta 6 (ITGB6), mRNA.  
gb:AF338730.1 /DEF=Homo sapiens potassium voltage-gated channel, Shab-related subfamily, member 2 (KCNB2), mRNA. 
gb:NM_031269.1 /DEF=Homo sapiens PRO1386 protein (PRO1386), mRNA. 
gb:NM_017959.1 /DEF=Homo sapiens hypothetical protein FLJ20802 (FLJ20802), mRNA. 
gb:NM_001447.1 /DEF=Homo sapiens FAT tumor suppressor (Drosophila) homolog 2 (FAT2), mRNA.  
gb:NM_002176.1 /DEF=Homo sapiens interferon, beta 1, fibroblast (IFNB1), mRNA. 
gb:NM_000716.1 /DEF=Homo sapiens complement component 4-binding protein, beta (C4BPB), mRNA.  
gb:NM_020328.1 /DEF=Homo sapiens activin A receptor, type IB (ACVR1B), transcript variant 3, mRNA.  
gb:NM_002144.1 /DEF=Homo sapiens homeo box B1 (HOXB1), mRNA. 
gb:NM_022975.1 /DEF=Homo sapiens fibroblast growth factor receptor 2 (FGFR2), transcript variant 8, mRNA.  
gb:NM_022976.1 /DEF=Homo sapiens fibroblast growth factor receptor 2 (FGFR2), transcript variant 9, mRNA.  
gb:NM_004495.1 /DEF=Homo sapiens neuregulin 1 (NRG1), transcript variant HRG-gamma, mRNA.   
gb:NM_021777.1 /DEF=Homo sapiens a disintegrin and metalloproteinase domain 28 (ADAM28), transcript variant 3, mRNA.  
gb:NM_022375.1 /DEF=Homo sapiens oculomedin (OCLM), mRNA.  
gb:NM_005058.1 /DEF=Homo sapiens RNA binding motif protein, Y chromosome, family 1, member A1 (RBMY1A1), mRNA.   
gb:NM_002036.1 /DEF=Homo sapiens Duffy blood group (FY), mRNA. 
gb:NM_020479.1 /DEF=Homo sapiens ankyrin 1, erythrocytic (ANK1), transcript variant 6, mRNA.  
gb:NM_020480.1 /DEF=Homo sapiens ankyrin 1, erythrocytic (ANK1), transcript variant 7, mRNA.  
gb:NM_004510.1 /DEF=Homo sapiens interferon-induced protein 75, 52kD (IFI75), mRNA.  
gb:U01157.1 /DEF=Human glucagon-like peptide-1 receptor mRNA with CA dinucleotide repeat, complete cds.  
gb:NM_004991.1 /DEF=Homo sapiens myelodysplasia syndrome 1 (MDS1), mRNA. 
gb:NM_004976.1 /DEF=Homo sapiens potassium voltage-gated channel, Shaw-related subfamily, member 1 (KCNC1), mRNA.   
gb:NM_001049.1 /DEF=Homo sapiens somatostatin receptor 1 (SSTR1), mRNA.  
gb:NM_006538.1 /DEF=Homo sapiens BCL2-like 11 (apoptosis facilitator) (BCL2L11), mRNA.  
gb:NM_020297.1 /DEF=Homo sapiens ATP-binding cassette, sub-family C (CFTRMRP), member 9 (ABCC9), mRNA.   
gb:NM_003493.1 /DEF=Homo sapiens H3 histone family, member T (H3FT), mRNA.  
gb:NM_004189.1 /DEF=Homo sapiens SRY (sex determining region Y)-box 14 (SOX14), mRNA.  
gb:NM_003537.1 /DEF=Homo sapiens H3 histone family, member L (H3FL), mRNA.  
gb:NM_020389.1 /DEF=Homo sapiens putative capacitative calcium channel (trp7), mRNA. 
gb:NM_019093.1 /DEF=Homo sapiens UDP glycosyltransferase 1 family, polypeptide A3 (UGT1A3), mRNA.   
gb:NM_000614.1 /DEF=Homo sapiens ciliary neurotrophic factor (CNTF), mRNA.  
gb:NM_016431.1 /DEF=Homo sapiens mitogen-activated protein kinase 8 interacting protein 2 (MAPK8IP2), mRNA.   
Consensus includes gb:BG327863 CD24 antigen (small cell lung carcinoma cluster 4 antigen) 
Consensus includes gb:AI424923 adaptor-related protein complex 3, delta 1 subunit /FL=gb:AF002163.1 
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gb:J02923.1 /DEF=Human 65-kilodalton phosphoprotein (p65) mRNA, complete cds.  
gb:BC003143.1 /DEF=Homo sapiens, dual specificity phosphatase 6, clone MGC:3789, mRNA, complete cds.   
gb:AF074000.1 /DEF=Homo sapiens Po66 carbohydrate binding protein mRNA, complete cds.  
Consensus includes gb:BG165833 fatty acid desaturase 1  
gb:AF208043.1 /DEF=Homo sapiens IFI16b (IFI16b) mRNA, complete cds.  
gb:M13577.1 /DEF=Human myelin basic protein (MBP) mRNA, complete cds.  
gb:M25079.1 /DEF=Human sickle cell beta-globin mRNA, complete cds.  
gb:AF068266.1 /DEF=Homo sapiens EHT protein mRNA, complete cds.  
gb:BC001283.1 /DEF=Homo sapiens, Similar to nuclear factor IB, clone MGC:5146, mRNA, complete cds.  
gb:BC002690.1 /DEF=Homo sapiens, keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner), mRNA. 
gb:BC001743.1 /DEF=Homo sapiens, Similar to hypothetical protein FLJ10803, clone MGC:933, mRNA, complete cds.  
gb:U48437.1 /DEF=Human amyloid precursor-like protein 1 mRNA, complete cds.  
gb:M29644.1 /DEF=Human insulin-like growth factor I mRNA, complete cds.  
gb:BC001060.1 /DEF=Homo sapiens, paired box gene 8, clone MGC:2141, mRNA, complete cds.  
gb:AF072132.1 /DEF=Homo sapiens integrin alpha-7 mRNA, complete cds.  
Consensus includes gb:BC004864.1 /DEF=Homo sapiens, clone MGC:10576, mRNA, complete cds.  
Consensus includes gb:AI860917 glycoprotein Ib (platelet), beta polypeptide  
Consensus includes gb:AI628464  MAD (mothers against decapentaplegic, Drosophila) homolog 6  
gb:AF274863.1 /DEF=Homo sapiens secretory pathway component Sec31B-1 mRNA, alternatively spliced, complete cds.  
gb:AF083068.1 /DEF=Homo sapiens NAD+ ADP-ribosyltransferase 3 (ADPRT3) mRNA, complete cds.  
gb:BC004300.1 /DEF=Homo sapiens, Similar to villin-like, clone MGC:10896, mRNA, complete cds.  
gb:M34986.1 /DEF=Human erythropoietin receptor mRNA, complete cds. 
gb:D14826.1 /DEF=Human mRNA for hCREM (cyclic AMP-responsive element modulator) type 2 protein, complete cds.  
gb:U63041.1 /DEF=Human neural cell adhesion molecule CD56 mRNA, complete cds.  
gb:AF097419.1 /DEF=Homo sapiens 10IHW 9022 IkBL protein (NFKBIL1) mRNA, NFKBIL1-+738T allele, complete cds.   
Consensus includes gb:AA608820 KIAA0921 protein  
Consensus includes gb:AW205153 CLONE=IMAGE:2720104 /UG=Hs.57973 hypothetical protein  
Consensus includes gb:AA582460 ribosomal protein L5 /FL=gb:U66589.1 
gb:AF064484.1 /DEF=Homo sapiens natural resistance-associated macrophage protein 2 non-IRE form (NRAMP2) mRNA. 
gb:U06935.1 /DEF=Human thyrotroph embryonic factor (TEF) mRNA, complete cds. 
gb:AB013452.1 /DEF=Homo sapiens mRNA for ATPaseII, complete cds.  
gb:D28114.1 /DEF=Human mRNA for MOBP (myelin-associated oligodendrocytic basic protein), complete cds, clone hOPRP2.  
gb:U66584.1 /DEF=Human alphaA-crystallin (CRYAA) mRNA, complete cds. 
Consensus includes gb:R64001  CCR4-NOT transcription complex, subunit 4 
gb:AF009635.1 /DEF=Homo sapiens clone 17.7 immunoglobulin-like transcript 5 protein mRNA, complete cds. 
gb:M11734.1 /DEF=Human granulocytemacrophage colony-stimulating factor mRNA, complete cds.  
gb:BC001265.1 /DEF=Homo sapiens, Similar to hypothetical protein dJ462O23.2, clone MGC:5034, mRNA, complete cds.  
gb:AB033823.1 /DEF=Homo sapiens mRNA for h-TEKTIN-t, complete cds.  
gb:BC005196.1 /DEF=Homo sapiens, kallikrein 2, prostatic, clone MGC:12201, mRNA, complete cds.  
gb:AF323729.1 /DEF=Homo sapiens OSBP-related protein 7 mRNA, complete cds. 
gb:D38300.1 /DEF=Homo sapiens mRNA for prostaglandin E receotor EP3 subtype 4 isoform, complete cds.  
gb:U11287.1 /DEF=Human N-methyl-D-aspartate receptor subunit NR3 (hNR3) mRNA, complete cds.  
gb:J04948.1 /DEF=Human alkaline phosphatase (ALP-1) mRNA, complete cds.  
gb:BC000582.1 /DEF=Homo sapiens, Similar to KIAA0180 protein, clone MGC:2482, mRNA, complete cds.  
gb:AB033605.1 /DEF=Homo sapiens mRNA for pUb-R5, complete cds.  
gb:BC003408.1 /DEF=Homo sapiens, melanoma antigen, family A, 12, clone MGC:4914, mRNA, complete cds.  
gb:U71087.1 /DEF=Human MAP kinase kinase MEK5b mRNA, complete cds. 
gb:BC001279.1 /DEF=Homo sapiens, Similar to KIAA0626 gene product, clone MGC:5129, mRNA, complete cds.   
gb:AF214738.1 /DEF=Homo sapiens C9orf10b mRNA, complete cds, alternatively spliced. 
gb:AF241788.1 /DEF=Homo sapiens NPD011 (NPD011) mRNA, complete cds. 
gb:AF007748.1 /DEF=Homo sapiens karyopherin beta2b homolog mRNA, complete cds. 
gb:BC004552.1 /DEF=Homo sapiens, clone MGC:10646, mRNA, complete cds. 
gb:U26744.1 /DEF=Human dystrobrevin-gamma mRNA, complete cds. 
gb:BC001372.1 /DEF=Homo sapiens, Similar to ORF, clone MGC:2274, mRNA, complete cds.  
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gb:J04449.1 /DEF=Homo sapiens (clone NF 10) cytochrome P-450 nifedipine oxidase mRNA, complete cds.  
gb:AF064103.1 /DEF=Homo sapiens Cdc14A3 phosphatase mRNA, complete cds.  
gb:U46010.1 /DEF=Human HGF agonistantagonist mRNA, complete cds. 
gb:BC000052.1 /DEF=Homo sapiens, Similar to peroxisome proliferative activated receptor, alpha, clone MGC:2237, mRNA. 
gb:D86586.1 /DEF=Homo sapiens mRNA for SCGF-beta, complete cds.  
gb:M81590.1 /DEF=Homo sapiens serotonin 1D receptor (5-HT1D~) mRNA, complete cds. 
gb:U03891.2 /DEF=Homo sapiens phorbolin I mRNA, complete cds. 
gb:AF130071.1 /DEF=Homo sapiens clone FLB9023 PRO2425 mRNA, complete cds.  
gb:AF293342.1 /DEF=Homo sapiens RNF6 protein (RNF6) mRNA, complete cds, alternatively spliced.  
gb:BC006333.1 /DEF=Homo sapiens, clone MGC:12564, mRNA, complete cds. 
gb:AF122827.1 /DEF=Homo sapiens neurofibromatosis type 2 protein isoform Mer162 (NF2) mRNA, alternatively spliced. 
gb:AF130066.1 /DEF=Homo sapiens clone FLB8124 PRO2179 mRNA, complete cds.  
gb:M30894.1 /DEF=Human T-cell receptor Ti rearranged gamma-chain mRNA V-J-C region, complete cds.  
gb:AB008913.1 /DEF=Homo sapiens mRNA for Pax-4, complete cds.  
gb:D89788.1 /DEF=Homo sapiens mRNA for AML1, complete cds (acute myeloid leukemia 1; aml1 oncogene)  
gb:AF312386.1 /DEF=Homo sapiens clone L4 AML1AMP19 fusion protein (AML1AMP19 fusion) mRNA, complete cds.  
gb:AF116771.1 /DEF=Homo sapiens p51 delta mRNA, complete cds. 
gb:AF149096.1 /DEF=Homo sapiens transforming growth factor-alpha variant I mRNA. 
gb:AB012043.1 /DEF=Homo sapiens mRNA for NBR13, complete cds.  
gb:U85943.1 /DEF=Homo sapiens mRNA-associated protein mrnp41 mRNA, complete cds.  
gb:AF009007.1 /DEF=Homo sapiens immunoglobulin-like transcript 2c mRNA, complete cds.  
gb:M33653.1 /DEF=Human (clones HT-125,133) alpha-2 type IV collagen (COL4A2) mRNA, complete cds.  
gb:AB016900.1 /DEF=Homo sapiens HGC6.1.2 mRNA, complete cds.  
gb:U52913.1 /DEF=Human B219OB receptor isoform HuB219.2 precursor mRNA, complete cds.  
gb:AF004291.1 /DEF=Homo sapiens germ cell nuclear factor (GCNF) mRNA, complete cds.  
gb:AF117899.1 /DEF=Homo sapiens LDLR-FUT fusion protein (LDLR-FUT) mRNA, complete cds. 
gb:AF229067.1 /DEF=Homo sapiens PADI-H protein mRNA, complete cds.  
gb:D50479.1 /DEF=Homo sapiens mRNA for protein-tyrosine kinase, complete cds.  
gb:U70862.1 /DEF=Human nuclear factor I B3 mRNA, complete cds.  
gb:AB042825.1 /DEF=Homo sapiens RECQL5 gamma mRNA for DNA helicase recQ5 gamma, complete cds.   
gb:U73531.1 /DEF=Human G protein-coupled receptor STRL33.3 (STRL33) mRNA, complete cds.   
gb:AF081924.1 /DEF=Homo sapiens calciumcalmodulin-dependent protein kinase II beta 6 subunit (CAMKB) mRNA. 
gb:AF172449.1 /DEF=Homo sapiens clone 127 opioid growth factor receptor mRNA, complete cds.  
gb:AF000424.1 /DEF=Homo sapiens LST1 mRNA, cLST1C splice variant, complete cds.  
gb:U43279.1 /DEF=Human nucleoporin nup 36 mRNA, complete cds.  
gb:M13077.1 /DEF=Human placental alkaline phosphatase mRNA, complete cds 
gb:L23515.1 /DEF=Human Ig rearranged gamma-chain, V-DXP4-JH4b, complete cds. 
gb:L14458.1 /DEF=Human Ig rearranged kappa-chain gene V-J-region, complete cds.  
gb:L14455.1 /DEF=Human Ig rearranged mu-chain gene V-N-D-N-J-reion, complete cds.  
gb:K03226.1 /DEF=Human preprourokinase mRNA, complete cds.  
gb:AF349571.1 /DEF=Homo sapiens hemoglobin alpha-1 globin chain (HBA1) mRNA, complete cds.  
gb:BC005856.1 /DEF=Homo sapiens, clone MGC:2889, mRNA, complete cds.  
gb:BC005926.1 /DEF=Homo sapiens, ecotropic viral integration site 2B, clone MGC:14529, mRNA, complete cds.  
gb:BC006196.1 /DEF=Homo sapiens, tumor necrosis factor receptor superfamily, member 9, clone MGC:2172, mRNA. 
gb:AF319573.1 /DEF=Homo sapiens clone T2P4 3-5 exonuclease TREX2 (TREX2) mRNA, complete cds.  
gb:AB001733.1 /DEF=Homo sapiens mRNA for single-chain antibody, complete cds.  
gb:U88712.1 /DEF=Human phosphodiesterase 4C mRNA, complete cds.  
gb:AF187964.1 /DEF=Homo sapiens voltage gated potassium channel Kv4.3 short splice variant (Kv4.3) mRNA, complete cds.  
gb:AF110314.1 /DEF=Homo sapiens herpesvirus immunoglobulin-like receptor HIgR mRNA, complete cds.   
gb:AF222341.1 /DEF=Homo sapiens T-cell specific surface glycoprotein CD28 isoform 1 (CD28) gene, complete cds.   
gb:U27331.1 /DEF=Human alpha (1,3) fucosyltransferase (FUT6) mRNA, isoform I, complete cds.  
gb:AF138302.1 /DEF=Homo sapiens decorin variant C mRNA, complete cds.  
Consensus includes gb:AW277253 adenylate kinase 2 
Consensus includes gb:NM_000954.1 /DEF=Homo sapiens prostaglandin D2 synthase (21kD, brain) (PTGDS), mRNA.  
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Consensus includes gb:AL516854  putative translation initiation factor 
Consensus includes gb:AL575403 KIAA0620 protein 
Consensus includes gb:AW138902  highly similar to AF052178 Homo sapiens clone 24523  
Consensus includes gb:H65865 hypothetical protein FLJ13910 
gb:AB028998.1 /DEF=Homo sapiens mRNA for KIAA1075 protein, partial cds.  
Consensus includes gb:AI814660  protein kinase, cAMP-dependent, regulatory, type I, beta 
Consensus includes gb:AB014558.1 cryptochrome 2 (photolyase-like) 
Consensus includes gb:AA923354 monoamine oxidase A 
Consensus includes gb:AI703074 transcription factor 7-like 2 (T-cell specific, HMG-box) 
gb:AB002304.1 KIAA0306 protein /DEF=Human mRNA for KIAA0306 gene, partial cds. 
Consensus includes gb:AL080169.1 hypothetical protein DKFZP434C171  
Consensus includes gb:AI935123 CLONE=IMAGE:2464769 /UG=Hs.57548 ESTs 
Consensus includes gb:AL033377  Contains an exon similar to parts of BMP and Tolloid genes. 
Consensus includes gb:AI818736 similar to S. cerevisiae RER1 
Consensus includes gb:AW007573 DKFZP586L151 protein 
Consensus includes gb:AI640861 dynein, cytoplasmic, light intermediate polypeptide 2 
Consensus includes gb:N30342 KIAA0339 gene product 
Consensus includes gb:BE966372 hepatitis delta antigen-interacting protein A 
Consensus includes gb:AL531750 collagen, type VI, alpha 2 
Consensus includes gb:AI803302  Z-band alternatively spliced PDZ-motif 
Consensus includes gb:AI697108 mucin 5, subtype B, tracheobronchial 
Consensus includes gb:BE044614 tenascin XB 
Consensus includes gb:AI022387 heterogeneous nuclear ribonucleoprotein H1 (H) 
Consensus includes gb:BE673445 Homo sapiens chromosome 19, cosmid R28379 
Consensus includes gb:AW182892 guanylate kinase 1 
Consensus includes gb:NM_018957.1 /DEF=Homo sapiens SH3-domain binding protein 1 (SH3BP1), mRNA. 
Consensus includes gb:AK022846.1  highly similar to Human inositol polyphosphate 5-phosphatase (5ptase) mRNA.  
Consensus includes gb:BF671400 LIM protein (similar to rat protein kinase C-binding enigma) 
Consensus includes gb:AV686235 mannan-binding lectin serine protease 1 (C4C2 activating component of Ra-reactive factor) 
Consensus includes gb:AA971768 kinase suppressor of ras 
Consensus includes gb:AA741303 syntrophin, beta 2 (dystrophin-associated protein A1, 59kD, basic component 2) 
Consensus includes gb:AL524520  G protein-coupled receptor 49 
Consensus includes gb:AL050204.1 /DEF=Homo sapiens mRNA; cDNA DKFZp586F1223  
Consensus includes gb:AI732381 cytokeratin 20 
Consensus includes gb:AI307586 DKFZp566H0124  
Consensus includes gb:AI885290 spondin 1, (f-spondin) extracellular matrix protein 
Consensus includes gb:AI922937 hypothetical protein FLJ11282 
Consensus includes gb:AI435954 /FEA=ESThypothetical protein R31240_1 
Consensus includes gb:AA017721 DKFZp564N1662  
Consensus includes gb:AI829961 CD7 antigen (p41) 
Consensus includes gb:AA865601 Homo sapiens Chromosome 16 BAC clone CIT987SK-A-923A4 
Consensus includes gb:AF070526.1 /DEF=Homo sapiens clone 24787 mRNA sequence.  
Consensus includes gb:AB029030.1 /DEF=Homo sapiens mRNA for KIAA1107 protein, partial cds. / 
Consensus includes gb:AF070577.1 /DEF=Homo sapiens clone 24461 mRNA sequence.  
Consensus includes gb:X91817.1 /DEF=H.sapiens mRNA for transketolase-like protein (2418 bp).  
Consensus includes gb:BF432795 guanine nucleotide binding protein (G protein), gamma 7 
Consensus includes gb:AI478172 homogentisate 1,2-dioxygenase (homogentisate oxidase) 
Consensus includes gb:AW474434  Moderately similar to unknown H.sapiens 
Consensus includes gb:AF020774.1 Hair and skin epidermal-type 12-lipoxygenase-related protein (ALOX12E) mRNA  
Consensus includes gb:AI017382 KIAA1218 protein 
Consensus includes gb:BF058643 EGF-like repeats and discoidin I-like domains 3 
Consensus includes gb:AA772023 SWISNF related, actin dependent regulator of chromatin, subfamily a, member 4 
Consensus includes gb:AI263044  Homo sapiens clone 24626 mRNA sequence 
Consensus includes gb:AA725078 paired box gene 1  
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Consensus includes gb:AI656822 Homo sapiens mRNA; cDNA DKFZp434D024  
Consensus includes gb:NM_000608.1 /DEF=Homo sapiens orosomucoid 2 (ORM2), mRNA. 
Consensus includes gb:NM_005293.1 /DEF=Homo sapiens G protein-coupled receptor 20 (GPR20), mRNA.  
Consensus includes gb:NM_002169.1 /DEF=Homo sapiens interferon, alpha 5 (IFNA5), mRNA.  
Consensus includes gb:R99037acetyl-Coenzyme A carboxylase beta /FL=gb:U89344.1 gb:NM_001093.1 
Consensus includes gb:BE877796 collagen, type VIII, alpha 1 /FL=gb:NM_001850.1 
Consensus includes gb:BF215673 Drosophila Kelch like protein /FL=gb:NM_019117.1 
Consensus includes gb:U82671 Homo sapiens chromosome Xq28 melanoma antigen families A2a (MAGEA2A), A12 
(MAGEA12), A2b (MAGEA2B), A3 (MAGEA3) 
Consensus includes gb:U18549 /DEF=Human GPR6 G protein-coupled receptor gene, complete cds 
Consensus includes gb:AA004579 TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kD 
Consensus includes gb:AF007146.1 Homo sapiens clone 23686 and 23885 mRNA sequences 
Consensus includes gb:AU118874 Homo sapiens PAR5 gene, complete sequence 
Consensus includes gb:BG111168 chromosome 6 open reading frame 9 
Consensus includes gb:BF434424 spectrin, beta, non-erythrocytic 1 
Consensus includes gb:AL022165 Contains a probable Zinc Finger protein (pseudo)gene 
Consensus includes gb:BE794962 hypothetical protein 
Consensus includes gb:BF348061 neural cell adhesion molecule 1 
Consensus includes gb:AJ275469 /DEF=Homo sapiens partial IGVH3 gene for immunoglobulin heavy chain V region 
Consensus includes gb:AF070571.1 /DEF=Homo sapiens clone 24739 mRNA sequence.  
Consensus includes gb:AJ006701.1 /DEF=Homo sapiens mRNA for putative serinethreonine protein kinase, partial.  
Consensus includes gb:AK023845.1 weakly similar to PROBABLE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE FAF 
Consensus includes gb:AI123471 hypothetical protein MGC3178 
Consensus includes gb:X83301.1 /DEF=H.sapiens SMA5 mRNA.  
Consensus includes gb:AF035294.1 KIAA1024 protein 
Consensus includes gb:AC002550 G protein-coupled receptor, family C, group 5, member B 
Consensus includes gb:AL080134.1 /DEF=Homo sapiens mRNA; cDNA DKFZp434G043  
Consensus includes gb:AL021026 Contains FMO2 and FMO3 genes for Flavin-containing Monooxygenase 2 and 3 
Consensus includes gb:AV733308 integrin, alpha 6 
Consensus includes gb:AF090886.1 /DEF=Homo sapiens clone HQ0072.  
Consensus includes gb:AF339785.1 /DEF=Homo sapiens clone IMAGE:1963178, mRNA sequence.  
Consensus includes gb:S83390.1 /DEF=T3 receptor-associating cofactor-1 human, fetal liver, mRNA, 2930 nt.  
Consensus includes gb:AK021571.1 /DEF=Homo sapiens cDNA FLJ11509 
Consensus includes gb:AF054994.1 /DEF=Homo sapiens clone 23832 mRNA sequence.  
Consensus includes gb:AW301235 Homo Sapiens mRNA, partial cDNA sequence from cDNA selection, DCR1-16.0 
Consensus includes gb:AI189839 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
Consensus includes gb:AI561253 9 similar to Homo sapiens gene for glycosylphosphatidylinositol anchor attachment 1 (GPAA1) 
Consensus includes gb:AK021571.1  Homo sapiens cDNA FLJ11509 fis, clone HEMBA1002166 
Consensus includes gb:U79300.1 /DEF=Human clone 23629 mRNA sequence.  
Consensus includes gb:AU150691 Homo sapiens cDNA FLJ10577 fis, clone NT2RP2003367 
Consensus includes gb:AU146646 Homo sapiens cDNA FLJ10270 fis, clone HEMBB1001096 
Consensus includes gb:AK026980.1 highly similar to HSZNF37 Homo sapiens ZNF37A mRNA for zinc finger protein. 
Consensus includes gb:AU145354 Homo sapiens cDNA FLJ11396 fis, clone HEMBA1000604 
Consensus includes gb:AU147194 Homo sapiens cDNA FLJ12102 fis, clone HEMBB1002684 
Consensus includes gb:AF038194.1 /DEF=Homo sapiens clone 23821 mRNA sequence.  
Consensus includes gb:AU146952 Homo sapiens cDNA FLJ12046 fis, clone HEMBB1001962 
Consensus includes gb:BE740743 thyroid stimulating hormone receptor 
Consensus includes gb:AF035314.1 /DEF=Homo sapiens clone 23651 mRNA sequence.  
Consensus includes gb:AL080207.1 /DEF=Homo sapiens mRNA, DKFZP434G232 protein 
Consensus includes gb:AK022094.1 /DEF=Homo sapiens cDNA FLJ12032 fis, clone HEMBB1001880.  
Consensus includes gb:BG484069 Homo sapiens FANCA gene, exon 10a 
Consensus includes gb:AI073549  Contains a novel gene and an exon of the ESR1 gene for estrogen receptor 1 (NR3A1) 
Consensus includes gb:AK023515.1  Homo sapiens cDNA FLJ13453 fis, clone PLACE1003205 
Consensus includes gb:AK022322.1 /DEF=Homo sapiens cDNA FLJ12260 fis, clone MAMMA1001551. 
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Consensus includes gb:AK000861.1 /DEF=Homo sapiens cDNA FLJ20854 fis, clone ADKA01341. 
Consensus includes gb:L34409.1 Homo Sapiens (clone B3B3E13) chromosome 4p16.3 DNA fragment 
Consensus includes gb:AK021614.1 /DEF=Homo sapiens cDNA FLJ11552 fis, clone HEMBA1003021.  
Consensus includes gb:AA835004 hypothetical protein 
Consensus includes gb:N53959  Rhesus blood group, CcEe antigens 
Consensus includes gb:AK022363.1 /DEF=Homo sapiens cDNA FLJ12301 fis, clone MAMMA1001858.  
Consensus includes gb:AK025077.1 /DEF=Homo sapiens cDNA: FLJ21424 fis, clone COL04157. 
Consensus includes gb:AL158172 Contains the PLA2G5 gene for two isoforms of phospholiapse A2 group V 
Consensus includes gb:AK026820.1 /DEF=Homo sapiens cDNA: FLJ23167 fis, clone LNG09902.  
Consensus includes gb:AF009267.1 Homo sapiens clone FBA1 Cri-du-chat region mRNA 
Consensus includes gb:AC002544  KIAA0220 protein 
Consensus includes gb:AL049259.1 /DEF=Homo sapiens mRNA; cDNA DKFZp564E193 
Consensus includes gb:AU148005 /FEA=EST /DB_XREF=gi:11009526 /DB_XREF=est:AU148005 /CLONE=MAMMA1002355 
Consensus includes gb:AU147200 Homo sapiens cDNA FLJ12105 fis, clone HEMBB1002699 
Consensus includes gb:AK026040.1 /DEF=Homo sapiens cDNA: FLJ22387 fis, clone HRC07655.  
Consensus includes gb:AK023621.1 highly similar to Homo sapiens mRNA for KIAA0878 protein. 
Consensus includes gb:AF115765 /DEF=Homo sapiens Artemin gene, alternative forms, complete cds  
Consensus includes gb:U02309.1 /DEF=Human PAX-3 mRNA, partial cds.  
Consensus includes gb:AL031228 Contains  BING5, exons 11 to 15 of  BING4, GalT3 RPS18,SACM2L  
Consensus includes gb:AK022450.1highly similar to Homo sapiens mRNA for ganglioside sialidase.  
Consensus includes gb:AL109682.1 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 35394 
Consensus includes gb:AL137285.1 /DEF=Homo sapiens mRNA; cDNA DKFZp434D2416  
Consensus includes gb:R37427 Homo sapiens clone IMAGE 25997 
Consensus includes gb:Z22970.1  CD163 antigen 
Consensus includes gb:AK022215.1 /DEF=Homo sapiens cDNA FLJ12153 fis, clone MAMMA1000458.  
Consensus includes gb:X78931.1 /DEF=H.sapiens HZF8 mRNA for zinc finger protein. 
Consensus includes gb:X64116 poliovirus receptor 
Consensus includes gb:AL137713.1 /DEF=Homo sapiens mRNA; cDNA DKFZp434I0523  
Consensus includes gb:AU159276 Homo sapiens cDNA FLJ13867 fis, clone THYRO1001262 
Consensus includes gb:X95238.1 /DEF=H.sapiens mRNA for cysteine-rich secretory protein-1 delta.  
Consensus includes gb:AF086641 /DEF=Homo sapiens truncated tenascin XB (TNXB) gene, partial cds  
Consensus includes gb:U02520.1 /DEF=Human collagen type IV alpha 3 mRNA, partial cds.  
Consensus includes gb:Z49258  transketolase-like 1 
Consensus includes gb:AF103295.1 immunoglobulin heavy chain variable region  
Consensus includes gb:AK024949.1  Homo sapiens cDNA: FLJ21296 fis, clone COL02029 
Consensus includes gb:AK025363.1 /DEF=Homo sapiens cDNA: FLJ21710 fis, clone COL10087. 
Consensus includes gb:AK024949.1 /DEF=Homo sapiens cDNA: FLJ21296 fis, clone COL02029. 
Consensus includes gb:D38024 /DEF=Human facioscapulohumeral muscular dystrophy (FSHD) gene region 
Consensus includes gb:AL049252.1 /DEF=Homo sapiens mRNA; cDNA DKFZp564D193  
Consensus includes gb:X65232.1 /DEF=H.sapiens mRNA for Zinc-finger protein (ZNFpT7).  
Consensus includes gb:U25801.1 /DEF=Human Tax1 binding protein mRNA, partial cds.  
Consensus includes gb:AL049963.1 /DEF=Homo sapiens mRNA; cDNA DKFZp564A132 (from clone DKFZp564A132).  
Consensus includes gb:AL050219.1 /DEF=Homo sapiens mRNA; cDNA DKFZp586J1623 (from clone DKFZp586J1623).  
Consensus includes gb:AL121890 Contains a novel gene, a 40S ribosomal protein S21 pseudogene, 2 CpG islands 
Consensus includes gb:AF009660 /DEF=Homo sapiens T cell receptor beta locus, TCRBV7S3A2 to TCRBV12S2 region  
Consensus includes gb:AL022068 Contains a KRT18 (Cytokeratin 18, CK18)) pseudogene 
Consensus includes gb:AL022152 Contains two exons similar to MAGE gene family 
Consensus includes gb:AB022847.1 /DEF=Homo sapiens mRNA for norepinephrine transporter isoform 2, partial cds.  
Consensus includes gb:AL117447.1 /DEF=Homo sapiens mRNA; cDNA DKFZp586A0617  
Consensus includes gb:U58994 /DEF=Human ladinin (LAD) gene, complete cds 
Consensus includes gb:AL110190.1 /DEF=Homo sapiens mRNA; cDNA DKFZp564J2116  
Consensus includes gb:AK000185.1 /DEF=Homo sapiens cDNA FLJ20178 fis, clone COL09990. 
Consensus includes gb:AL133618.1 /DEF=Homo sapiens mRNA; cDNA DKFZp434C2021  
Consensus includes gb:U06641.1 /DEF=Human UDP glucuronosyltransferase mRNA, partial cds.  
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Consensus includes gb:AL353949.1 /DEF=Homo sapiens mRNA; cDNA DKFZp761P1114  
Consensus includes gb:AF164963.1 /DEF=Homo sapiens tumor antigen NA88-A pseudogene, complete sequence.  
Consensus includes gb:AK025325.1 /DEF=Homo sapiens cDNA: FLJ21672 fis, clone COL09025. 
Consensus includes gb:AK026856.1 /DEF=Homo sapiens cDNA: FLJ23203 fis, clone ADKA02487.  
Consensus includes gb:AL390857  Contains an HNRPA1 (heterogeneous nuclear ribonucleoprotein A1) pseudogene  
Consensus includes gb:U40372.1 /DEF=Human 3,5 cyclic nucleotide phosphodiesterase (HSPDE1C3A) mRNA, partial cds.  
Consensus includes gb:X91103.1 /DEF=H.sapiens mRNA for Hr44 protein. 
Consensus includes gb:AJ133768.1 /DEF=Homo sapiens mRNA for ZASP protein, partial, varient 2.  
Consensus includes gb:L23852.1 /DEF=Homo sapiens (clone Z146) retinal mRNA, 3 end and repeat region. 
Consensus includes gb:AL049545 Contains an RPL7 (60S Ribosomal Protein L7) pseudogene, a RAB1 pseudogene 
Consensus includes gb:AF098114.1 /DEF=Homo sapiens truncated alpha IIb protein mRNA, partial cds.  
Consensus includes gb:Y18284.1 /DEF=Homo sapiens mRNA for mannose binding lectin-associated serine protease-2 
Consensus includes gb:U52428 /DEF=Human fatty acid synthase gene, partial cds  
Consensus includes gb:AF007194.1 /DEF=Homo sapiens mucin (MUC3) mRNA, partial cds 
Consensus includes gb:X97875 H.sapiens EP4 prostaglandin receptor pseudogene  
Consensus includes gb:AC003079 Human BAC clone GS1-303P24 from 7q21-22  
Consensus includes gb:L37198.1 /DEF=Homo sapiens (clone B3B3E13) Huntingtons disease candidate region mRNA fragment.  
Consensus includes gb:AF135564.1 /DEF=Homo sapiens p50 killer cell activating receptor KAR-K1d mRNA. 
Consensus includes gb:AC006033 Homo sapiens BAC clone RP11-121A8 from 7p14-p13 
Consensus includes gb:X69383 /DEF=H.sapiens gene for T cell receptor gamma V region 5  
Consensus includes gb:AJ000388.1 /DEF=Homo sapiens mRNA for calpain-like protease CANPX. 
Consensus includes gb:AK000918.1  highly similar to Homo sapiens VAMP-associated protein of 33 kDa mRNA.  
Consensus includes gb:D25272.1 /DEF=Homo sapiens mRNA, clone:RES4-16. 
Consensus includes gb:AL034450 Contains high mobility group protein 2a 
Consensus includes gb:AW613387 Moderately similar to TYPH_HUMAN THYMIDINE PHOSPHORYLASE PRECURSOR  
Consensus includes gb:AI346187 Weakly similar to ALUE_HUMAN 
Consensus includes gb:AA741028  Moderately similar to ALUA_HUMAN 
Consensus includes gb:AI088162 Moderately similar to ALU3_HUMAN ALU SUBFAMILY SB1 
Consensus includes gb:AL583687 CLONE=CS0DJ008YL09 (5 prime)  
Consensus includes gb:BF448596 CLONE=IMAGE:3571902  
Consensus includes gb:AA457019  Weakly similar to ALU7_HUMAN ALU SUBFAMILY SQ  
Consensus includes gb:AW451230 Highly similar to KIAA0311 H.sapiens 
Consensus includes gb:BG151284 CLONE=IMAGE:4262274 /UG=Hs.322737 ESTs 
Consensus includes gb:BG281679 Highly similar to YXHUT thymidylate synthase H.sapiens 
Consensus includes gb:BF942161 CLONE=IMAGE:4118994  
Consensus includes gb:AW295066 CLONE=IMAGE:2730209 
Consensus includes gb:AW085172  Highly similar to KPCM_HUMAN PROTEIN KINASE C, MU TYPE H.sapiens 
Consensus includes gb:AA479678 Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX  
gb:NM_003498.1 /DEF=Homo sapiens stannin (SNN), mRNA. 
Consensus includes gb:BC001080.1 hypothetical protein MGC2749  
gb:NM_015894.1 /DEF=Homo sapiens SCG10-like-protein (SCLIP), mRNA.  
gb:NM_022552.2 /DEF=Homo sapiens DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), mRNA.  
gb:NM_024894.1 /DEF=Homo sapiens hypothetical protein FLJ14075 (FLJ14075), mRNA. 
gb:NM_017734.1 /DEF=Homo sapiens hypothetical protein FLJ20271 (FLJ20271), mRNA.  
gb:NM_024663.1 /DEF=Homo sapiens hypothetical protein FLJ11583 (FLJ11583), mRNA.  
gb:NM_024095.1 /DEF=Homo sapiens hypothetical protein MGC5540 (MGC5540), mRNA. 
gb:NM_020353.1 /DEF=Homo sapiens phospholipid scramblase 4 (LOC57088), mRNA. 
gb:NM_014154.1 /DEF=Homo sapiens HSPC056 protein (HSPC056), mRNA.  
gb:NM_017629.1 /DEF=Homo sapiens hypothetical protein FLJ20033 (FLJ20033), mRNA. 
gb:NM_024630.1 /DEF=Homo sapiens hypothetical protein FLJ20984 (FLJ20984), mRNA. 
gb:NM_024648.1 /DEF=Homo sapiens hypothetical protein FLJ22222 (FLJ22222), mRNA.  
Consensus includes gb:AB020675.1 /DEF=Homo sapiens mRNA for KIAA0868 protein, partial cds.  
gb:NM_018696.1 /DEF=Homo sapiens elaC (E.coli) homolog 1 (ELAC1), mRNA.  
gb:NM_024526.1 /DEF=Homo sapiens hypothetical protein FLJ21522 (FLJ21522), mRNA.  
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gb:NM_024712.1 /DEF=Homo sapiens hypothetical protein FLJ13824 (FLJ13824), mRNA.  
gb:NM_020659.1 /DEF=Homo sapiens tweety (Drosophila) homolog 1 (TTYH1), mRNA.  
gb:NM_001643.1 /DEF=Homo sapiens apolipoprotein A-II (APOA2), mRNA.  
gb:NM_021197.1 /DEF=Homo sapiens WAP four-disulfide core domain 1 (WFDC1), mRNA.  
gb:NM_013246.1 /DEF=Homo sapiens cardiotrophin-like cytokine; neurotrophin-1B-cell stimulating factor-3 (CLC), mRNA.  
gb:NM_004669.1 /DEF=Homo sapiens chloride intracellular channel 3 (CLIC3), mRNA.  
gb:NM_024500.1 /DEF=Homo sapiens likely ortholog of mouse polydom (POLYDOM), mRNA.  
gb:NM_024515.1 /DEF=Homo sapiens hypothetical protein MGC4645 (MGC4645), mRNA.  
gb:NM_001231.1 /DEF=Homo sapiens calsequestrin 1 (fast-twitch, skeletal muscle) (CASQ1) mRNA.  
gb:NM_024689.1 /DEF=Homo sapiens hypothetical protein FLJ14103 (FLJ14103), mRNA. 
gb:NM_017699.1 /DEF=Homo sapiens hypothetical protein FLJ20174 (FLJ20174), mRNA 
gb:NM_016511.1 /DEF=Homo sapiens C-type lectin-like receptor-1 (LOC51267), mRNA.  
gb:NM_014332.1 /DEF=Homo sapiens small muscle protein, X-linked (SMPX), mRNA.  
gb:NM_016931.1 /DEF=Homo sapiens NADPH oxidase 4 (NOX4), mRNA. 
gb:NM_024758.1 /DEF=Homo sapiens hypothetical protein FLJ23384 (FLJ23384), mRNA. / 
gb:NM_021924.1 /DEF=Homo sapiens mucin and cadherin-like (MUCDHL), mRNA.  
gb:NM_024838.1 /DEF=Homo sapiens hypothetical protein FLJ22002 (FLJ22002), mRNA.  
gb:NM_016613.1 /DEF=Homo sapiens AD021 protein (LOC51313), mRNA.  
gb:NM_015995.1 /DEF=Homo sapiens Kruppel-like factor 13 (KLF13), mRNA.  
gb:NM_021804.1 /DEF=Homo sapiens angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 (ACE2), mRNA.  
gb:NM_017888.1 /DEF=Homo sapiens hypothetical protein FLJ20581 (FLJ20581), mRNA.  
gb:NM_024753.1 /DEF=Homo sapiens hypothetical protein FLJ11457 (FLJ11457), mRNA.  
gb:NM_023067.1 /DEF=Homo sapiens forkhead transcription factor FOXL2 (BPES), mRNA.  
gb:NM_000396.1 /DEF=Homo sapiens cathepsin K, mRNA. 
gb:NM_005209.1 /DEF=Homo sapiens crystallin, beta A2 (CRYBA2), mRNA.  
gb:NM_022352.1 /DEF=Homo sapiens caspase recruitment domain protein 9 (LOC64170), mRNA.  
gb:NM_016298.1 /DEF=Homo sapiens muscle disease-related protein (LOC51725), mRNA.  
gb:NM_025214.1 /DEF=Homo sapiens CTCL tumor antigen se57-1 (SE57-1), mRNA.  
gb:NM_020655.1 /DEF=Homo sapiens junctophilin 3 (JPH3), mRNA.  
gb:NM_024677.1 /DEF=Homo sapiens hypothetical protein FLJ14001 (FLJ14001), mRNA.  
gb:NM_024791.1 /DEF=Homo sapiens hypothetical protein FLJ22756 (FLJ22756), mRNA.  
gb:NM_021827.1 /DEF=Homo sapiens hypothetical protein FLJ23514 (FLJ23514), mRNA. 
gb:NM_012269.1 /DEF=Homo sapiens hyaluronoglucosaminidase 4 (HYAL4), mRNA. 
gb:NM_017790.1 /DEF=Homo sapiens homolog of mouse C2PA (FLJ20370), mRNA.  
gb:NM_024796.1 /DEF=Homo sapiens hypothetical protein FLJ22639 (FLJ22639), mRNA.  
gb:NM_014579.1 /DEF=Homo sapiens zinc transporter (ZIP2), mRNA.  
gb:NM_018961.1 /DEF=Homo sapiens ubiquitin associated and SH3 domain containing, A (UBASH3A), mRNA.  
gb:NM_024869.1 /DEF=Homo sapiens hypothetical protein FLJ14050 (FLJ14050), mRNA.  
gb:NM_016593.1 /DEF=Homo sapiens oxysterol 7alpha-hydroxylase (CYP39A1), mRNA.  
gb:NM_024876.1 /DEF=Homo sapiens hypothetical protein FLJ12229 (FLJ12229), mRNA.  
gb:NM_022161.1 /DEF=Homo sapiens livin inhibitor-of-apotosis (LIVIN), mRNA.  
gb:NM_012139.1 /DEF=Homo sapiens deafness locus associated putative guanine nucleotide exchange factor (DELGEF), mRNA.  
gb:NM_018678.1 /DEF=Homo sapiens lipopolysaccharide specific response-68 protein (LSR68), mRNA.  
gb:NM_014406.1 /DEF=Homo sapiens potassium calcium-activated channel, subfamily M, beta 3-like (KCNMB3L), mRNA.  
gb:NM_020346.1 /DEF=Homo sapiens differentiation-associated Na-dependent inorganic phosphate cotransporter (DNPI), mRNA. 
gb:NM_025008.1 /DEF=Homo sapiens hypothetical protein FLJ13544 (FLJ13544), mRNA.  
gb:NM_017713.1 /DEF=Homo sapiens hypothetical protein FLJ20211 (FLJ20211), mRNA. 
gb:NM_013227.1/DEF=Homo sapiens chondroitin sulfate proteoglycan 1, mRNA.  
gb:NM_018262.1 /DEF=Homo sapiens hypothetical protein FLJ10897 (FLJ10897), mRNA.  
gb:NM_024763.1 /DEF=Homo sapiens hypothetical protein FLJ23129 (FLJ23129), mRNA. 1 
gb:NM_024888.1 /DEF=Homo sapiens hypothetical protein FLJ11535 (FLJ11535), mRNA. 
gb:NM_020377.1 /DEF=Homo sapiens cysteinyl leukotriene CysLT2 receptor; cDNA   
gb:NM_016610.1 /DEF=Homo sapiens Toll-like receptor 8 (LOC51311), mRNA.  
gb:NM_018065.1 /DEF=Homo sapiens hypothetical protein FLJ10346 (FLJ10346), mRNA.  
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gb:NM_013359.1 /DEF=Homo sapiens zinc finger protein 221 (ZNF221), mRNA.  
gb:NM_014099.1 /DEF=Homo sapiens PRO1768 protein (PRO1768), mRNA.  
gb:NM_014127.1 /DEF=Homo sapiens PRO0456 protein (PRO0456), mRNA. 
gb:NM_014273.1 /DEF=Homo sapiens disintegrin-like and metalloprotease type 1 motif 6 (ADAMTS6), mRNA.   
gb:NM_017965.1 /DEF=Homo sapiens hypothetical protein FLJ20839 (FLJ20839), mRNA.  
gb:NM_018601.1 /DEF=Homo sapiens hypothetical protein PRO1446 (PRO1446), mRNA. 
gb:NM_018606.1 /DEF=Homo sapiens hypothetical protein PRO1787 (PRO1787), mRNA.  
gb:AK026737.1 /DEF=Homo sapiens fibronectin 1, cDNA.  
gb:NM_020669.1 /DEF=Homo sapiens uncharacterized gastric protein ZA52P (LOC57399), mRNA.   
gb:NM_024980.1 /DEF=Homo sapiens hypothetical protein FLJ12132 (FLJ12132), mRNA.  
gb:NM_016109.1 /DEF=Homo sapiens PPAR(gamma) angiopoietin related protein (PGAR), mRNA.  
gb:NM_017941.1 /DEF=Homo sapiens hypothetical protein FLJ20721 (FLJ20721), mRNA.  
gb:NM_014100.1 /DEF=Homo sapiens PRO1770 protein (PRO1770), mRNA.  
gb:NM_006394.1 /DEF=Homo sapiens regulated in glioma (RIG), mRNA.  
gb:NM_023038.1 /DEF=Homo sapiens a disintegrin and metalloproteinase domain 19 (meltrin beta) (ADAM19), mRNA.   
gb:NM_015977.1 /DEF=Homo sapiens Williams-Beuren syndrome chromosome region 14 (WBSCR14), mRNA.  
gb:NM_022139.1 /DEF=Homo sapiens GDNF family receptor alpha 4 (GFRA4), mRNA.  
gb:NM_018723.1 /DEF=Homo sapiens ataxin 2-binding protein 1 (A2BP1), mRNA.  
gb:NM_016528.1 /DEF=Homo sapiens hydroxyacid oxidase 3 (medium-chain) (HAO3), mRNA. 
gb:NM_030764.1 /DEF=Homo sapiens SH2 domain-containing phosphatase anchor protein 1 (SPAP1), mRNA.  
gb:NM_030788.1 /DEF=Homo sapiens DC-specific transmembrane protein (LOC81501), mRNA.  
gb:NM_014009.1 /DEF=Homo sapiens immunodeficiency, polyendocrinopathy, enteropathy, X-linked (IPEX), mRNA.  
gb:NM_024123.1 /DEF=Homo sapiens putative Ly-6 superfamily member (G6E), mRNA. 
gb:NM_013941.1 /DEF=Homo sapiens olfactory receptor, family 10, subfamily C, member 1 (OR10C1), mRNA.  
gb:NM_013288.1 /DEF=Homo sapiens DNA binding protein for surfactant protein B (HUMBINDC), mRNA.   
gb:NM_023919.1 /DEF=Homo sapiens taste receptor, family B, member 4 (TRB4), mRNA. 
gb:NM_030772.1 /DEF=Homo sapiens connexin 59 (GJA10), mRNA.  
gb:NM_030760.1 /DEF=Homo sapiens endothelial differentiation, sphingolipid G-protein-coupled receptor, 8 (EDG8), mRNA.  
gb:NM_030753.1 /DEF=Homo sapiens wingless-type MMTV integration site family, member 3 (WNT3), mRNA. 
gb:AL136572.1 /DEF=Homo sapiens mRNA; cDNA DKFZp761I2123 (from clone DKFZp761I2123); complete cds. 
gb:AF326591.1 /DEF=Homo sapiens fenestrated-endothelial linked structure protein (FELS) mRNA, complete cds.  
Consensus includes gb:BC000794.1 /DEF=Homo sapiens, pre-mRNA splicing factor similar to S. cerevisiae Prp18 mRNA. 
gb:BC000122.1 /DEF=Homo sapiens, Similar to nuclear localization signals binding protein 1, clone MGC:3104, mRNA. 
Consensus includes gb:AL046979  tensin 
Consensus includes gb:BF058465  G-rich RNA sequence binding factor 1 
Consensus includes gb:AW086021 hypothetical protein FLJ23407 
Consensus includes gb:AI694562 /FEA=EST /DB_XREF=gi:4971902 /DB_XREF=est:wd72g08.x1 /CLONE=IMAGE:2337182  
Consensus includes gb:AI191771  wingless-type MMTV integration site family, member 6 
Consensus includes gb:NM_000847.1 /DEF=Homo sapiens glutathione S-transferase A3 (GSTA3), mRNA.  
Consensus includes gb:AU145025 Homo sapiens cDNA FLJ14025 fis, clone HEMBA1003667 
Consensus includes gb:AF216693 Homo sapiens interleukin-1 receptor antagonist homolog 1 (IL1HY1) gene, complete cds  
Consensus includes gb:BG387770  Weakly similar to C57785 zinc finger protein ZNF140 H.sapiens 
Consensus includes gb:AI742810 Moderately similar to CRGD_HUMAN GAMMA CRYSTALLIN D H.sapiens 
Consensus includes gb:BG025063 CLONE=IMAGE:4364304 
Consensus includes gb:AW009884  Highly similar to HUMAN PROTEIN PHOSPHATASE 2A, BETA 
 
Downregulated genes (n=161)b
gb:M97935.1 /DEF=Homo sapiens transcription factor ISGF-3 mRNA, complete cds. 
Cluster Incl. M99436:Human transducin-like enhancer protein (TLE2) mRNA, complete cds  
Cluster Incl. AA209463:zq84h11.s1 Homo sapiens cDNA, 3  end /clone=IMAGE-648357 
Consensus includes gb:AI439556 upregulated by 1,25-dihydroxyvitamin D-3  
gb:NM_006472.1 /DEF=Homo sapiens upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.  
gb:NM_021079.1 /DEF=Homo sapiens N-myristoyltransferase 1 (NMT1), mRNA. 
gb:NM_003088.1 /DEF=Homo sapiens singed (Drosophila)-like (sea urchin fascin homolog like) (SNL), mRNA.  
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gb:NM_004740.1 /DEF=Homo sapiens TGFB1-induced anti-apoptotic factor 1 (TIAF1), mRNA.  
gb:NM_005526.1 /DEF=Homo sapiens heat shock transcription factor 1 (HSF1), mRNA.  
gb:NM_014822.1 /DEF=Homo sapiens SEC24 (S. cerevisiae) related gene family, member D (SEC24D), mRNA.  
gb:NM_005474.2 /DEF=Homo sapiens histone deacetylase 5 (HDAC5), mRNA.  
Consensus includes gb:U55968/CLONE=26508 /UG=Hs.166318 lipin 2 /FL=gb:D87436.1 gb:NM_014646.1 
gb:NM_000937.1 /DEF=Homo sapiens polymerase (RNA) II (DNA directed) polypeptide A (220kD) (POLR2A), mRNA.  
gb:NM_006486.1 /DEF=Homo sapiens fibulin 1 (FBLN1), transcript variant D, mRNA.  
Consensus includes gb:AI363836 fumarate hydratase  
gb:NM_005886.1 /DEF=Homo sapiens katanin p80 (WD40-containing) subunit B 1 (KATNB1), mRNA.  
gb:NM_004860.2 /DEF=Homo sapiens fragile X mental retardation, autosomal homolog 2 (FXR2), mRNA.   
gb:NM_003164.1 /DEF=Homo sapiens syntaxin 5A (STX5A), mRNA. 
gb:NM_000560.1 /DEF=Homo sapiens CD53 antigen (CD53), mRNA. 
gb:NM_014921.1 /DEF=Homo sapiens lectomedin-2 (KIAA0821), mRNA.  
Consensus includes gb:AI734228 WW domain binding protein 4 (formin binding protein 21)  
gb:NM_006297.1 /DEF=Homo sapiens X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), mRNA. 
gb:NM_003199.1 /DEF=Homo sapiens transcription factor 4 (TCF4), mRNA.  
gb:NM_016194.1 /DEF=Homo sapiens hypothetical protein (DKFZp586O1922), mRNA.  
gb:NM_005044.1 /DEF=Homo sapiens protein kinase, X-linked (PRKX), mRNA.  
gb:NM_013279.1 /DEF=Homo sapiens chromosome 11open reading frame 9 (C11ORF9), mRNA.  
gb:NM_020309.1 /DEF=Homo sapiens brain-specific Na-dependent inorganic phosphate cotransporter (BNPI), mRNA.   
gb:M58581.1 /DEF=Human carnitine palmitoyltransferase (CPT1) mRNA, complete cds.  
Consensus includes gb:AI933301 KH-type splicing regulatory protein (FUSE binding protein 2)  
gb:NM_013255.1 /DEF=Homo sapiens muskelin 1, intracellular mediator containing kelch motifs (MKLN1), mRNA.  
gb:NM_022172.1 /DEF=Homo sapiens pyruvate carboxylase (PC), nuclear gene encoding mitochondrial protein, mRNA 
gb:NM_014732.1 /DEF=Homo sapiens KIAA0513 gene product (KIAA0513), mRNA. 
gb:NM_006315.1 /DEF=Homo sapiens ring finger protein 3 (RNF3), mRNA.  
gb:NM_000048.1 /DEF=Homo sapiens argininosuccinate lyase (ASL), mRNA. 
gb:NM_003141.1 /DEF=Homo sapiens Sjogren syndrome antigen A1 (SSA1), mRNA.   
gb:NM_003550.1 /DEF=Homo sapiens MAD1 (mitotic arrest deficient, yeast, homolog)-like 1 (MAD1L1), mRNA.  
gb:NM_005855.1 /DEF=Homo sapiens receptor (calcitonin) activity modifying protein 1 (RAMP1), mRNA.  
gb:NM_005225.1 /DEF=Homo sapiens E2F transcription factor 1 (E2F1), mRNA.  
gb:NM_000033.2 /DEF=Homo sapiens ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1), mRNA.  
gb:NM_000168.2 /DEF=Homo sapiens GLI-Kruppel family member GLI3 (GLI3), mRNA.  
gb:NM_003450.1 /DEF=Homo sapiens zinc finger protein 174 (ZNF174), mRNA. 
gb:NM_002557.1 /DEF=Homo sapiens oviductal glycoprotein 1, 120kD (mucin 9, oviductin) (OVGP1), mRNA.  
gb:NM_002200.1 /DEF=Homo sapiens interferon regulatory factor 5 (IRF5), mRNA.  
gb:NM_003874.1 /DEF=Homo sapiens CD84 antigen (leukocyte antigen) (CD84), mRNA. 
Consensus includes gb:BF001594 peptidylprolyl isomerase (cyclophilin)-like 2 /FL=gb:U37219.1 gb:NM_014337.1 
gb:NM_005924.1 /DEF=Homo sapiens mesenchyme homeo box 2 (growth arrest-specific homeo box) (MEOX2), mRNA.  
gb:AF191653.1 /DEF=Homo sapiens diphosphoinositol polyphosphate phosphohydrolase type 2 beta (NUDT4) mRNA 
gb:NM_001492.3 /DEF=Homo sapiens growth differentiation factor 1 (GDF1), mRNA.  
gb:NM_003655.1 /DEF=Homo sapiens chromobox homolog 4 (Drosophila Pc class) (CBX4), mRNA.   
gb:AF112345.1 /DEF=Homo sapiens integrin alpha 10 subunit (ITGA10) mRNA, complete cds.  
gb:NM_001917.1 /DEF=Homo sapiens D-amino-acid oxidase (DAO), mRNA. 
gb:NM_004262.1 /DEF=Homo sapiens airway trypsin-like protease (HAT), mRNA. 
gb:NM_012301.1 /DEF=Homo sapiens atrophin-1 interacting protein 1; activin receptor interacting protein 1 (KIAA0705), mRNA. 
gb:NM_000180.1 /DEF=Homo sapiens guanylate cyclase 2D, membrane (retina-specific) (GUCY2D), mRNA.  
gb:NM_006599.1 /DEF=Homo sapiens nuclear factor of activated T-cells 5, tonicity-resonsive (NFAT5), mRNA.  
gb:NM_002043.1 /DEF=Homo sapiens gamma-aminobutyric acid (GABA) receptor, rho 2 (GABRR2), mRNA.  
gb:NM_012181.1 /DEF=Homo sapiens FK506-binding protein 8 (38kD) (FKBP8), mRNA.  
gb:NM_013421.1 /DEF=Homo sapiens gamma-glutamyltransferase 1 (GGT1), transcript variant 2, mRNA.  
gb:M73554.1 /DEF=Human bcl-1 mRNA, complete CDs. 
Consensus includes gb:BF125756 Homo sapiens mRNA; cDNA DKFZp564N1272  
gb:AF092132.1 /DEF=Homo sapiens PAK2 mRNA, complete cds.  
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Consensus includes gb:AI438999 nuclear receptor coactivator 3  
gb:AF001690.1 /DEF=Homo sapiens EXT like protein 3 (EXTL3) mRNA, complete cds 
Consensus includes gb:AI753638 KIAA0772 gene product  
gb:BC002827.1 /DEF=Homo sapiens, tropomyosin 4, clone MGC:3641, mRNA, complete cds.  
gb:BC004153.1 /DEF=Homo sapiens, Similar to poly(rC)-binding protein 4, clone MGC:2386, mRNA, complete cds.  
gb:BC004434.1 /DEF=Homo sapiens, clone MGC:3975, mRNA, complete cds. 
gb:BC002649.1 /DEF=Homo sapiens, H1 histone family, member 2, clone MGC:3992, mRNA, complete cds.  
gb:AL136710.1 /DEF=Homo sapiens mRNA; cDNA DKFZp566P0524 (from clone DKFZp566P0524); complete cds. 
gb:U50383.1 /DEF=Human retinoic acid-responsive protein (NN8-4AG) mRNA, complete cds. 
gb:BC000723.1 /DEF=Homo sapiens, Similar to carnitine acetyltransferase, clone MGC:1564, mRNA, complete cds.  
Consensus includes gb:AA761181 CD24 antigen (small cell lung carcinoma cluster 4 antigen)  
Consensus includes gb:AW193656 inhibitor of growth 1 family, member 1  
gb:BC002477.1 /DEF=Homo sapiens, clone MGC:3090, mRNA, complete cds.  
gb:BC004349.1 /DEF=Homo sapiens, Similar to RAN binding protein 3, clone MGC:1177, mRNA, complete cds.  
gb:AF288390.1 /DEF=Homo sapiens B3GALT2 mRNA, complete cds.  
gb:BC002557.1 /DEF=Homo sapiens, Similar to GATA-binding protein 2, clone MGC:2306, mRNA, complete cds.  
gb:U27336.1 /DEF=Human alpha (1,3) fucosyltransferase (FUT6) mRNA, minor transcript II, complete cds.  
gb:AF231056.1 /DEF=Homo sapiens BRG1-Associated Factor 250a (BAF250a) mRNA, complete cds.   
gb:M55575.1 /DEF=Human branched chain alpha-keto acid dehydrogenase (BCKDHB) E1-beta subunit mRNA, complete cds.  
gb:AF119889.1 /DEF=Homo sapiens PRO2667 mRNA, complete cds. 
gb:BC006363.1 /DEF=Homo sapiens, exostoses (multiple)-like 3, clone MGC:12750, mRNA, complete cds.  
gb:U80918.1 /DEF=Homo sapiens transcription factor (NF-ATcC) mRNA, complete cds.  
gb:AF067524.1 /DEF=Homo sapiens PITSLRE protein kinase beta SV12 isoform (CDC2L2) mRNA, complete cds.  
gb:BC003683.1 /DEF=Homo sapiens, Similar to flotillin 2, clone MGC:5052, mRNA, complete cds.  
gb:L20492.1 /DEF=Human gamma-glutamyl transpeptidase mRNA, complete cds.  
gb:M20206.1 /DEF=Human laminin B1 mRNA, complete cds.  
Consensus includes gb:AB014538.1 /DEF=Homo sapiens mRNA for KIAA0638 protein, partial cds. 
Consensus includes gb:AA812224 KIAA0770 protein 
Consensus includes gb:AI393355 KIAA0630 protein 
Consensus includes gb:AI357376 homolog of yeast ubiquitin-protein ligase Rsp5; potential epithelial sodium channel regulator 
Consensus includes gb:N30339 collagen, type V, alpha 1 
Consensus includes gb:AL536319  KIAA0993 protein 
Consensus includes gb:AB014574.1 /DEF=Homo sapiens mRNA for KIAA0674 protein, partial cds.  
Consensus includes gb:AW054826  highly similar to AF055023 Homo sapiens clone 24723 mRNA  
Consensus includes gb:T62872 KIAA1232 protein 
Consensus includes gb:AI567426 KIAA1547 protein 
Consensus includes gb:AL583340 KIAA0602 protein 
Consensus includes gb:AI992251CLONE=IMAGE:2499767 /UG=Hs.184581 ESTs 
Consensus includes gb:AA114166 CLONE=IMAGE:564004 /UG=Hs.23964 sin3-associated polypeptide, 18kD 
Consensus includes gb:BG230758 Weakly similar to T31475 hypothetical protein Y62F5A.1b - Caenorhabditis elegans C.elegans 
Consensus includes gb:AI934469 KIAA0779 protein 
Consensus includes gb:AV705938 neuronal Shc adaptor homolog 
Consensus includes gb:AB014573.1 /DEF=Homo sapiens mRNA for KIAA0673 protein, partial cds.  
Consensus includes gb:BE858194 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 26539 
Consensus includes gb:N25325 calmodulin 1 (phosphorylase kinase, delta) 
Consensus includes gb:BF984434 C-terminal binding protein 1 
Consensus includes gb:AV704353 Conserved gene telomeric to alpha globin cluster 
Consensus includes gb:BE138647 KIAA0741 gene product 
gb:U69268.1 NAD (H)-specific isocitrate dehydrogenase gamma subunit mRNA, alternatively spliced, partial cds. 
Consensus includes gb:W84525 DKFZP586B2420 protein 
Consensus includes gb:AB007877.1 /DEF=Homo sapiens KIAA0417 mRNA, complete cds.  
Consensus includes gb:AF043899.1 /DEF=Homo sapiens amphiphysin IIc1 mRNA, complete cds.  
Consensus includes gb:NM_002503.1 /DEF=Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta (NFKBIB), mRNA.  
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Consensus includes gb:AL551046 Human DNA from chromosome 19-specific cosmid F25965, genomic sequence 
Consensus includes gb:R39094  KIAA1085 protein 
Consensus includes gb:U70544.1 /DEF=Homo sapiens HLA class II DRB4 null antigen (HLA-DRB4) pseudogene mRNA. 
Consensus includes gb:S65921.1 /DEF=anti-colorectal carcinoma light chain=glycoprotein CANAG-50 specific IgG1 kappa 
Consensus includes gb:AF103295.1 /DEF=Homo sapiens clone N97 immunoglobulin heavy chain variable region mRNA 
Consensus includes gb:AK024457.1 /DEF=Homo sapiens mRNA for FLJ00049 protein, partial cds.  
Consensus includes gb:AF009205.1 /DEF=Homo sapiens clone L5 unknown mRNA, partial cds.  
Consensus includes gb:AL137428.1 /DEF=Homo sapiens mRNA; cDNA DKFZp761N1323  
Consensus includes gb:X07024.1 /DEF=Human X chromsome mRNA for CCG1 protein inv. in cell proliferation.  
Consensus includes gb:S76475.1 /DEF=neurotrophic tyrosine kinase, receptor, type 3 
Consensus includes gb:AL050308 Contains a NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, pseudogene 
Consensus includes gb:AI001784 Highly similar to A42735 ribosomal protein L10, cytosolic H.sapiens 
gb:NM_016031.1 /DEF=Homo sapiens elongation of very long chain fatty acids-like 1 (ELOVL1), mRNA.   
gb:NM_025082.1 /DEF=Homo sapiens hypothetical protein FLJ13111 (FLJ13111), mRNA. 
gb:NM_022917.1 /DEF=Homo sapiens hypothetical protein FLJ21959 (FLJ21959), mRNA.  
gb:NM_023071.1 /DEF=Homo sapiens hypothetical protein FLJ13117 (FLJ13117), mRNA. 
gb:NM_018231.1 /DEF=Homo sapiens hypothetical protein FLJ10815 (FLJ10815), mRNA. 
gb:NM_024585.1 /DEF=Homo sapiens hypothetical protein FLJ22160 (FLJ22160), mRNA.  
gb:NM_013385.2 /DEF=Homo sapiens pleckstrin homology, Sec7 and coiledcoil domains 4 (PSCD4), mRNA.  
gb:NM_017586.1 /DEF=Homo sapiens chromosome 9 open reading frame 7 (C9ORF7), mRNA.  
gb:NM_015711.1 /DEF=Homo sapiens glioma tumor suppressor candidate region gene 1 (GLTSCR1), mRNA.  
gb:NM_020228.1 /DEF=Homo sapiens PR domain containing 10 (PRDM10), mRNA. / 
gb:NM_014353.1 /DEF=Homo sapiens RAB26, member RAS oncogene family (RAB26), mRNA.  
gb:NM_020664.1 /DEF=Homo sapiens 2,4-dienoyl CoA reductase 2, peroxisomal (DECR2), mRNA.  
gb:NM_017741.1 /DEF=Homo sapiens hypothetical protein FLJ20280 (FLJ20280), mRNA.  
Consensus includes gb:AI992095 mesenchymal stem cell protein DSC43 
gb:NM_000908.1 /DEF=Homo sapiens natriuretic peptide receptor Cguanylate cyclase C (NPR3), mRNA. 
gb:NM_017726.1 /DEF=Homo sapiens hypothetical protein FLJ20251 (FLJ20251), mRNA.  
gb:NM_018063.1 /DEF=Homo sapiens hypothetical protein FLJ10339 (FLJ10339), mRNA. 
gb:NM_007059.1 /DEF=Homo sapiens kaptin (actin-binding protein) (KPTN), mRNA.  
gb:NM_030915.1 /DEF=Homo sapiens hypothetical protein DKFZp566J091 (DKFZP566J091), mRNA.  
gb:NM_031301.1 /DEF=Homo sapiens hypothetical protein DKFZp564D0372 (DKFZP564D0372), mRNA.  
gb:NM_018482.1 /DEF=Homo sapiens KIAA1249 protein (KIAA1249), mRNA.  
gb:NM_023076.1 /DEF=Homo sapiens hypothetical protein FLJ23360 (FLJ23360), mRNA.  
gb:NM_022467.1 /DEF=Homo sapiens N-acetylgalactosamine-4-O-sulfotransferase (GALNAC-4-ST1), mRNA.  
gb:BC002382.1 /DEF=Homo sapiens, COX15 (yeast) homolog, cytochrome c oxidase assembly protein, mRNA 
gb:U15642.1 /DEF=Human transcription factor E2F-5 mRNA, complete cds. 
gb:AF282167.1 /DEF=Homo sapiens DRC3 mRNA, complete cds.  
Consensus includes gb:AV741657  leucine zipper protein 1 
Consensus includes gb:AK024269.1 weakly similar to TROPOMYOSIN 1, FUSION PROTEIN 33.  
Consensus includes gb:BF436315 /FEA=EST /DB_XREF=gi:11448630 /DB_XREF=est:7p06b05.x1 /CLONE=IMAGE:3644888  
Consensus includes gb:AI057637 Weakly similar to 2109260A B cell growth factor H.sapiens 
Consensus includes gb:BF437591 RNA binding motif protein 3 
Consensus includes gb:AL117626.1 /DEF=Homo sapiens mRNA; cDNA DKFZp434B105; partial cds.   
Consensus includes gb:AF218012.1 /DEF=Homo sapiens clone PP3795 unknown mRNA. 
Consensus includes gb:AV700403 /FEA=EST /DB_XREF=gi:10302374 /DB_XREF=est:AV700403 /CLONE=GKBADA01  
Consensus includes gb:AW974816 Weakly similar to ALU1_HUMAN ALU SUBFAMILY J  
 
a Genes represented in Figure 6G, left graph, week 8, gray bar. 
b Genes represented in Figure 6G, right graph, week 8, gray bar.
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Supplementary Table S4. Changes in expression level of markers of dedifferentiation and multi-
lineage differentiation potential in 293T cells treated with Jurkat extract 
 
Name 
Jurkat cells (fold 
upregulation)a
Jurkat extract-treated cells (fold 
upregulation over 8 weeks) a
Somatic cell markers 
LMNA 0.9 0.9 – 2.1 
LMNB1 0.7 1.2 – 2.2 
LMNB2 1.4 0.5 – 1.3 
NPR3 1.4 1.4 – 3.4 
   
Embryonic, germ cell and stem cell markers 
OCT4 and Oct4-responsive genes 
POU5F1 0.2 0.05 – 0.2 
SOX2 0.25 0.8 – 1.2 
UTF1 0.1 0.05 – 0.1 
REX1 0.4 0.6 – 2.3 
FOXD3 0.75 0.9 – 1.9 
Telomerase and telomerase-associated factors 
TERT 0.9 0.6 – 1.8 
TERF1 0.3 0.6 – 5.2 
TERF2 1.3 1.6 – 3.1 
Others 
POU3F1 1.5 0.7 – 1.8 
ALP1 1.4 0.7 – 1.5 
ALP1 1.3 0.8 – 2.2 
CD44 0.8 0.7 – 1.1 
LIF 0.2 0.2 – 1.5 
FZD9 0.4 0.8 – 1.9 
TEF 0.7 0.8 – 2.0 
SCGF 1.1 0.8 – 1.0 
GCNF 1.3 0.6 – 1.0 
SPINK2 3.0 0.9 – 2.7 
DKK2 0.8 5.5 – 9.3 
INTA6 1.9 0.4 – 1.2 
   
Markers of potential lineage- specific differentiation 
Osteogenic lineage 
BMP1 0.2 0.5 – 1.9 
BMP2 0.5 0.5 – 2.5 
OGN 1.5 1.4 – 2.7 
CTSK 1.1 1.2 – 1.6 
TNFRSF11B 0.6 0.3 – 0.5 
Endothelial lineage 
VWF 3.5 0.4 – 2.7 
NOS3 1.8 0.7 – 1.3 
Myogenic lineage 
MYF5 0.9 0.2 – 1.0 
TMP1 2.2 0.9 – 3.9 
MYH11 0.75 0.7 – 1.0 
Neurogenic lineage 
NTS 3.0 1.9 – 2.8 
NRG1 1.3 0.8 – 1.1 
MBP 2.3 0.8 – 1.3 
MOBP 1.4 0.3 – 1.6 
NCAM1 0.9 0.5 – 1.0 
CD56 0.75 0.5 – 1.5 
Adipogenic lineage 
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ADRP 0.8 0.6 – 1.0 
APOA2 0.6 0.5 – 1.1 
APOD 0.3 0.6 – 1.0 
APOE 2.1 0.3 – 1.0 
APOC1 1.1 0.8 – 1.9 
PPARG2 0.2 0.3 – 0.6 
FAD1 0.9 0.2 – 2.3 
Chondrogenic lineage 
COL4A3 1.2 0.8 – 1.6 
COL5A2 1.8 1.0 – 2.0 
COL8A1 1.8 0.5 – 1.9 
COLL1A1 1.9 0.9 – 2.8 
CSPG2 0.2 0.5 – 1.7 
AGC1 1.3 0.7 – 1.4 
DSPG3 0.1 0 3 – 1.4 
CSPG1 2.2 0.9 – 1.2 
FNP 0.1 1.2 – 2.5 
FN1 0.1 0.1 – 1.8 
 
a Range of -fold upregulation over weeks 1-8, relative to 293T cells. 
b Also upregulated in 293T cells exposed to 293T extract.  
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Analyses of molecular events associated with reprogramming somatic nuclei to pluripotency are scarce. We previously
reported the reprogramming of epithelial cells by extract of undifferentiated embryonal carcinoma (EC) cells. We now
demonstrate reprogramming of DNA methylation and histone modiﬁcations on regulatory regions of the developmen-
tally regulated OCT4 and NANOG genes by exposure of 293T cells to EC cell extract. OCT4 and NANOG are transcrip-
tionally up-regulated and undergo mosaic cytosine-phosphate-guanosine demethylation. OCT4 demethylation occurs as
early as week 1, is enhanced by week 2, and is most prominent in the proximal promoter and distal enhancer. Targeted
OCT4 and NANOG demethylation does not occur in 293T extract-treated cells. Retinoic acid-mediated differentiation of
reprogrammed cells elicits OCT4 promoter remethylation and transcriptional repression. Chromatin immunoprecipitation
analyses of lysines K4, K9, and K27 of histone H3 on OCT4 and NANOG indicate that primary chromatin remodeling
determinants are acetylation of H3K9 and demethylation of dimethylated H3K9. H3K4 remains di- and trimethylated.
Demethylation of trimethylated H3K9 and H3K27 also occurs; however, trimethylation seems more stable than dimethy-
lation. We conclude that a central epigenetic reprogramming event is relaxation of chromatin at loci associated with
pluripotency to create a conformation compatible with transcriptional activation.
INTRODUCTION
Reprogramming of a differentiated somatic cell into a plu-
ripotent cell may have applications in regenerative medi-
cine, and as such, several approaches are being examined to
produce embryonic stem (ES)-like cells. Nuclear transplan-
tation into oocytes has demonstrated that functional nuclear
reprogramming is possible, through the production of nu-
clear transfer ES cells (Cibelli et al., 1998; Munsie et al., 2000;
Wakayama et al., 2001) and cloned animals (Wilmut et al.,
2002; Gurdon and Byrne, 2003). Fusion of somatic cells with
ES or embryonal carcinoma (EC) cells also elicits a repro-
gramming of the somatic genome within the hybrids, dem-
onstrated by X chromosome reactivation (Tada et al., 2001),
changes in gene expression proﬁle, and acquisition of ES cell
properties, including contribution to all germ layers in ter-
atomas and in aggregation chimeras (Tada et al., 1997, 2001;
Pells et al., 2002; Terada et al., 2002; Ying et al., 2002; Cowan
et al., 2005). Recently, retroviral transduction and constitu-
tive expression of four factors (Oct4, Sox2, Klf4, and c-Myc)
was also shown to induce an ES cell-like behavior in mouse
ﬁbroblasts, similar to that reported by fusion with ES cells
(Takahashi and Yamanaka, 2006). A fourth approach to repro-
gramming entails treatment of reversibly permeabilized so-
matic cells with an extract of another differentiated cell type
(Håkelien et al., 2002) or of undifferentiated, pluripotent ES or
EC cells (Taranger et al., 2005). Notably, epithelial 293T cells
treated with extract of undifferentiated human EC (NCCIT)
cells induces expression of genes associated with pluripo-
tency, such as OCT4 and NANOG; causes down-regulation
of somatic cell-speciﬁc genes, such as lamin A (LMNA); and
enhances in vitro differentiation capacity (Taranger et al.,
2005). From these observations, it is increasingly clear that
exposure of a somatic genome to factors derived from plu-
ripotent cells or eggs is sufﬁcient to elicit partial or complete
reprogramming of nuclear function.
All reprogramming approaches investigated to date seem to
involve modiﬁcations of the epigenome. Methylation in the
5-position of a cytosine in a cytosine-phosphate-guanosine
(CpG) dinucleotide is a heritable modiﬁcation that favors
genomic integrity, ensures proper regulation of gene expres-
sion, and is essential for long-term gene silencing (Antequera,
2003). Partial DNA demethylation in restricted areas in the
Oct4/OCT4 regulatory region has been reported previously
(Tada et al., 1997; Simonsson and Gurdon, 2004; Cowan et al.,
2005; Takahashi and Yamanaka, 2006), and it is proposed be
required for activation of the gene (Simonsson and Gurdon,
2004). These studies have been extended with the demon-
stration that the Nanog promoter is also demethylated in
nuclear transfer ES cells (Blelloch et al., 2006), in ﬁbro-
blast–ES cell hybrids (Cowan et al., 2005), and in transduced
cells (Takahashi and Yamanaka, 2006). Additionally, acety-
lation and methylation of lysine (K) residues in the amino-
terminal tail of histones H3 and H4, which regulate chroma-
tin assembly on promoters and thereby promoter activation
(Lachner and Jenuwein, 2002), have been shown in mouse
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thymocyte–ES cell hybrids (Kimura et al., 2004). A limitation
of cell fusion or transduction approaches to nuclear repro-
gramming, however, is the mixing of genomic sequences,
making epigenetic analyses of the reprogrammed cells de-
pendent on single nucleotide polymorphism or species spec-
iﬁcity of the sequences examined. In the cell extract system,
only a limited nonquantitative assessment of demethylation
has been reported on OCT4 (Taranger et al., 2005), and no
quantiﬁable indications exist to date of epigenetic repro-
gramming of the human OCT4 and NANOG loci.
Here, we provide evidence of reprogramming of DNA
methylation and histone modiﬁcations on the NANOG pro-
moter and throughout the OCT4 regulatory region in human
epithelial cells as a result of transient exposure to EC cell
extract. Bisulﬁte sequencing analysis of OCT4 and NANOG
regulatory regions reveals mosaic DNA demethylation over
time. Assessment of six modiﬁcations of histone H3 by using
a novel quick and quantitative chromatin immunoprecipita-
tion (Q2ChIP) assay indicates that chromatin remodeling
also takes place on OCT4 and NANOG to establish a confor-
mation compatible with transcriptional activation. Subse-
quent stimulation of extract-treated cells with retinoic acid
(RA) promotes a remethylation of OCT4, arguing for speci-
ﬁcity of the methylation changes elicited by the extract.
Because only the somatic cell genome is present in the
extract, the approach constitutes a useful tool for investigat-
ing the molecular processes behind nuclear reprogramming.
MATERIALS AND METHODS
Antibodies and Reagents
Antibodies against H3K9ac (catalog no. 06-942), H3K9m2 (07-441), H3K9m3
(07-442), and H3K27m3 (05-851) were from Upstate Biotechnology (Lake
Placid, NY). Antibodies against H3K4m2 (Ab7766) and H3K4m3 (Ab8580)
were from Abcam (Cambridge, United Kingdom). Other reagents were from
Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
Cells
293T cells and undifferentiated human EC cells (NCCIT) were cultured in
RPMI 1640 medium containing 10% fetal calf serum (complete RPMI me-
dium) (Taranger et al., 2005). Cells treated with extracts were seeded at
100,000 cells/well in a 48-well plate and cultured in 250 l of complete RMPI
medium after membrane resealing. In some experiments, cells were also
induced to differentiate with 10 M RA in bacterial culture plates for up to 3
wk as described previously (Taranger et al., 2005).
Reprogramming Extracts
Extracts of NCCIT cells or control 293T cells were prepared as described
(Taranger et al., 2005). In short, cells were washed in phosphate-buffered
saline (PBS) and in cell lysis buffer, and then they were sedimented and
resuspended in cell lysis buffer. Cells were sonicated on ice; the lysate was
sedimented at 15,000  g for 15 min; and the supernatant was aliquoted,
frozen in liquid nitrogen, and stored at 80°C. Extracts were diluted with
H2O before use to adjust osmolarity to 300 mOsm.
Plasma Membrane Permeabilization and Extract
Treatment
The procedure was as reported previously (Taranger et al., 2005) with minor
modiﬁcations. In short, 500,000 293T cells were washed in 500 l of cold Ca2-
and Mg2-free Hanks’ balanced salt solution (HBSS) and resuspended in 490
l of ice-cold HBSS. Tubes were placed in a H2O bath at 37°C for 2 min, and
10 l of Streptolysin O (SLO; 100 g/ml stock diluted 1:10 in cold HBSS;
Sigma-Aldrich) was added (ﬁnal concentration, 200 ng/ml). Samples were
incubated horizontally in a H2O bath for 30 min at 37°C with occasional
agitation and placed on ice. Note that optimal SLO concentration and time of
incubation need to be adjusted for each SLO batch. Samples were diluted with
1 ml of cold HBSS, and cells were sedimented at 120  g for 5 min at 4°C.
Permeabilization was assessed by uptake of a ﬂuorescent dextran in separate
samples 24 h after resealing and replating the cells (Taranger et al., 2005).
Permeabilized cells (500,000) were suspended in 500 l of NCCIT or 293T
extract (control) containing an ATP-regenerating system and 1 mM of each
nucleotide triphosphate. Tubes were incubated horizontally for 1 h at 37°C in
a H2O bath with occasional agitation. To reseal membranes, the extract was
diluted with complete RPMI medium containing 2 mM CaCl2, and cells were
seeded at 100,000 cells/well in a 48-well plate. After 4 h, ﬂoating cells were
removed, and plated cells were cultured in complete RPMI medium.
Bisulﬁte Sequencing
DNA was puriﬁed by two phenol chloroform isoamyalcohol extractions,
followed by one extraction with chloroform isoamylalcohol, and then the
DNA was ethanol-precipitated. DNA was dissolved indifferently in H2O or
TE buffer (10 mM Tris-HCl, pH 8.0, and 10 mM EDTA). Bisulﬁte conversion
(Warnecke et al., 2002) was performed using the MethylEasy DNA bisulﬁte
modiﬁcation kit as described by the manufacturer (Human Genetic Signa-
tures, Sydney, Australia). Converted DNA was used fresh or stored at20°C.
Converted DNA was ampliﬁed by polymerase chain reaction (PCR) by using
primers published previously (Deb-Rinker et al., 2005) or designed with
MethPrimer (www.urogene.org/methprimer/index1.html) (Supplemental
Table 1). PCR conditions were 95°C for 10 min and 40 cycles of 95°C for 1 min,
50/55/58°C for 1 min (temperature was primer-dependent; see Supplemental
Table 1), and 72°C for 1 min, followed by 10 min at 72°C. PCR products were
puriﬁed with the GenElute Mammalian Genomic DNA Miniprep kit (Sigma-
Aldrich) and then cloned into bacteria by TOPO TA cloning (Invitrogen,
Carlsbad, CA) and reverse-sequenced using M13 primers (MWG Biotech,
High Point, NC). Sequences of 10 bacterial clones per genomic region exam-
ined are represented as rows of circles, with each circle symbolizing the
methylation state of one CpG. Chi-square tests were done to compare per-
centages of methylation between cell types or treatments. Unpaired t tests
were performed to compare 1) the extent of methylation of a speciﬁc CpG
deducted from 10 sequences, and 2) numbers of methylated CpGs in a given
sequence, between cell populations. The t test results are provided in Tables
1 and 2 and throughout the text.
Chromatin Immunoprecipitation (Q2ChIP)
To minimize sample loss during the ChIP procedure and maximize ChIP
speciﬁcity, we recently developed and validated a quick and quantitative
Q2ChIP assay (Dahl and Collas, 2007) also used in this study. To prepare
antibody–bead complexes, paramagnetic beads (Dynabeads protein A; Dynal
Biotech, Oslo, Norway) were washed twice in radioimmunoprecipitation
assay (RIPA) buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.5 M EGTA, 1%
Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, and 140 mM NaCl), and then
they were resuspended in 1 volume of RIPA buffer. Beads (10 l) were added
to 90 l of RIPA buffer containing 2.4 g of primary antibody in a 0.2-ml PCR
tube, and then they were incubated on a rotator for 2 h at 4°C. For DNA–
protein cross-linking, 20 mM of the histone deacetylase inhibitor sodium
butyrate was added to cells immediately before harvesting (and to all solu-
tions thereafter). Cells were ﬁxed in suspension with 1% formaldehyde for 8
min in PBS at 1–2  106 cells/ml, and ﬁxation was stopped with 125 mM
glycine for 5 min. All subsequent steps were performed on ice or at 4°C.
Cross-linked cells were washed twice in PBS/20 mM butyrate and lysed by a
sixfold dilution in lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1%
SDS, and protease inhibitors) containing 20 mM butyrate. Aliquots of 200 l
were sonicated each for 10  30 s on ice to generate chromatin fragments of
500 base pairs. The lysate was sedimented at 10,000  g for 10 min, the
supernatant was collected, and chromatin concentration was determined by
A260 from an aliquot diluted 100-fold.
Chromatin diluted (2 A260 units) in RIPA buffer/20 mM butyrate was
transferred to a 0.2-ml tube containing antibody–bead complexes (see above),
and the sample was rotated at 40 rpm for 2 h at 4°C. Immune complexes were
washed three times in RIPA buffer and once in TE buffer, each for 4 min at 4°C
on a rotator set at 40 rpm. The ChIP material was transferred to a new tube,
and TE was replaced with 150 l of elution buffer (20 mM Tris-HCl, pH 7.5,
5 mM EDTA, 20 mM butyrate, and 50 mM NaCl) containing 1% SDS and 50
g/ml proteinase K. Samples were incubated for 2 h at 68°C on a Thermo-
mixer at 1300 rpm (Eppendorf, Hamburg, Germany). Elution buffer was
recovered, the ChIP material was reextracted for 5 min, and both supernatants
were pooled. Another 200-l elution buffer was added to the eluted material,
and DNA was extracted once with phenol-chloroform isoamyl alcohol, once
with chloroform isoamyl alcohol, and then ethanol precipitated.
Immunoprecipitated DNA was analyzed in triplicates by real-time PCR
starting from 5 l of DNA (from a total of 150 l). PCR conditions were 95°C
for 3 min and 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. ChIP
PCR primers are listed in Supplemental Table 1. Data are presented as -fold
enrichment of precipitated DNA associated with a given histone modiﬁcation,
relative to a 1/100 dilution of input chromatin (Feldman et al., 2006; Dahl and
Collas, 2007). ChIPs were performed in two separate experiments as well as
from 293T extract-treated cells, 293T cells, and NCCIT cells.
Real-Time Reverse Transcription (RT)-PCR
RT-PCR was carried from 1 g of total RNA by using the Iscript cDNA
synthesis kit (Bio-Rad, Hercules, CA). cDNA (20 l) was diluted 1:10, and 5 l
was used in each of triplicate quantitative PCRs on a MyiQ real-time PCR
detection system with IQ SYBR Green (Bio-Rad). Primers used are listed in
Supplemental Table 2. PCR conditions were 95°C for 3 min and 40 cycles of
95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Data were analyzed using
C. T. Freberg et al.
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formulas of (Pfafﬂ, 2001) with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as normalization control.
RESULTS
Up-Regulation of OCT4 and NANOG Expression in EC
Extract-treated Cells
Permeabilized epithelial 293T cells exposed for 1 h to a
whole-cell postchromosomal supernatant of undifferenti-
ated NCCIT cells, resealed and cultured, formed colonies of
tightly packed cells over time with a morphology character-
istic of NCCIT cells (Figure 1A). Colony formation was
independent of cell density, and it did not occur among cells
treated with a control 293T cell extract. Quantitative RT-PCR
analysis of gene expression in these cultures 4 wk after
extract treatment, in two separate experiments, indicates
that OCT4 and NANOG were strongly up-regulated from
levels barely detectable by real-time RT-PCR (Figure 1B).
Moderate down-regulation of LMNA expression also oc-
curred, supporting the absence of detection of lamins A and
C in the nuclear envelope of EC extract-treated cells
(Taranger et al., 2005). None of these changes were detected
in 293T extract-treated cells (Figure 1B). As expected, expres-
sion of the constitutively expressed lamin B1 (LMNB1) gene
was not altered by extract treatment (Figure 1B).
OCT4 and NANOG Promoters Undergo Partial DNA
Demethylation in EC Extract-treated Cells
To determine whether the EC extract was capable of eliciting
epigenetic modiﬁcations on exogenous chromatin templates,
we ﬁrst examined DNA methylation changes in the OCT4,
NANOG, and LMNA promoter regions. Bisulﬁte sequencing
analysis was carried out to establish 5-3 CpG methylation
proﬁles across the OCT4 proximal promoter (PP, which
included the transcription start site, or TSS), the proximal
enhancer (PE), and the distal enhancer (DE). Nine amplicons
(referred to as OCT4 regions 1–9) were examined, collec-
tively covering 47 potentially methylated CpG dinucleotides
within nucleotides 2995 to 66 relative to the TSS (Figure
2, bisulﬁte sequencing [BiS] primers; see Supplemental Fig-
ure 1 for sequence information). Three regions were also
examined in the NANOG promoter, encompassing a total of
14 CpGs within nucleotides 1503 to 163 relative to the
TSS (Figure 2 and Supplemental Figure 1). The proximal
LMNA promoter region examined encompassed nine CpGs
within nucleotides 277 to 92 relative to the TSS (Figure 2
and Supplemental Figure 1).
The OCT4 region examined was methylated in 293T cells
and largely unmethylated in NCCIT cells (p 	 104; Figure
3A; see Table 1 for statistical analysis). This methylation
pattern was consistent with the pattern of expression of
Figure 1. Morphological changes of 293T
cells elicited by EC extract treatment are asso-
ciated with transcriptional up-regulation of
pluripotency genes. (A) Morphology of 293T
cells, NCCIT cells, and 293T cells 4 wk after
treatment with two different EC extracts (ex-
periments 1 and 2) or with a 293T cell extract.
Bar, 200 m. (B) Quantitative RT-PCR analysis
of expression of OCT4, NANOG, LMNA, and
LMNB1 in each cell group relative to mRNA
level in 293T cells (mean SD from 2 separate
analyses in each experiment, each with tripli-
cate RT-PCRs). mRNA levels in NCCIT cells
are also shown.
Figure 2. OCT4, NANOG, LMNA, and GAPDH regulatory regions
examined by bisulﬁte sequencing and by ChIP in this study. Local-
ization of amplicons generated with BiS and ChIP primers are
shown. Numbers are nucleotide numbers in relation to the tran-
scription start site (TSS; 1). Sequence coverage in the OCT4 locus
is shown in Supplemental Table 1. CR1-CR4 on OCT4 refer to
conserved regions 1–4; DE, distal enhancer; PE, proximal enhancer;
and PP, proximal promoter.
Epigenetic Reprogramming by Cell Extract
Vol. 18, May 2007 1545
OCT4 in NCCIT and 293T cells. Nevertheless, in NCCIT
cells, the 5 end of the DE (region 1) was overall methylated,
whereas regions 6 and 7 in the PE were more, and mosa-
ically, methylated than the rest of the region (Figure 3A).
This observation was consistent with OCT4 methylation pro-
ﬁles reported in the undifferentiated EC cell line, NT2 (Deb-
Rinker et al., 2005). Likewise, the NANOG promoter was 67%
methylated in 293T cells but unmethylated in NCCIT cells
(p 	 104; Figure 3A; Table 1). Thus, the OCT4 and NANOG
regulatory regions examined display sufﬁciently distinct
methylation patterns to be analyzed in extract-treated cells.
Last, we found that the LMNA promoter was hypomethyl-
ated both in 293T and NCCIT cells, with, however, CpG no.
1 being more methylated in 293T cells (p	 0.001; Figure 3A).
Figure 3. Transient exposure of 293T cells to EC extract elicits DNA demethylation of OCT4 and NANOG. (A) Bisulﬁte sequencing analysis
of OCT4, NANOG, and LMNA methylation in 293T and NCCIT cells. Top numbers indicate CpG number relative to the TSS. Global
percentages of methylated cytosines (%Me) are shown. Each row of circles for a given amplicon represents the methylation status of each CpG
in one bacterial clone for that region. Series of 10 clones are shown. Bottom numbers (under B) refer to amplicon number, i.e., the OCT4 and
NANOG regions examined (see Figure 2). (B) 293T cells treated with EC extract (2 experiments, experiments 1 and 2) or with 293T extract were
analyzed as described in A. (C and D) Percentages of methylated cytosines in each position in OCT4, NANOG, and LMNA determined from
data shown in A and B. On the x-axes, CpG no. 1 is the 5-most cytosine examined in each region. Positions of genomic regions examined
are shown. For t test analysis, see Table 1 and text.
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Absence of methylation in the LMNA promoter in NCCIT
cells, despite the lack of LMNA expression, is reminiscent of
the unmethylated state of silent gene promoters poised for
transcription in undifferentiated ES cells (Azuara et al., 2006).
Proﬁles of 5-3 CpG methylation in the OCT4, NANOG, and
LMNA regulatory regions in 293T and NCCIT cells are rep-
resented graphically in Figure 3C as the average methylation
state of a given CpG on the basis of 10 sequences per
amplicon.
CpG methylation in the OCT4 and NANOG promoters
were next examined in two independent reprogramming
experiments, 4 wk after exposure to EC extract (experiments
1 and 2) or to 293T extract (Figure 3, B and D). OCT4 was
partially demethylated in both experiments to reach meth-
ylation levels of 73 and 66%, compared with 91% in 293T
extract-treated controls (p 	 0.001; chi-square test) and 89%
in untreated 293T cells (p 	 0.001; chi-square test; see Table
1 for t test analyses). Nevertheless, demethylation did not
occur consistently throughout the OCT4 regulatory locus.
The most susceptible areas were OCT4 regions 2 and 3 in the
DE, region 5 in the PE, and region 9 surrounding the TSS in
the PP. OCT4 regions 6 and 7, which are relatively methyl-
ated in NCCIT cells, remained unaffected by extract treat-
ment. Furthermore, although OCT4 methylation was
slightly mosaic between 293T cells (presumably as an artifact
of extended culture; Figure 3A), mosaicism was enhanced
after extract treatment (Figure 3B), most likely due to a
variable response of the cells to extract. We concluded that
EC extract promotes partial demethylation of OCT4, in
agreement with transcriptional activation of the gene.
The NANOG promoter was also demethylated within 4
wk of extract exposure in both reprogramming attempts
(Figure 3, B and D; p 	 0.001, chi-square tests; see t test
analyses in Table 1). As little as 39% methylation was de-
tected in the regions examined (Figure 3B, experiment 2).
Again, demethylation did not occur in all cells or alleles, and
it resulted in a mosaic methylation pattern (Figure 3B).
Nonetheless, all regions examined were affected. In partic-
ular, CpGs no. 3, 4, and 11–14 were signiﬁcantly demethyl-
ated in both experiments relative to 293T extract-treated
cells (p 	 0.001). We did not notice any changes in methyl-
ation of the LMNA promoter in treated or control cells
relative to 293T cells (Figure 3, B and D).
We next determined how early OCT4 demethylation took
place after extract treatment, focusing on regions that
showed the most pronounced demethylation in the previous
experiment, namely, regions 2, 3, and 9. Demethylation oc-
curred as early as 1 wk after treatment with EC extract in
two additional experiments (experiments A and B) but not
in 293T extract-treated cells (57 and 56% methylation in
experiment A and B versus 89% in 293T extract-treated cells;
p 	 103 [chi-square test] and p 	 104 [t tests]; Figure 4, A
and B). Demethylation was most pronounced in DE region 2
and PP region 9, near the TSS. Demethylation was enhanced
by week 2 (region 9; p 	 0.001 [t test] relative to week 1;
Figure 4, A and B) and correlated with transcriptional acti-
vation of OCT4 (Figure 4D). To our surprise, however, de-
methylation of NANOG (region 1) was not detected by week
1 or 2 (Figure 4C), despite activation of the gene (Figure 4D).
This suggests that demethylation may have occurred else-
where in the NANOG promoter. Note that NANOG expres-
sion at week 1 in experiment A and B (Figure 4D) was
apparently higher than that at week 4 in experiment 1 and 2
(Figure 1B), despite the relatively higher methylation level of
region 1 (compare Figures 3B and 4C). However, NANOG
expression in untreated 293T cells is barely detectable by
real-time RT-PCR, and small variations in PCR efﬁciency
and/or in background NANOG mRNA levels in 293T cells
between experiments may translate into dramatic differ-
ences in the relative mRNA level calculated in extract-
treated cells. Thus, expression levels in experiment 1 and 2
(Figure 1B) may not be compared with those of Figure 4D.
Collectively, our results indicate that EC extract is capable
of inducing demethylation of OCT4 and NANOG regulatory
regions in exogenous genomes. Different regions across the
OCT4 promoter and enhancer are differentially demethyl-
ated, and CpGs around the TSS of OCT4 seem to be particu-
larly susceptible to demethylation. Demethylation in the
NANOG promoter was more uniform than that of OCT4, but
this might have been due to fewer numbers of CpGs examined.
Table 1. t test analysis of the numbers of methylated CpGs between treatments or cell types at wk 4 after EC or 293T extract treatment
Gene
Comparison of nos. of methylated CpGs between cell types (p values)a
Exp. 1 Exp. 2 293T extract 293T NCCIT
OCT4b
p 
 0.365 X
p values p 	 0.001 X X X
p 	 0.001 X X X
p 
 0.629 X
p 	 0.0001 X
p 	 0.0001 X
NANOGc
p 
 0.198 X
p values p 
 0.01 X X
p 	 0.001 X
p 
 0.01 X X
p 	 0.001 X
p 
 0.827 X
p 	 0.0001 X
p 	 0.0001 X
a Unpaired t tests. Data expressed as two-tailed p values with X referring to treatment or cell type with which comparison is made.
b Regions 1–9 were analyzed (see Figure 3).
c Regions 1–3 were analyzed (see Figure 3).
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EC Extract Modiﬁes Histone Lysine Methylation and
Acetylation on OCT4 and NANOG
In addition to DNA methylation, posttranslational modiﬁ-
cations of the amino-terminal tails of core histones, notably
histone H3, contribute to the regulation of gene expression.
We determined whether treatment of 293T cells with EC
extract modiﬁed lysines (K) 4, 9, and 27 on histone H3. To
accommodate relatively small cell numbers available for
ChIP analysis in this study, and to optimize detection of
small differences in lysine methylation and acetylation, we
recently modiﬁed a conventional ChIP protocol (Spencer et
al., 2003). Q2ChIP minimizes sample loss with a cross-link-
ing step in suspension, it preserves acetylated epitopes by
inhibiting histone deacetylase activity early in the process,
and it enhances ChIP speciﬁcity by eliminating background
through a tube-shift step after washes of the ChIP material
(Dahl and Collas, 2007). Four weeks after EC extract (experi-
ments 1 and 2; see above) or 293T extract treatment, chromatin
was prepared for ChIP analysis of changes in three marks of
transcriptionally active chromatin (H3K9ac, H3K4m2, and
H3K4m3) and in three repressive marks (H3K9m2, H3K9m3,
and H3K27m3) on OCT4, NANOG and on the constitutively
active GAPDH promoter. Regions examined are shown in
Figure 2, and the data are illustrated in Figure 5.
We ﬁrst examined histone modiﬁcations in 293T and
NCCIT cells. As expected from expression in NCCIT cells,
the OCT4 promoter and enhancer contained acetylated
H3K9 and barely detectable di- and trimethylated H3K9 or
trimethylated H3K27 (Figure 5A). In contrast, 293T cells
harbored H3K9m2, H3K9m3, and H3K27m3 but low levels
of acetylated H3K9. Di- and trimethylated H3K4 was de-
tected in both cell types, in agreement with expression, or
potential for expression, of the gene (Figure 5A). All histone
modiﬁcations occurred similarly throughout the OCT4 proxi-
mal promoter (OCT4-E:PP amplicon), the proximal enhancer
(OCT4-D:PE and OCT4-C:PE amplicons), and the distal en-
hancer (OCT4-B:DE and OCT4-A:DE amplicons). The NANOG
promoter displayed high levels of H3K9ac, H3K4m2, and
H3K4m3 together with low levels of H3K9 and H3K27 meth-
ylation in NCCIT cells (Figure 5B), again consistent with
expression of the gene. In contrast, heterochromatin marks
(H3K9m2, H3K9m3, and H3K27m3) were abundant in 293T
cells (Figure 5B). Last, no signiﬁcant differences were de-
tected for any histone H3 modiﬁcation on the GAPDH
promoter (Figure 5C). In agreement with its constitutive
expression, GAPDH exhibited acetylated H3K9, di- and tri-
methylated H3K4, and background levels of methylation on
H3K9 or H3K27.
Figure 4. DNA demethylation of OCT4 correlates with transcriptional activation in EC extract-treated cells. (A) Bisulﬁte sequencing analysis
of OCT4 regions 2, 3, and 9 at weeks 1 and 2 after EC extract (experiments A and B) and 293T extract treatments. (B) Percentages of
methylation of each CpG in OCT4 region 9 at weeks 1 and 2. (C) Bisulﬁte sequencing analysis of NANOG region 1 at weeks 1 and 2 in cells
as described in A. (D) Real-time RT-PCR analysis of OCT4 and NANOG expression in two reprogramming experiments 1 wk after EC extract
treatment. Means of triplicate RT-PCRs (SE bars are negligible).
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Figure 5. EC extract treatment elicits changes in histone H3 methylation and acetylation on OCT4 and NANOG. 293T cells were treated with
EC extract in two separate experiments (experiments 1 and 2) or exposed to 293T extract. Cells were cultured for 4 wk and analyzed by
Q2ChIP for indicated histone modiﬁcations. Untreated 293T and NCCIT cells were also examined. Data are presented as -fold enrichment of
precipitated DNA associated with a given histone modiﬁcation relative to a 100-fold dilution of input chromatin. (A) Five genomic regions
on OCT4 (OCT4-A to OCT4-E) were analyzed (see Figure 2, ChIP primers). (B) NANOG promoter. (C) GAPDH promoter. Each data point is
from a triplicate real-time PCR (error bars are negligible and are not shown).
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Treatment with EC extract promoted acetylation and de-
methylation of H3K9 (m2 and m3) together with a reduction
of H3K27m3 on OCT4 (Figure 5A, blue and green columns).
Demethylation of H3K9m2 was consistently more pronounced
than that of H3K9m3 or H3K27m3, suggesting that a trim-
ethylated state is more stable than a dimethylated state. As
expected from our observations in 293T and NCCIT cells, no
changes in H3K4 methylation were detected. Furthermore,
293T extract treatment maintained low H3K9ac and elevated
H3K4m2 and H3K4m3 levels (Figure 5A). Demethylation of
H3K9m2 and H3K9m3 occurred, however, albeit to a lesser
extent than in EC extract-treated cells, particularly in theOCT4-E:
PP, OCT4-D:PE, and OCT4-B:DE regions. OCT4-C:PE and
OCT4-A:DE regions were demethylated to the same extent.
In addition, 293T extract-treated cells maintained elevated
H3K27m3 particularly in the DE (OCT4-A:DE, OCT4-B:DE)
but showed similar H3K27m3 patterns as in EC extract-
treated cells in the PE and PP (Figure 5A).
The NANOG promoter also underwent H3K9 acetylation
in EC extract-treated cells, together with moderate increases
in di- and trimethylated H3K4, demethylation of H3K9m2,
moderate demethylation of H3K9m3, and weak demethyl-
ation of H3K27m3 (Figure 5B). Moreover, histone modiﬁca-
tion proﬁles in 293T extract-treated cells were similar to
those of 293T cells, except for some demethylation of H3K9m2
(Figure 5B). Last, no changes took place on the GAPDH
promoter (Figure 5C), indicating that changes on OCT4 and
NANOG were speciﬁc.
In summary, histone modiﬁcation changes detected on
OCT4 and NANOG regulatory regions after EC extract treat-
ment are indicative of a remodeling of chromatin on these
promoters to acquire an epigenetic state characteristic of
pluripotent cells. Acetylation and demethylation of H3K9
occur in an EC extract-speciﬁc manner and are indicative of
transcriptional activation of these genes.
Retinoic Acid Causes Remethylation of the OCT4
Promoter in Reprogrammed Cells
To ascertain the speciﬁcity of OCT4 demethylation elicited
by EC extract, we determined whether the promoter was
responsive to induction of differentiation with RA. First,
stimulation of NCCIT cells with 10 M RA for 3 wk strongly
down-regulated OCT4 and NANOG expression and acti-
vated nestin (NES) transcription, an early marker of neuro-
nal differentiation (Figure 6A). OCT4 repression correlated
with heavy DNA methylation in the PP (region 9) and DE
(regions 2 and 3), establishing the responsiveness of these
regions to RA in NCCIT cells (Figure 6B; compare with
Figure 3A, NCCIT).
Second, stimulation of reprogrammed cells with RA start-
ing 3 wk after extract treatment (experiments A and B)
down-regulated OCT4 expression (Figure 6C). Remarkably,
remethylation of OCT4 occurred in both batches of repro-
grammed cells (Figure 6, D and E; see Table 2 for t test
analyses). Note that only region 9 was examined here, be-
cause it was previously shown to be very responsive to EC
extract treatment. OCT4 remethylation in reprogrammed cells
occurred to the same extent as in RA-treated NCCIT cells
(Figure 6E and Table 2). In contrast, reprogrammed cells kept
in culture for 6 wk without RA maintained a relatively hypom-
ethylated proﬁle, in agreement with elevated OCT4 mRNA
levels (Figure 6, C–E). Finally, as anticipated, OCT4 re-
mained highly methylated in 293T extract-treated cells ex-
posed to RA (Figure 6E). We concluded that demethylation
of OCT4 elicited by EC extract treatment is a functionally
signiﬁcant epigenetic response, because it can be reverted by
induction of differentiation.
DISCUSSION
This report demonstrates the epigenetic reprogramming of
OCT4 and NANOG as a result of transient treatment of 293T
epithelial cells with extract of EC cells. We previously re-
ported an nonquantitative assessment of demethylation of
eight CpGs in EC extract-treated cells within OCT4 region 5
in the PE (Taranger et al., 2005). We now show mosaic CpG
demethylation throughout the OCT4 regulatory region and
in the NANOG promoter. Targeted OCT4 and NANOG de-
methylation is speciﬁc for EC extract, and it does not occur
in 293T extract-treated cells. OCT4 demethylation is physi-
ologically relevant, because it is associated with activation of
the gene, whereas RA-mediated differentiation elicits its
remethylation along with transcriptional repression. DNA
demethylation is accompanied by methylation and acetyla-
tion changes on lysines 4, 9, and 27 of histone H3 on the
OCT4 PP, PE, and DE as well as on the NANOG promoter,
to create a chromatin conﬁguration compatible with tran-
scriptional activation.
Reprogramming of DNA Methylation on OCT4 and
NANOG Regulatory Regions
EC extract-induced demethylation produces mosaic methyl-
ation proﬁles on OCT4 and NANOG upstream regulatory
sequences. On the basis of previous immunological obser-
vations of Oct4 protein expression (Taranger et al., 2005), not
all cells are expected to be reprogrammed to the same extent.
Our results are reminiscent of partial demethylation of Oct4
and Nanog in mouse ﬁbroblasts constitutively overexpress-
ing Oct4, Sox2, Klf4, and c-Myc (Takahashi and Yamanaka,
2006). Apparent partial reprogramming in our system may
be due the examination of a heterogeneous cell population,
or assuming that enzyme(s) causing demethylation originate
from the EC extract, to a restricted enzyme access to target
sequences. This may be alleviated by incubation of puriﬁed
nuclei or deproteinized chromatin, which in Xenopus eggs
accelerates demethylation (Simonsson and Gurdon, 2004),
rather than cells. Interestingly, reprogramming of OCT4
methylation is as efﬁcient in somatic–ES cell hybrids (Cowan
et al., 2005) as by nuclear transplantation (Simonsson and
Gurdon, 2004), two situations where nuclei are directly ex-
posed to the putative reprogramming factors.
Reprogramming of OCT4 DNA methylation by extract
treatment is targeted to speciﬁc, nonrandom areas, which
may be more sensitive to demethylation. The most signiﬁ-
cant DNA demethylation detected occurs in regions 2 and 3
in the DE and in region 9 in the PP. Regions 2 and 3
encompass putative elements for transcription factors, in-
cluding COUP-T, MZF1, GATA-2, HNF4, and three Sp1
elements. Region 9, surrounding the TSS, covers several
MZF1, ADR1 (whose promoter binding is promoted by loss
of histone deacetylation; Verdone et al., 2002), HSF, GATA-1,
GATA-2, and Sp1 elements (www.cbrc.jp/htbin/nph-tfsearch).
The NANOG promoter region demethylated by extract treat-
ment is rich in putative HSF; ADR1, CdxA, AP-1/4, IRF-1,
Cap, and c-Rel elements. Whether all these elements are
involved in transcription activation and whether methyl-
ation modulates their binding to DNA remain uncertain.
Nonetheless, DNA demethylation, together with hyper-
acetylation and hypomethylation of H3K9 (see below), con-
tribute to loosening chromatin structure and thereby to the
binding of transcription factors.
Demethylation in the OCT4 PP (region 9) took place
within 1 wk of extract treatment and was slightly enhanced
by week 2. By week 1, extract-treated cells have undergone
three rounds of replication (cells are quiescent for the ﬁrst
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48 h after extract treatment), so whether reprogramming-
associated demethylation is a replication-dependent process
or an active replication-independent process remains un-
known. This also holds true for cell fusion or transduction
reprogramming strategies, because clonal selection of the
reprogrammed cells occurs before analysis (Cowan et al.,
2005; Takahashi and Yamanaka, 2006). However, repro-
gramming of Oct4 methylation in Xenopus oocytes occurs in
the absence of replication, transcription, or protein synthesis
(Simonsson and Gurdon, 2004), and as such, it may involve
active demethylating activity. Interestingly, the Aid/Apobec
1 members of the family of 5-methylcytosine deaminases are
expressed in a cluster containing Nanog and other pluripo-
tency genes in oocytes, embryonic germ cells, and ES cells
(Morgan et al., 2004), three cell types known to be able to
reprogram somatic genomes (Tada et al., 1997, 2001; Wilmut
et al., 2002; Gurdon et al., 2003). Activity of Aid/Apobec
deaminases results in C3T transitions in methylated DNA,
or to demethylation in connection with repair of the T:G mis-
match (Morgan et al., 2004). As such, Aid/Apobec deaminases
may play a role in epigenetic reprogramming.
Retinoic acid stimulation of the reprogrammed cells
promotes OCT4 remethylation and transcriptional down-
regulation. Down-regulation of OCT4 is expected to cor-
relate with the establishment of a repressive chromatin
structure as demonstrated previously in NCCIT cells (Dahl
and Collas, 2007), and with the dissociation of transcription
regulators from the PP (Minucci et al., 1996) to ensure long-
term silencing. Our data indicate that in reprogrammed
cells, the OCT4 locus behaves epigenetically as in NCCIT
cells, in which OCT4 is fully methylated in regions 2, 3 (DE),
and 9 (PP) after RA stimulation (Figure 6; also see Deb-
Rinker et al., 2005). So, the (partially) demethylated OCT4
promoter in reprogrammed cells retains the ability to un-
dergo further ad hoc epigenetic modiﬁcations upon differ-
entiation.
Figure 6. Retinoic acid induces remethylation of the OCT4 promoter in EC extract-treated cells. (A) Real-time RT-PCR analysis of OCT4,
NANOG, and NES expression in RA-stimulated NCCIT cells (mean of triplicate PCRs; error bars negligible). (B) DNA methylation of OCT4
regions 2, 3, and 9 in NCCIT cells after 3 wk of RA stimulation. (C) Real-time RT-PCR analysis of OCT4 expression in EC extract-treated cells
(experiments A and B) 3 wk after exposure to extract (Start) and after one additional week of culture with 0 (RA) or 10 M RA (RA). (D)
Methylation of OCT4 region 9 in EC extract-treated cells exposed for 3 wk to RA, starting 3 wk after extract exposure as described in C. (E)
Percentage of methylation of individual CpGs in indicated cell types. For t test analyses, see Table 2.
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Remodeling Chromatin through Posttranslational
Modiﬁcations of Histone H3 on OCT4 and NANOG
The most prominent histone modiﬁcation speciﬁcally elic-
ited by EC extract on the OCT4 PP, PE, and DE and on the
NANOG promoter is acetylation of H3K9. This takes place in
the context of minimal hypermethylation of already di- and
trimethylated H3K4, which mark genes either transcription-
ally active (H3K4m3) or competent for transcription (H3K4m2)
(Santos-Rosa et al., 2002). These changes are consistent with
chromatin remodeling on the Oct4 promoter in mouse thymo-
cyte–ES cell hybrids, except for the marked trimethylation of
(initially unmethylated) H3K4 detected in the thymocyte nuclei
(Kimura et al., 2004). Transcriptional activation of Oct4 in
mouse ﬁbroblasts treated with ES cell extract requires ATP
hydrolysis, most likely for nuclear import of transcription
factors (Håkelien et al., 2002; Landsverk et al., 2002) and for
the activity of chromatin remodeling complexes (Kingston
and Narlikar, 1999; Aalfs et al., 2001). Oct4 activation by ES
cell extract or Xenopus egg extract also requires the Brg1
subunit of the SWI/SNF complex (Hansis et al., 2004; Taranger
et al., 2005). Promoter-speciﬁc targeting of SWI/SNF may
involve H3K4 (hyper)methylation on OCT4 and NANOG
and prime the loci for further transcription-permissive re-
modeling (H3K4 methylation per se is not sufﬁcient to allow
transcription as H3K4 is methylated on both OCT4 and
NANOG in 293T cells). This additional remodeling presum-
ably occurs by recruitment of histone acetyl transferases,
whose activity results in the marked acetylation of H3K9 on
OCT4 and NANOG. Therefore, a key reprogramming event
is relaxation of chromatin to create a conformation compat-
ible with transcriptional activation.
Trimethylation of H3K27 is a facultative heterochromatin
mark that promotes the recruitment of Polycomb group
proteins for gene silencing (Cao et al., 2002; Czermin et al.,
2002; Orlando, 2003). Interestingly, in ES cells, H3K27m3 can
also mark transcriptionally silent, albeit acetylated, promot-
ers for activation upon differentiation (Azuara et al., 2006).
We detected some H3K27m3 demethylation on OCT4 in EC
extract-treated cells but essentially none on NANOG. Be-
cause both promoters are acetylated on H3K9, this again
illustrates the heterogeneity of the cell populations exam-
ined and suggests that the loci have been partially repro-
grammed. To support this view, these modiﬁcations were
not as prominent as in NCCIT cells, in which both genes are
transcribed at a higher level than in reprogrammed cells.
Notably, H3K27m3 seems to be fully demethylated in thy-
mocyte–ES cell hybrids, suggesting a more extensive chro-
matin remodeling in this system (Kimura et al., 2004). Glo-
bally, however, the changes reported as a result of EC
extract treatment reﬂect a remodeling of chromatin on OCT4
and NANOG indicative of a transition from a potentially
active to an active promoter.
Our results indicate that the primary epigenetic determi-
nants of OCT4 and NANOG reprogramming by EC cell
extract are DNA demethylation, and acetylation and de-
methylation of H3K9. Demethylation of H3K9m2 clearly
occurs; however, trimethylated histone marks tend to re-
main more stable: demethylation of H3K9m3 or H3K27m3
was less pronounced than that of H3K9m2. Interestingly,
modulation of repressive histone modiﬁcations such as
H3K9 trimethylation is a feature of fertilized embryos,
which is also not faithfully reproduced by somatic cell nu-
clear transfer (Santos et al., 2003). Furthermore, nuclear
transplantation into Xenopus oocytes has shown that, in-
deed, repressive complexes do not readily disassemble
(Kikyo and Wolffe, 2000). It is clear, therefore, that demeth-
ylation of trimethylated repressive histone marks remains a
limiting factor in nuclear reprogramming, irrespective of the
approach. Identiﬁcation of the molecular mechanism driv-
ing histone demethylation (Shi et al., 2004; Armstrong et al.,
2006; Schneider and Shilatifard, 2006) is likely to constitute a
signiﬁcant step toward improving nuclear reprogramming
efﬁciency.
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Supplementary Fig. 1 
OCT4 genomic sequence GenBank No. AJ297527 
Dddd   Translation initiation start codon 
Dddd  Area covered by bisulfite primer pair: Forward primer; reverse primer; overlapping
 primer (3’ end of reverse/5’ end of forward 
Green: Exons (mRNA sequence GenBank No.NM_002701) 
t  Transcription start site (TSS)  
CpG CpG examined  
-3204 ggagaggtgg gcctcacctg ggtcccctgg cagtgctctg tgaagggtct tgacattgca 
-3144 cctgtaataa taaaggtgtg tgtgaagtat ctttttatgg tgactttcta aaacccaggg 
-3084 aatcatggga ccagttctga tgactcagcc tggcttccag tctcctccag gcccaacggt
-3024 ggcccccagc actggttggg gcctgggaga gctggccttg gctgaagtga agccacctac 
-2964 ccttcaggca taacaggaca gtgagaagga aggaaagcct gcctcaacct cccatcagcc 
-2904 ctgagcaccc cagaaggggg ccggctagga gtctaggcat gcaggaggct gacccctgac 
-2844 tgggctcata tccagccaca aggcagccag ggatccaggc acccacccct tgtctgcgtc 
-2784 cctctcggga atgggcctct tgcccaggcc agaaatacac cacctacagt acaaattata 
-2724 atctaaaaac aagagggtgg tgttgagtgg ggaaattggg gaaggtgttt taggagccac
-2664 taggaaaatg ggcagcaggg actctctgga ctggcttggg aagagcgctt ttggggaacc 
-2604 tggaggatgg caagctgaga aacactggtg tggagattcc agccaaatcc caggcctgcc 
-2544 cctccccctc ctctgagagg ccgtcttctt ggcagacagc agagagatgc atgacaaagg 
-2484 tgccgtgatg gttctgtcct ggggattgag atggctgggg aggggcctcc tcctgttccg 
-2424 aagcatgttc ctcccacccc caccaggccc cataatctac gctgccttttg ggcattaaa
-2364 ggccgagaag tgaacacagc tgcaacccca ctgccttgta gaccttccgg cagacctgtg 
-2304 gcaggtattg aaatgcacgc atacaattag gctcaaaaag tctacacaga caggagatgg 
-2244 gcacacgaac agaggcaaca taagagtggg ggaaaagtct caaaagactc acggatgcca
 -2184 ccaagatgaa gacagctggc cacgggacac ccatcccctt agaaggcaga tagagccact 
 -2124 gaccccagca gacaagccca ggcagggctg agcctggagc ctgcaatgag aagccttact 
 -2064 taagtcgaca gaggtcagcg tgcccagtcc agacctggcc ttctggcctt cgaagctgtg 
 -2004 gggagccctg gcccagagcc ccctctggag cccccagact taccccaggc cctccactga 
 -1944 gatcaagttt tgggagcaga cagacaaaca tcatccctca cagacaggca ttccgttggc 
 -1884 tattctcttg caaacagaat caagcactag accagcagca tgagcctcag gatactcagg 
 -1824 ccaggcccag aaaaacagac cctgaagggg agcttagggc agccttcctg cacgcctcca 
 -1764 caaatcactc tccacctcct ctgcgtcttt ctgccagcca gccccactaa acaaagcaca 
 -1704 tccctcaatc tgccaggctc ggggagggac gcacgatgaa gctggacgcc tgagtccccc 
 -1644 agaggaagga ggaactagat acctaggtcc ctgtgggggg cccttggtgc ccgtctgagg 
 -1584 ctcagtcttt gaggggattg cagagggggg ttgctggagc tccttttagc gtctctgaag 
 -1524 gggattctgt gtgaggggat tgggactggg gggttgggga gcaggaagca gtccccaggg 
 -1464 gagccatcca ggcccattca agggttgagc acttgtttag ggttagagct gccccctctg 
 -1404 gggaccggga ttgtccagcc aaggccattg tcctgccccc ttcccccagt ccctcccagg 
 -1344 cttctttgaa cctgaagtca gatatttttt ctccacaccc cccaccccct ggttttcccc 
 -1284 acccagggcc tagggctgga ggcctgggcc agggaggtgg gggagggaga acggggccta 
 -1224 ccgtggtatt agatgtctga gttttggttg agaggggagc aaggaacctg atgtgcaggt 
 -1164 tccatagtgg agggggccca aagcgggtgt cttatcactc tgtttcagca aaggttggga 
 -1104 aactgaggcc cagtcagtcc aaagtctggt cccttgaagg ggaagtaggg accaacccct
 -1044 tagtctgtta gatgaggaga gtctggagtc tgattctgga agacggaggg gtggggggat
 -984 gggggggtgg ggggatatag cacggaggcc ttgtctggca gtctactctt gaagatgggg 
 -924 tgaaatttgg caggctgggc agatggtgcc aggcacccag gctgcggggt ggctggattt 
 -864 ggccagtatc gggatgggaa tgcctaggat tctggatgga tcgggggaag gcataaggga 
 -804 gcagctggcc attgtgctta tggctgttga tgcattgagg gatagcgcca cacacacatt 
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 -744 caataaattt gaggagctga gagggtgact ggcccctgaa ggcacagtgc cagaggtctg 
 -684 tggagagggg gtcaagcacc tgggttcctg aagaacatgg aggtgtggga gtgattccag 
 -624 acagctggga tgtgcagagc ctgagagagt gccagggagc gggttgggag ttgaaagttg 
 -564 ggtgtggtgg ctcacgcctt taatcatgac actgggcggc agaggcggga ggatttcttg 
 -504 aggacaggaa ttcaagacca gcctgggtaa catagcaagg ccccatctta ctaaaaataa 
 -444 aaaaactaac agggcacagt ggtccaagcc tgtagtccca gccacttagg aggctggagc
 -384 agaaggattg ctttggccca gtagatcgag gctacattga gccatcattg tactccactg 
 -324 cactccagtc tgggcaacaa agtgagaccc tgtcttaaaa aataaaaata aaaaaagttt
 -264 ctgtggggga cctgcactga ggtcctggag gggcgccagt tgtgtctccc ggttttcccc 
 -204 ttccacagac accattgcca ccaccattag gcaaacatcc ttcgcctcag tttctccccc
 -144 cacctccctc tcctccaccc atccaggggg cggggccaga ggtcaaggct agtgggtggg
  -84 actggggagg gagagagggg ttgagtagtc ccttcgcaag ccctcatttc accaggcccc 
  -24 cggcttgggg cgccttcctt ccccatggcg ggacacctgg cttcggattt cgccttctcg 
   37 ccccctccag gtggtggagg tgatgggcca ggggggccgg agccgggctg ggttgatcct 
   97 cggacctggc taagcttcca aggccctcct ggagggccag gaatcgggcc gggggttggg 
  157 ccaggctctg aggtgtgggg gattccccca tgccccccgc cgtatgagtt ctgtgggggg 
  217 atggcgtact gtgggcccca ggttggagtg gggctagtgc cccaaggcgg cttggagacc 
  277 tctcagcctg agggcgaagc aggagtcggg gtggagagca actccgatgg ggcctccccg 
  337 gagccctgca ccgtcacccc tggtgccgtg aagctggaga aggagaagct ggagcaaaac 
  397 ccggaggagt cccaggacat caaagctctg cagaaagaac tcgagcaatt tgccaagctc 
  457 ctgaagcaga agaggatcac cctgggatat acacaggccg atgtggggct caccctgggg
  517 gttctatttg ggaaggtatt cagccaaacg accatctgcc gctttgaggc tctgcagctt
  577 agcttcaaga acatgtgtaa gctgcggccc ttgctgcaga agtgggtgga ggaagctgac
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NANOG Ensembl Gene ID: ENSG00000111704
http://www.ensembl.org/Homo_sapiens/geneseqview?db=core&gene=ENSG000001117
04&flank5_display=3056&flank3_display=800&exon_display=core&exon_ori=fwd&snp_
display=off&line_numbering=off&submit=Update
Dddd   Translation initiation start codon 
Dddd  Area covered by bisulfite primer pair; forward primer; reverse primer
Green: Exon (mRNA sequence GenBank No.NM_024865) 
g  Putative transcription start site (TSS) 
CpG CpG examined  
   -3204 tccatctcaa aaaaaaaaaa aaaaaaattg ccctcacaga gcttatattc tagtggtagt 
   -3144 agggggataa atcagatagg tagctagcta gctagctaga taaatagata gatagacaga 
   -3084 tagtatatta cctgtgtcgc ctggccaaag ggtaggttca catttggcat gtgtgtcaac 
   -3024 tcaagctgca cttgaccttt cctaatcatc tccaacacta cctattgccc tatccaaatc 
   -2964 ctatcacttg aattattcaa aaagtctccc atcttcattt tggtgggatt tggtcagctc 
   -2904 ctttactgca acctgtttta tcaggaaggt ctttatgacc tgtattttgt gctgacctcc 
   -2844 tatctcatcc tatgacttag aacaccttaa ccatctggga atgcagccca gtaggtttca 
   -2784 gcctcatttt acccagctcc tattgaagat ggagtcgttc tggttcacac agctctgata 
   -2724 gtaatctgct cactaagtgt tagttgccgt gttctctccc acaactccct cctgttgcac 
   -2664 ccctgccttt gagtcctgct aaacaacagt attggaaccc atcattttct ctcatgcctt 
   -2604 tacccaaact gttagttttc tggtattccc ttctctccac atttttcctt ctcagatcac 
   -2544 tgaggatcgt ccaatcttcc ctgcccatcc ctcccctacc ccaacctcca ttatttgtac 
   -2484 tctcttagca tccagtgcac tttttttcct tacttattac acaactttac acttacaatt 
   -2424 aacattataa ttgtcttttt ggtctatttg atctactcta ctaaatcttt tttttttttt 
   -2364 ttttgagaca aggtctcact gtgcctcctc ggctggagtg cagtggcgtg atctcggctc 
   -2304 gctgcaacct ccgcctctgg agttcaagtg attctcctgt ctcagcctcc ctagtagatg 
   -2244 ggattacagg cgtgcaccac cacgcccagc ccagttaatt tttgtatttt tagtacagac 
   -2184 agggtttcac catgttggtc aggctggtct tgaactcctg atctcagatg atgcacctgg 
   -2124 ctcggcctcg caaagtgctg ggattacagg tgtgagccac cgtgcccagc cgttagctca 
   -2064 ttttaacaca tccttagtcc agcctgttcc aaaaaatcta aagtcagata gcttcctaaa 
   -2004 cctcaacttt attccaattg ctttccttgg cgaagaatgt agtaagtcgg ccttccagcc 
   -1944 accagcccct tccctttggt ctttcactcc ggaggctctt accctagaca caatgggaca 
   -1884 gggagcgggg gatgggggaa ttcagctcag gcttttatgc aaagaccccc ttctgcaaag 
   -1824 aacaaagctt ctggtacctg ccctttggag agctgcgggc aagctcagcc tcggtgagtc 
   -1764 ttggtggcct tgacagcccc cacttaacaa actgtgctga ttaagagaga caggagggca
   -1704 agtttttccc ttcttttaaa gaaatcatcc tatttcctac gagacataga ctatctgcct 
   -1644 gaagcatgat gtactagccc cactcaccgg ctccctgatg cccctatgct taatcttctc 
   -1584 cggaatggta gtctgagaag aaaaaagatt acgcccaatt tcatttcctt gtttcacatc 
   -1524 aagcaatact tttcgagtct ttgcattgtg aacaaaagtc agcttgtgtg ggagcaaagc
   -1464 cagctgctct gggtgcagac ccaggagcag agtgcagagg agaatgagtc aaagagtttt
   -1404 gtcttcaaaa attacataat cgggatttgc taagagttta cttttcggta tggaagactg 
   -1344 gaaaagagaa agaaatctta ggtttcttga atgttgggtt tgggaatagg aaggaaaatc 
   -1286 gaaaactgta gactttgtcc ataaatgtta gtgctggaac cccactctaa aaactttgtt 
   -1224 cctttggaaa acacctccct tcccccagaa acacacacac ccacacgaga tgggcacgga 
   -1164 gtagtcttga aagacatgac aaatcaccag acctgggaag aagctaaaga gccagaggga 
   -1104 aaaagccaga agtcgactac ctgggaggag ggatagacaa gaaaccaaac taaaggaaac 
   -1044 taaggtaggt gctgaaaaca agtaccattt tcaacattaa ctgatgcctt ggcttcatgc 
    -984 tataatgcca tgttgtgttt cactataacc tcagagtgaa tgaaagagga aaatggagct 
    -924 agttgaaatt tctgcctaaa ctagccagat tttgagacac taagttatct caaatcaaga 
    -864 aatcacccta atgagaattt caataacctc aggaatttaa ggtgcatgca tcccccaccc 
    -804 cccccttttt tttttgagac gtagtcccgc tctgttgccc aggctggagt acagtggcgc 
    -744 gatatcggct caccacaacc tctgcctccc aggttcaagg gattctcccg cctcagcttc 
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    -684 cagagtagct gggactacag acacccacca ccatgcgtgg ctaatttttg tatttttagt 
    -624 agagaggggg tttcgccatg ttggccaggc tggtttcaaa ctcctgactt caggtgatcc 
    -564 gcctgccacg gcctcccaat ttactgggat tacaggggtg ggccaccgcg cccggccttt 
    -504 ttcttaattt ttaaaaatat taaagtttta tcccattcct gttgaaccat attcctgatt
    -444 taaaagttgg aaacgtggtg aacctagaag tatttgttgc tgggtttgtc ttcaggttct
    -384 gttgctcggt tttctagttc cccacctagt ctgggttact ctgcagctac ttttgcatta 
    -324 caatggcctt ggtgagactg gtagacggga ttaactgaga attcacaagg gtgggtcagt 
    -264 agggggtgtg cccgccagga ggggtgggtc taaggtgata gagccttcat tataaatcta 
 -204 gagactccag gattttaacg ttctgctgga ctgagctggt tgcctcatgt tattatgcag
-144 gcaactcact ttatcccaat ttcttgatac ttttccttct ggaggtccta tttctctaac 
-84 atcttccaga aaagtcttaa agctgcctta accttttttc cagtccacct cttaaatttt 
 -24 ttcctcctct tcctctatac taacatgagt gtggatccag cttgtcccca aagcttgcct
 36 tgctttgaag catccgactg taaagaatct tcacctatgc ctgtgatttg tgggcctgaa
 96 gaaaactatc catccttgca aatgtcttct gctgagatgc ctcacacgga gactgtctct
  156 cctcttccct cctccatgga tctgcttatt caggacagcc ctgattcttc caccagtccc
 216 aaaggcaaac aacccacttc tgcagagaat agtgtcgcaa aaaaggaaga caaggtccca
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Supplementary Fig. 1 (cont.) 
LMNA genomic sequence GenBank No. AL135927 
Dddd Proximal promoter (Genbank No. AL 003955) 
Dddd   Translation initiation start codon 
Dddd  Area covered by bisulfite primer pair; forward primer; reverse primer
Green: Exon 1 (mRNA sequence GenBank No. NM_170707) 
g  Putative transcription start site (TSS) 
CpG CpG examined  
    -2606 gaattcaagg ttgcagtgag ctatgatcct gccaccgcac tccagcctgg gcgacagacc 
    -2546 aagattctca aaaaaagagc ggggaggtct aggacaggaa gggttaagtg tggtttagct 
    -2486 ttcccagcct ggaaaggaag ccaggccaag cagctgggta ggggaaaagg gggcactgag 
    -2426 tgccagggag gggctgaggc agtgggaaca gcatgaaccc ttccctcacg tttcactggc 
    -2366 ttacccctcc tgcctctgct tctggtgtgg agaagaacaa gactttttat tgtctgggaa 
    -2306 gctgagggtg ggtgccacgc cctgggggag agaagccata ttctgggccc cctcatccgg 
    -2246 gtgcatccct agtgctcacc atgctgccca ggcaccctca ctgagatgag aactttcctt 
    -2186 gttcccctcc cctaataacc aaagttcctg ccttaatccc actccagtcc ctcatccacc 
    -2126 ccgaggccag gcttcagaac ccagaactga gggcctgtcc agccctgctt tccttgtgtt 
    -2066 tgagggaagc cctgatatct tggagctgta caaggtagca acataatttg atttccctgg 
    -2006 ttgctcatcg gaggataagc tgtgggaggc agttgggcag ggcatgcagg cagatgggac 
    -1946 ccaggcctca atgctgtcac ctcttagaga ggataaggtg ggacgggcat ggtggctcac 
    -1886 atctgtaatc ccagaacttt gggaagctga ggcaggcaga ttacctgagg tcgggagttt 
    -1826 gagaccagtt tggccaacat ggtgaaaccc catctctact aaaaataaaa ataaaaaaaa 
    -1766 aattagctgg gcttggtggc aggtgcctat aatcccagct actcaggagg ctgaggcagg 
    -1706 agaatctctt gaacccggga ggtggagatt gcaatgagct gagatcatgc cactgcactc 
    -1646 cagcctgggt gagagagcaa gacttaatct caaaaaaaca aacaaacaaa caaaaaaaac 
    -1586 aaacaaacag aggatgaggt ggatggtggg accaggatag gggccaggat gaggggaggg 
    -1526 gagtggaagg cttatcaaaa gggtccttgg tgaggcctga ggatggaggc tccagagcct 
    -1466 gaggtagcga accctgggga cctgagtgat ctcgttttgt gagagagcct ggcccctccc 
    -1406 cagagccagc tgcagaatgg acctggccag agaggaaagt agagatgagt atggtgctgg 
    -1346 cctttgcagc cagcaaggct gtggggtctt tgctgttcct gtcccccact accttcttgc 
    -1286 cccccactac cttctttctg gctgaaacca ggatagagac ccaacattgg ctgtccagcc 
    -1226 cccagccctg ctcccccttt caggcccctc tgggaaccac agaaatctgg gacctagtgt 
    -1166 cttggcaacg taatgaatgc atgcacagct ctggtatctg ttttaaatta tccattaaaa 
    -1106 taagtacagt tctgggggaa aaaaataagt tgactgggtg cggtaagcag tagaaaggga 
    -1046 ctgaaggggg aaggaaccca ggcagtgctt gggtccaaag gaaggggaca ggagatggaa 
     -986 ggggcagtgc ctggctccta ttcttggctt tctttagggg acttctttag gggactgtgg 
     -926 cttgttgctt gggtctaaaa acgaatgctt ggctttgaag agagatagat tggggcaaaa 
     -866 gaaagaaaaa aagggacccc ccaaactcct tgatccctgg ccccaaactg ggggcataaa 
     -806 ggaactcagg ttccagaact ttgctccccc cagggaaccc aggcattcct tctccacccc 
     -746 actcctggca cactgagatg cagctctgaa tgggctgccc acgtgtggag gggggttggg 
     -686 gtgactcact attactactg ggaggacagg gggagccagt ggtggaagaa gggtgagtca
     -626 cactgatggg caccagcctc agccctcccc ccactttcct ggctcccagc cctgcctacc 
     -566 tgaccctctc ccttgctttg cgcccacttc cctctctttc tccccgaccc ttttgcccac 
     -506 ccactctccc tccttggctc tgccctctag cccagaaggt ctgaggcaat gggggcaagc 
     -446 ttggagccga cagtgctgag caggcaggag ccaagagagg ggaagcttga gcctcacgca 
     -386 gttaggggtg cgctggagag ggtggggccc gactccgcca caccccaacg gtccttcccc 
     -326 ctcctcacca ctcccgcccc cacccccaat ggatctggga ctgccccttt aagagtagtg
     -266 gcccctcctc ccttcagagg aggacctatt agagcctttg ccccggcgtc ggtgactcag
 -206 tgttcgcggg agcgccgcac ctacaccagc caacccagat cccgaggtcc gacagcgccc 
-146 ggcccagatc cccacgcctg ccaggagcaa gccgagagcc agccggccgg cgcactccga 
 -86 ctccgagcag tctctgtcct tcgacccgag ccccgcgccc tttccgggac ccctgccccg 
-26 cgggcagcgc tgccaacctg ccggccatgg agaccccgtc ccagcggcgc gccacccgca 
34 gcggggcgca ggccagctcc actccgctgt cgcccacccg catcacccgg ctgcaggaga 
94 aggaggacct gcaggagctc aatgatcgct tggcggtcta catcgaccgt gtgcgctcgc 
154 tggaaacgga gaacgcaggg ctgcgccttc gcatcaccga gtctgaagag gtggtcagcc 
214 gcgaggtgtc cggcatcaag gccgcctacg aggccgagct cggggatgcc cgcaagaccc 
274 ttgactcagt agccaaggag cgcgcccgcc tgcagctgga gctgagcaaa gtgcgtgagg 
334 agtttaagga gctgaaagcg cggtgagttc gcccaggtgg ctgcgtgcct ggcggggagt 
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Supplementary Table 1. Bisulfite sequencing and ChIP primers used in this study.
Gene
name 
Primer pair Forward primer (F)  
Reverse primer (R)  
Seq. coverage 
relative to TSS 
Annealing
temp. (oC)
Bisulfite sequencing primers 
OCT4 Oct4-1 F: TTTTTAGTTTTTTTTAGGTTTAAa -2995 to -2723 50 
  R: TAAACAAAAAACCCATTCCCa   
 Oct4-2 F: TTAGGAAAATGGGTAGTAGGGATTTa -2609 to -2417 58 
  R: TACCCAAAAAACAAATAAATTATAAAACCTa   
 Oct4-3 F: ATTTGTTTTTTGGGTAGTTAAAGGTa -2344 to -2126 58 
  R: CCAACTATCTTCATCTTAATAACATCCa   
 Oct4-4 F: GGATGTTATTAAGATGAAGATAGTTGGa -2136 to -1721 58 
  R: CCTAAACTCCCCTTCAAAATCTATTa   
 Oct4-5 F: AATAGATTTTGAAGGGGAGTTTAGGa -1755 to -1574 58 
  R: TTCCTCCTTCCTCTAAAAAACTCAa   
 Oct4-6 F: GAAGGGGAAGTAGGGATTAATTTTa -1014 to -720 58 
  R: CAACAACCATAAACACAATAACCAAa   
 Oct4-7 F: TAGTTGGGATGTGTAGAGTTTGAGAa -567 to -309 58 
  R: TAAACCAAAACAATCCTTCTACTCCa   
 Oct4-8 F: AAGTTTTTGTGGGGGATTTGTATa -215 to -29 58 
  R: CCACCCACTAACCTTAACCTCTAa   
 Oct4-9 F: GTTAGAGGTTAAGGTTAGTGGGTGa -57 to +66 58 
  R: AAACCTTAAAAACTTAACCAAATCCa    
NANOG Nanog-1 F: AGAGATAGGAGGGTAAGTTTTTTTT -1503 to -1254 58 
  R: ACTCCCACACAAACTAACTTTTATTC   
 Nanog-2 F: GAGTTAAAGAGTTTTGTTTTTAAAAATTAT -1203 to -911 58 
  R: TCCCAAATCTAATAATTTATCATATCTTTC   
 Nanog-3 F: TTAATTTATTGGGATTATAGGGGTGa -334 to -163 55 
  R: AACAACAAAACCTAAAAACAAACC   
LMNA Lmna F: GAAGGGTGAGTTATATTGATGGGTAT -277 to +92 58 
  R: ACTCTTAAAAAAACAATCCCAAATC   
ChIP primers    
OCT4 Oct4-A F: GAGGATGGCAAGCTGAGAAA 
R: CTCAATCCCCAGGACAGAAC 
-2546 to -2379 60 
 Oct4-B F: ACCCCACTGCCTTGTAGACCT 
R: CACGCTGACCTCTGTCGACTT 
-2284 to -1986 60 
 Oct4-C F: AGCCCCACTAAACAAAGCAC 
R: GCAATCCCCTCAAAGACTGA 
-1669 to -1508 60 
 Oct4-D F: GTTGGGGAGCAGGAAGCA 
R: GGGGCAGCTCTAACCCTAAA 
-1435 to -1353 60 
 Oct4-E F: AGTCTGGGCAACAAAGTGAGA 
R: AGAAACTGAGGAGAAGGATG 
-262 to -94 60 
NANOG Nanog F: GTTCTGTTGCTCGGTTTTCT 
R: TCCCGTCTACCAGTCTCACC 
-173 to -79 60 
GAPDH Gapdh F: CTGAGCAGACCGGTGTCACATC 
R: GAGGACTTTGGGAACGACTGAG 
-486 to -320 60 
a From Deb-Rinker et al. (2005).
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Supplementary Table 2. Real time RT-PCR primers used in this study.  
Gene name 
Forward primer (F) 5’3’
Reverse primer (R) 5’3’
Annealing
temp. (oC)
GAPDH F: TCGGAGTCAACGGATTTGGT 
R: TTGCCATGGGTGGAATCATA 
60
LMNA F: CTGTGGTTGAGGACGACGAG 
R: TGCGGTAGCTGCGAGTGA 
60
LMNB1 F: AAGGCGAAGAAGAGAGGTTGAAG 
R: GCGGAATGAGAGATGCTAACACT 
60
NANOG F: CAAAGGCAAACAACCCACTT 
R: TCTGCTGGAGGCTGAGGTAT 
60
NES F: CACCTGTGCCAGCCTTTCTTA 
R: TTTCCTCCCACCCTGTGTCT 
60
OCT4 F: AAGCGATCAAGCAGCGACTAT 
R: GGAAAGGGACCGAGGAGTACA 
60
III
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